CPC1ChristopherCannonChristopher Paul Cannon, M.D.42.33510370000000-71.1061649000000077834Cannon, ChristopherPaulI am a cardiologist at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. I also serve as Executive Director of Cardiometabolic Trials at the Baim Institute of Clinical Research. Over the past 27 years, I have been the principal investigator of more than 18 multicenter clinical trials including TACTICS-TIMI 18, PROVE IT-TIMI 22, IMPROVE IT and currently the RE-DUAL PCI trial. My research has focused on management and prevention of acute coronary syndromes (ACS) with a goal of trying to directly improve patient care. Collaborating with others, we have helped establish various antithrombotic and interventional strategies for ACS, as well as long-term lipid management approaches for prevention that are included in current international guidelines. More recently, I am also studying prevention approaches in diabetes and in atrial fibrillation. Finally, I help lead registries and quality improvement educational initiatives with an aim toward implementation of research advances in clinical practice.617/278-0146Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:awardConferredByaward conferred byprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:awardOrHonorawards and honorsAward or Honor ReceiptDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson10492849Cannon CP, Sayah AJ, Walls RMClinical cardiologyPrehospital thrombolysis: an idea whose time has come. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV10-9.Clin Cardiol1999-08-01T00:00:001999Prehospital thrombolysis: an idea whose time has come.10551684Cannon CPJournal of the American College of CardiologyOvercoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1395-402.J Am Coll Cardiol1999-11-01T00:00:001999Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.10608011Cannon CP, Tracy RJournal of thrombosis and thrombolysisClotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy. J Thromb Thrombolysis. 1995; 2(2):95-106.J Thromb Thrombolysis1995-01-01T00:00:001995Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.11100010Cannon CPAmerican heart journalExploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Am Heart J. 2000 Dec; 140(6 Suppl):S154-60.Am Heart J2000-12-01T00:00:002000Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents.Authorship 10459006Cannon CPNew developments in acute coronary syndromesNew developments in acute coronary syndromes. 2001.2001-01-01T00:00:002001New developments in acute coronary syndromesAuthorship 10455009Authorship 10477733Authorship 1046177129443375Storey RF, Ardissino D, Vignali L, Cairns R, Becker RC, Cannon CP, Mahaffey KW, Himmelmann A, Katus HA, James SK, Wallentin LThrombosis and haemostasisIschaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thromb Haemost. 2018 02; 118(2):427-429.Thromb Haemost2018-01-29T00:00:002018Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study.29385366Cannon CP, Lip GYH, Oldgren JThe New England journal of medicineDual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2018 02 01; 378(5):485-486.N Engl J Med2018-02-01T00:00:002018Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.29490032Ibrahim NE, Gaggin HK, Turchin A, Patel HK, Song Y, Trebnick A, Doros G, Maya JF, Cannon CP, Januzzi JLEuropean heart journal. Cardiovascular pharmacotherapyHeart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. Eur Heart J Cardiovasc Pharmacother. 2019 01 01; 5(1):3-11.Eur Heart J Cardiovasc Pharmacother2019-01-01T00:00:002019Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction.29407094Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JLInternational journal of cardiologyAddition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry®. Int J Cardiol. 2018 03 01; 254:222-223.Int J Cardiol2018-01-28T00:00:002018Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry®.10208996Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald ECirculationRelationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999 Apr 20; 99(15):1945-50.Circulation1999-04-20T00:00:001999Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group.10492847Cannon CPClinical cardiologyBreaking the therapeutic barriers: new strategies for acute coronary syndromes. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV1-2.Clin Cardiol1999-08-01T00:00:001999Breaking the therapeutic barriers: new strategies for acute coronary syndromes.12034420Cannon CPThe American journal of medicineOral glycoprotein IIb/IIIa inhibition--great idea, but it didn't work. Am J Med. 2002 Jun 01; 112(8):673-5.Am J Med2002-06-01T00:00:002002Oral glycoprotein IIb/IIIa inhibition--great idea, but it didn't work.Cannon CPAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 2005.2005-01-01T00:00:002005Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationSteinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CPJ Am Coll CardiolCurrent trends in the prevalence of metabolic syndrome risk factors. J Am Coll Cardiol. 2006; 47(4):312A.2006-02-21T00:00:002006Current trends in the prevalence of metabolic syndrome risk factorsCannon CPCase study: Use of combination IIb/IIIa inhibition and reduced dose thrombolysis for acute myocardial infarctionCase study: Use of combination IIb/IIIa inhibition and reduced dose thrombolysis for acute myocardial infarction. 1999.1999-01-01T00:00:001999Case study: Use of combination IIb/IIIa inhibition and reduced dose thrombolysis for acute myocardial infarctionCannon CP.Practice implications of endpoint trials in CV risk factor managementPractice implications of endpoint trials in CV risk factor management. 2005.2005-12-01T00:00:002005Practice implications of endpoint trials in CV risk factor managementDanias PGCannon CP, series editor. Contemporary CardiologyCardiovascular MRI: 150 multiple choice questions and answers. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-01-01T00:00:002008Cardiovascular MRI: 150 multiple choice questions and answersAuthorship 10510204Authorship 10509303Authorship 10527412Authorship 10517633Authorship 1053020229521450Udell JA, Fonarow GC, Maddox TM, Cannon CP, Frank Peacock W, Laskey WK, Grau-Sepulveda MV, Smith EE, Hernandez AF, Peterson ED, Bhatt DLClinical cardiologySustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clin Cardiol. 2018 Jun; 41(6):758-768.Clin Cardiol2018-05-11T00:00:002018Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.29512936Baum SJ, Cannon CPClinical cardiologyPCSK9 inhibitor valuation: A science-based review of the two recent models. Clin Cardiol. 2018 Apr; 41(4):544-550.Clin Cardiol2018-03-07T00:00:002018PCSK9 inhibitor valuation: A science-based review of the two recent models.29526502Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach MKidney internationalEfficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018 06; 93(6):1397-1408.Kidney Int2018-03-08T00:00:002018Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.29537291Cavallari I, Cannon CP, Braunwald E, Goodrich EL, Im K, Lukas MA, O'Donoghue MLEuropean journal of preventive cardiologyMetabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 05; 25(8):830-838.Eur J Prev Cardiol2018-03-14T00:00:002018Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome.29543954de Boer IH, Bakris G, Cannon CPJAMAIndividualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320.JAMA2018-04-03T00:00:002018Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations.Karha J, Cannon CPBhatt DL, editor. Platelets in Cardiovascular Disease.ADP Receptor Antagonists. Bhatt DL, editor. Platelets in Cardiovascular Disease. 2008; 87-123.2008-03-01T00:00:002008ADP Receptor Antagonists14979625Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJClinical cardiologyDoes initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004 Feb; 27(2):80-6.Clin Cardiol2004-02-01T00:00:002004Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes?15971459Januzzi JL, Buros J, Cannon CPClinical cardiologyPeripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. Clin Cardiol. 2005 May; 28(5):238-42.Clin Cardiol2005-05-01T00:00:002005Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial.15990742Gomberg-Maitland M, Murphy SA, Moliterno DJ, Cannon CPAmerican heart journalAre we appropriately triaging patients with unstable angina? Am Heart J. 2005 Apr; 149(4):613-8.Am Heart J2005-04-01T00:00:002005Are we appropriately triaging patients with unstable angina?19258838Cannon CP, Hoekstra JW, Larson DM, Mencia WA, Cornish J, Carter RD, Berry CA, Karcher RBCritical pathways in cardiologyIndividual quality improvement in acute coronary syndromes: a performance improvement initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):43-8.Crit Pathw Cardiol2009-03-01T00:00:002009Individual quality improvement in acute coronary syndromes: a performance improvement initiative.16226164Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald EJournal of the American College of CardiologyRelationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1417-24.J Am Coll Cardiol2005-10-18T00:00:002005Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.16253583Dupuis J, Tardif JC, Rouleau JL, Ricci J, Arnold M, Lonn E, Roux R, Title LM, Amyot R, Bonafede N, Woo A, Cannon CPThe American journal of cardiologyIntensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol. 2005 Nov 01; 96(9):1207-13.Am J Cardiol2005-09-06T00:00:002005Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).16537575O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald ECirculationLipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11; 113(14):1745-52.Circulation2006-03-14T00:00:002006Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.19380329Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CPEuropean journal of heart failureBaseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009 Jun; 11(6):542-50.Eur J Heart Fail2009-04-19T00:00:002009Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.Khan MG, editorCannon CP, series editor. Contemporary CardiologyHeart disease diagnosis and therapy: A practical approach. Cannon CP, series editor. Contemporary Cardiology. 2005; 529.2005-01-01T00:00:002005Heart disease diagnosis and therapy: A practical approachCannon CP, Topol EJ, Steinhubl SEarly and sustained dual oral antiplatelet therapy following percutaneous coronary interventionEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. 2003.2003-01-01T00:00:002003Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventionKrum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CP, for the MEDAL Steering CommitteeJoint Congress of the European Society & International Society of Hypertension, Berlin, GermanyWhich baseline parameters influence risk of congestive heart failure in arthritis patients receiving NSAIDs & COX-2 inhibitors? Multivariate analysis of 34,701 patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Program. Joint Congress of the European Society & International Society of Hypertension, Berlin, Germany. 2008.2008-06-14T00:00:002008Which baseline parameters influence risk of congestive heart failure in arthritis patients receiving NSAIDs & COX-2 inhibitors? Multivariate analysis of 34,701 patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) ProgramCannon CPGlobal use of strategies: To open occluded arteries (GUSTO) IV in acute coronary syndromes (ACS): What happened?Global use of strategies: To open occluded arteries (GUSTO) IV in acute coronary syndromes (ACS): What happened?. 2000.2000-01-01T00:00:002000Global use of strategies: To open occluded arteries (GUSTO) IV in acute coronary syndromes (ACS): What happened?Cannon CP, Conti CR, Boden WE, Wenger NKThe paradigm of ischemic heart disease-implications for optimizing patient managementThe paradigm of ischemic heart disease-implications for optimizing patient management. 2007.2007-03-26T00:00:002007The paradigm of ischemic heart disease-implications for optimizing patient managementCannon CPAcute coronary syndrome and peripheral arterial disease: Applying diagnostics for early detection and interventionAcute coronary syndrome and peripheral arterial disease: Applying diagnostics for early detection and intervention. 2008.2008-05-15T00:00:002008Acute coronary syndrome and peripheral arterial disease: Applying diagnostics for early detection and interventionBhatt D, Cannon CP, Peacock F, Reiner JEvolving treatment strategies in acute myocardial infarctionEvolving treatment strategies in acute myocardial infarction. 2003.2003-01-01T00:00:002003Evolving treatment strategies in acute myocardial infarctionBuros JL, Nguyen MC, Murphy SA, Southard MC, Ciaglo K, Takao ST, Hochberg C, Sabatine MS, Cannon CP, Braunwald E, Gibson CMCirculationThe association of culprit and non-culprit myocardial perfusion with clinical events following and ST-elevation MI (STEMI): An analysis from the CLARITY-TIMI 28 study. Circulation. 2007; 116(16):II-673.2007-10-16T00:00:002007The association of culprit and non-culprit myocardial perfusion with clinical events following and ST-elevation MI (STEMI): An analysis from the CLARITY-TIMI 28 studyHarrington R, Cannon CP, Topol E, Rose MDefining optimal care for patients with acute coronary syndromesDefining optimal care for patients with acute coronary syndromes. 2002.2002-01-01T00:00:002002Defining optimal care for patients with acute coronary syndromesCannon CPQuick reference cards: ACC/AHA unstable angina guidelinesQuick reference cards: ACC/AHA unstable angina guidelines. 2000.2000-01-01T00:00:002000Quick reference cards: ACC/AHA unstable angina guidelinesOz MC, Goldstein DJ, editorsCannon CP, series editor. Contemporary CardiologyMinimally invasive cardiac surgery. Cannon CP, series editor. Contemporary Cardiology. 1999; 237.1999-01-01T00:00:001999Minimally invasive cardiac surgeryBrown T, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Pina IL, Safford MM, Fonarow GCQCORPredictors of non-referral to cardiac rehabilitation in the American Heart Association's Get With the Guidelines Program. QCOR. 2008.2008-01-01T00:00:002008Predictors of non-referral to cardiac rehabilitation in the American Heart Association's Get With the Guidelines ProgramAuthorship 1055282329581078White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RMThe American journal of medicineAlogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med. 2018 07; 131(7):813-819.e5.Am J Med2018-03-23T00:00:002018Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.7860900Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CH, Flaker GCJournal of the American College of CardiologyAngiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1995 Mar 01; 25(3):582-9.J Am Coll Cardiol1995-03-01T00:00:001995Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.9327688Gibson CM, Marble SJ, Rizzo MJ, Moynihan J, McLean C, Ryan K, Sparano A, Piana RN, McCabe C, Cannon CPAmerican heart journalRelation between injections before 90-minute angiography and coronary patency: results of the thrombolysis in myocardial infarction 4 trial. Am Heart J. 1997 Sep; 134(3):351-4.Am Heart J1997-09-01T00:00:001997Relation between injections before 90-minute angiography and coronary patency: results of the thrombolysis in myocardial infarction 4 trial.9408715Cannon CPControlled clinical trialsClinical perspectives on the use of composite endpoints. Control Clin Trials. 1997 Dec; 18(6):517-29; discussion 546-9.Control Clin Trials1997-12-01T00:00:001997Clinical perspectives on the use of composite endpoints.9929748Tanasijevic MJ, Cannon CP, Antman EMClinical cardiologyThe role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol. 1999 Jan; 22(1):13-6.Clin Cardiol1999-01-01T00:00:001999The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease.10091021Cannon CPCurrent opinion in cardiologyTime to treatment of acute myocardial infarction revisited. Curr Opin Cardiol. 1998 Jul; 13(4):254-66.Curr Opin Cardiol1998-07-01T00:00:001998Time to treatment of acute myocardial infarction revisited.Authorship 1022291010653841Every NR, Hochman J, Becker R, Kopecky S, Cannon CPCirculationCritical pathways : a review. Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association. Circulation. 2000 Feb 01; 101(4):461-5.Circulation2000-02-01T00:00:002000Critical pathways : a review. Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association.11059440Braunwald E, Califf RM, Cannon CP, Fox KA, Fuster V, Gibler WB, Harrington RA, King SB, Kleiman NS, Theroux P, Topol EJ, Van de Werf F, White HD, Willerson JTThe American journal of medicineRedefining medical treatment in the management of unstable angina. Am J Med. 2000 Jan; 108(1):41-53.Am J Med2000-01-01T00:00:002000Redefining medical treatment in the management of unstable angina.Cannon CPACP Journal ClubCommentary on glycoprotein IIb/IIIa inhibitors to reduce combined endpoints in acute coronary syndromes. ACP Journal Club. 2001; (March/April):49.2001-01-01T00:00:002001Commentary on glycoprotein IIb/IIIa inhibitors to reduce combined endpoints in acute coronary syndromesCannon CPTreating both cholesterol and inflammationTreating both cholesterol and inflammation. 2005.2005-01-01T00:00:002005Treating both cholesterol and inflammationKrum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering CommitteeAm Soc HypertensionDifferential effect of baseline antihypertensive medications of bood pressure changes in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008.2008-01-01T00:00:002008Differential effect of baseline antihypertensive medications of bood pressure changes in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study17044845Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PMAnnals of human geneticsInfluence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006 Nov; 70(Pt 6):705-16.Ann Hum Genet2006-11-01T00:00:002006Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia.17351840Opotowsky AR, McWilliams JM, Cannon CPJournal of general internal medicineGender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med. 2007 Jan; 22(1):55-61.J Gen Intern Med2007-01-01T00:00:002007Gender differences in aspirin use among adults with coronary heart disease in the United States.17980250Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RFJournal of the American College of CardiologySafety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.J Am Coll Cardiol2007-10-23T00:00:002007Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.18042049Kumar A, Cannon CPJournal of interventional cardiologyImportance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol. 2007 Dec; 20(6):447-57.J Interv Cardiol2007-12-01T00:00:002007Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.18154743Steinberg BA, Cannon CPThe American journal of cardiologyCannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol. 2007 Dec 17; 100(12A):27P-32P.Am J Cardiol2007-12-17T00:00:002007Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.Authorship 108403918435949Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald EThe American journal of cardiologyRelation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 01; 101(9):1232-8.Am J Cardiol2008-03-05T00:00:002008Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy.11868039Cannon CPAmerican heart journalTo cath or not to cath? That used to be the question. Am Heart J. 2002 Mar; 143(3):377-80.Am Heart J2002-03-01T00:00:002002To cath or not to cath? That used to be the question.11997276Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald ECirculationRelationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23; 105(16):1909-13.Circulation2002-04-23T00:00:002002Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction.Authorship 111557318823986Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CPGastroenterologyLower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov; 135(5):1517-25.Gastroenterology2008-08-03T00:00:002008Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.19046736Cannon CPClinical cornerstoneObesity-related cardiometabolic complications. Clin Cornerstone. 2008; 9(1):11-9; discussion 20-2.Clin Cornerstone2008-01-01T00:00:002008Obesity-related cardiometabolic complications.19122587Cannon CP, Acharjee SReviews in cardiovascular medicinePercutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes. Rev Cardiovasc Med. 2008; 9(4):280-2.Rev Cardiovasc Med2008-01-01T00:00:002008Percutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes.29668889Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DLEuropean heart journalSafety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018 05 14; 39(19):1726-1735a.Eur Heart J2018-05-14T00:00:002018Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.20031871Roe MT, Chen AY, Cannon CP, Rao S, Rumsfeld J, Magid DJ, Brindis R, Klein LW, Gibler WB, Ohman EM, Peterson EDCirculation. Cardiovascular quality and outcomesTemporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):414-20.Circ Cardiovasc Qual Outcomes2009-07-28T00:00:002009Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries.20435228Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh JLancet (London, England)Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 01; 375(9725):1536-44.Lancet2010-05-01T00:00:002010Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Authorship 10582262Authorship 10573591029652078Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CPClinical cardiologyTotal cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clin Cardiol. 2018 Aug; 41(8):1022-1027.Clin Cardiol2018-08-16T00:00:002018Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.15173052Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa FCirculationThe clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. Circulation. 2004 Jun 01; 109(21):e302-4.Circulation2004-06-01T00:00:002004The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.15529022Ray KK, Cannon CPCurrent opinion in lipidologyIntensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004 Dec; 15(6):637-43.Curr Opin Lipidol2004-12-01T00:00:002004Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.15653037Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CMJournal of the American College of CardiologyAssociation of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.J Am Coll Cardiol2005-01-18T00:00:002005Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction.16368287Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CPAmerican heart journalCombination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006 Jan; 151(1):25-31.Am Heart J2006-01-01T00:00:002006Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.19189606Albanese J, Birnbaum M, Cannon C, Cappiello J, Chapman E, Paturas J, Smith SPrehospital and disaster medicineFostering disaster resilient communities across the globe through the incorporation of safe and resilient hospitals for community-integrated disaster responses. Prehosp Disaster Med. 2008 Sep-Oct; 23(5):385-90.Prehosp Disaster Med2008-09-01T00:00:002008Fostering disaster resilient communities across the globe through the incorporation of safe and resilient hospitals for community-integrated disaster responses.19571087Gilbert NF, Yasko AW, Oates SD, Lewis VO, Cannon CP, Lin PPThe Journal of bone and joint surgery. American volumeAllograft-prosthetic composite reconstruction of the proximal part of the tibia. An analysis of the early results. J Bone Joint Surg Am. 2009 Jul; 91(7):1646-56.J Bone Joint Surg Am2009-07-01T00:00:002009Allograft-prosthetic composite reconstruction of the proximal part of the tibia. An analysis of the early results.19652090Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DLCirculationQuality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7.Circulation2009-08-03T00:00:002009Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program.19667305Wang TY, Fonarow GC, Hernandez AF, Liang L, Ellrodt G, Nallamothu BK, Shah BR, Cannon CP, Peterson EDArchives of internal medicineThe dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med. 2009 Aug 10; 169(15):1411-9.Arch Intern Med2009-08-10T00:00:002009The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes.19594486Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CPAlimentary pharmacology & therapeuticsPrescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009 Oct; 30(7):767-74.Aliment Pharmacol Ther2009-07-07T00:00:002009Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines.19789064Cannon CP, Kumar AClinical cornerstoneTreatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009; 9(4):55-68; discussion 69-71.Clin Cornerstone2009-01-01T00:00:002009Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.19804082McLean DS, Cannon CPFuture cardiologyA point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiol. 2006 May; 2(3):255-67.Future Cardiol2006-05-01T00:00:002006A point-of-care assay to measure platelet aggregation in patients taking clopidogrel.20215905Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CPCritical pathways in cardiologyCost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol. 2010 Mar; 9(1):14-8.Crit Pathw Cardiol2010-03-01T00:00:002010Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.20495519Truong QA, Garrido-Castro AC, Cannon CPReviews in cardiovascular medicinePatent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair? Rev Cardiovasc Med. 2010; 11(1):53-6.Rev Cardiovasc Med2010-01-01T00:00:002010Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair?19958873Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Wilson PW, Watson KE, Steg PGAmerican heart journalEthnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45.Am Heart J2009-12-01T00:00:002009Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry.22391250Kohli P, Cannon CPThe Medical clinics of North AmericaTriglycerides: how much credit do they deserve? Med Clin North Am. 2012 Jan; 96(1):39-55.Med Clin North Am2012-01-01T00:00:002012Triglycerides: how much credit do they deserve?22507980Kohli P, Cannon CPEuropean heart journalA new approach to managing the 'statin-intolerant' patient? Eur Heart J. 2012 May; 33(9):1040-3.Eur Heart J2012-04-16T00:00:002012A new approach to managing the 'statin-intolerant' patient?23021325Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held CJournal of the American College of CardiologyFactors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23; 60(17):1623-30.J Am Coll Cardiol2012-09-26T00:00:002012Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.23172660Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HMJournal of lipid researchMeasurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72.J Lipid Res2012-11-19T00:00:002012Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.23192967Clinical cardiologyStatement on matching language to the type of evidence used in describing outcomes data. Clin Cardiol. 2012 Dec; 35(12):713.Clin Cardiol2012-11-28T00:00:002012Statement on matching language to the type of evidence used in describing outcomes data.Cannon CP, Steinhubl S, Topol E, Easton DClinical implications of CREDO: New evidence for long-term dual antiplatelet therapyClinical implications of CREDO: New evidence for long-term dual antiplatelet therapy. 2003.2003-01-01T00:00:002003Clinical implications of CREDO: New evidence for long-term dual antiplatelet therapyAuthorship 10634236Authorship 1062107429710336Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue MLJAMA cardiologyAssociation of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.JAMA Cardiol2018-06-01T00:00:002018Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.28742645Larkin A, LaCouture M, Geissel K, Barr P, Bates ER, Cannon CP, Bhatt DLCritical pathways in cardiologyQuality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions. Crit Pathw Cardiol. 2017 09; 16(3):96-101.Crit Pathw Cardiol2017-09-01T00:00:002017Quality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions.Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, Al-Awqati QAm J Physiol (Cell Physiol)Isolation and culture of HC03 secreting cells. Am J Physiol (Cell Physiol). 1989; 256:C1004-11..1989-01-01T00:00:001989Isolation and culture of HC03 secreting cellsCannon CPCor Art DisThe era of platelet glycoprotein IIb/IIIa inhibition: Overview. Cor Art Dis. 1999; 10:545-6.1999-01-01T00:00:001999The era of platelet glycoprotein IIb/IIIa inhibition: OverviewCannon CPAdvances in the understanding of acute coronary syndromeAdvances in the understanding of acute coronary syndrome. 2002.2002-01-01T00:00:002002Advances in the understanding of acute coronary syndromeWiviott SD, Cannon CPGerstenblith G, editor. Cardiovascular Disease in the ElderlyUnstable angina non-ST-elevation myocardial infarction in the elderly. Gerstenblith G, editor. Cardiovascular Disease in the Elderly. 2005; 141-58.2005-01-01T00:00:002005Unstable angina non-ST-elevation myocardial infarction in the elderlyCannon CPTACTICS TIMI 18TACTICS TIMI 18. 2000.2000-01-01T00:00:002000TACTICS TIMI 18Authorship 1034562Cannon CP, Bhatt DLClinical trials update from the annual scientific session of the American College of Cardiology. 2006; 98(12A):36Q-41Q.2006-12-01T00:00:002006Clinical trials update from the annual scientific session of the American College of CardiologyCannon CPGuideline for UA/NSTEMIGuideline for UA/NSTEMI. 2002.2002-01-01T00:00:002002Guideline for UA/NSTEMIBlock PC, Cannon CPIIb/IIIa inhibition in acute coronary syndromesIIb/IIIa inhibition in acute coronary syndromes. 1998.1998-01-01T00:00:001998IIb/IIIa inhibition in acute coronary syndromesMorrow DA, Cannon CPACC Curr J RevChest pain and biomarkers: Has troponin supplanted CK-MB?. ACC Curr J Rev. 2001; (Jan/Feb):18-21.2001-01-01T00:00:002001Chest pain and biomarkers: Has troponin supplanted CK-MB?Cannon CPPfeffer M, editor. Cardiology Scientific UpdatesThe clopidogrel in unstable angina to prevent recurrent events (CURE) trial. Pfeffer M, editor. Cardiology Scientific Updates. 2002; 1-6.2002-01-01T00:00:002002The clopidogrel in unstable angina to prevent recurrent events (CURE) trialCannon CP, Hawkins D, McKeever ACardiology Special EditionGuide to cardiovascular events. Cardiology Special Edition. 2005; 11:39-49.2005-01-01T00:00:002005Guide to cardiovascular eventsCannon CP, Libby P, Smith S, Ballantyne CMAdvances in lipid management. 2005; 1-30.2005-01-01T00:00:002005Advances in lipid managementFuster V, Cannon CP, Ferguson J, Weber MACC 2003: Sportif II and ascotACC 2003: Sportif II and ascot. 2003.2003-01-01T00:00:002003ACC 2003: Sportif II and ascotKrum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering CommitteeAm Soc HypertensionMultivariate analysis of blood pressure change in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008.2008-01-01T00:00:002008Multivariate analysis of blood pressure change in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) studyGluck S, Cannon C, Al-Awqati QProc Natl Acad Sci USAExocytosis regulates rinary acidification in the turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci USA. 1982; 79:4327-31.1982-01-01T00:00:001982Exocytosis regulates rinary acidification in the turtle bladder by rapid insertion of H+ pumps into the luminal membraneWiviott SD, Morrow DA, O'Donoghue M, Sabatine MS, Murphy SA, Cannon CPJ Am Coll CardiolThe TIMI risk index for myocardial infarction predicts post-MI LV ejection fraction: A CLARITY - TIMI 28 substudy. J Am Coll Cardiol. 2006; 47(4):224A.2006-02-21T00:00:002006The TIMI risk index for myocardial infarction predicts post-MI LV ejection fraction: A CLARITY - TIMI 28 substudyCannon CPThe TIMI 11B troponin substudyThe TIMI 11B troponin substudy. 1999.1999-01-01T00:00:001999The TIMI 11B troponin substudyMoliterno D, Cannon CP, Ohman EM, Spinler SAThe Evolving Management of Atherothrombotic and Occlusive Vascular DiseasesImproving strategies and outcomes. The Evolving Management of Atherothrombotic and Occlusive Vascular Diseases. 2000.2000-01-01T00:00:002000Improving strategies and outcomesZahger D, Cercek B, Cannon CP, Jordan M, Shah PK, for the TIMI-4 InvestigatorsJ Thromb ThrombolysisThrombolytic therapy for acute myocardial infraction in patients with prior coronary bypass surgery: Results from the Thrombolysis In Myocardial Infarction (TIMI) 4 Trial. J Thromb Thrombolysis. 1995; 2:45-50..1995-01-01T00:00:001995Thrombolytic therapy for acute myocardial infraction in patients with prior coronary bypass surgery: Results from the Thrombolysis In Myocardial Infarction (TIMI) 4 TrialOrnato JP, Cannon CP, Gibler WB, Gonzales ERCritical pathways for the evaluation and treatment of chest pain.Critical pathways for the evaluation and treatment of chest pain. 1997.1997-01-01T00:00:001997Critical pathways for the evaluation and treatment of chest painCannon CPTranslating evidence into guidelines and applying them in practice: The long chain of qualityTranslating evidence into guidelines and applying them in practice: The long chain of quality. 2007.2007-08-06T00:00:002007Translating evidence into guidelines and applying them in practice: The long chain of qualityCannon CPPfeffer MA, series editor. Cardiology Scientific UpdateNew strategies for the treatment of acute coronary syndromes. Pfeffer MA, series editor. Cardiology Scientific Update. 1999.1999-01-01T00:00:001999New strategies for the treatment of acute coronary syndromesMenon V, Harrington RA, Hochman J, Cannon CP, Goodman SD, Wilcox RG, Schunemann H, Ohman EMChestThrombolysis and adjunctive therapy in acute myocardial infarction. Chest. 2004; 126:549S-575S.2004-01-01T00:00:002004Thrombolysis and adjunctive therapy in acute myocardial infarctionCannon CPAcute myocardial infarction - the first 73 hoursAcute myocardial infarction - the first 73 hours. 1997.1997-03-01T00:00:001997Acute myocardial infarction - the first 73 hoursCannon CP, Gibson CM, Topol EJ, Ornato JP, Weintraub WS, King SNew pathways for aggressive management of ACSNew pathways for aggressive management of ACS. 2001.2001-01-01T00:00:002001New pathways for aggressive management of ACS17884359Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald EThe American journal of cardiologyEffect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 01; 100(7):1047-51.Am J Cardiol2007-07-18T00:00:002007Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).Authorship 10659143Authorship 1064230229752128Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JLInternational journal of cardiologyRetraction notice to Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry® [International Journal of Cardiology 254 (2018) 222-223]. Int J Cardiol. 2018 03 01; 254:R1.Int J Cardiol2018-03-01T00:00:002018Retraction notice to Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry® [International Journal of Cardiology 254 (2018) 222-223].29769203Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad FJournal of the American Heart AssociationEarly and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).J Am Heart Assoc2018-05-16T00:00:002018Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.16843176Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV, Smith SC, Ferguson TB, Peterson EDJournal of the American College of CardiologyAcute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006 Jul 18; 48(2):281-6.J Am Coll Cardiol2006-06-21T00:00:002006Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.16875903Cannon CP, Curtis SP, Bolognese JA, Laine LAmerican heart journalClinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006 Aug; 152(2):237-45.Am Heart J2006-08-01T00:00:002006Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.17183556Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AWCancerPeriosteal margin in soft-tissue sarcoma. Cancer. 2007 Feb 01; 109(3):598-602.Cancer2007-02-01T00:00:002007Periosteal margin in soft-tissue sarcoma.17493466Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV, Ohman EM, Gibler WB, Roe MTThe American journal of cardiologyTiming of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.Am J Cardiol2007-03-26T00:00:002007Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).17667869Steinberg BA, Ballantyne CM, Bhatt DL, Montalescot G, Mehta S, O'Hagan P, Poole-Wilson PA, Cannon CPCritical pathways in cardiologyAn annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5.Crit Pathw Cardiol2007-06-01T00:00:002007An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry.17954494Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, Newby LK, Ravkilde J, Tang WH, Christenson RH, Cannon CP, Storrow ABClinical chemistryNational Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007 Dec; 53(12):2086-96.Clin Chem2007-10-22T00:00:002007National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure.18215600McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CPAmerican heart journalEffect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J. 2008 Feb; 155(2):298-302.Am Heart J2008-02-01T00:00:002008Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.18324928Cannon CPJournal of internal medicineCombination therapy in the management of mixed dyslipidaemia. J Intern Med. 2008 Apr; 263(4):353-65.J Intern Med2008-04-01T00:00:002008Combination therapy in the management of mixed dyslipidaemia.18721504Steinberg BA, French WJ, Peterson E, Frederick PD, Cannon CPThe American journal of cardiologyIs coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction? Am J Cardiol. 2008 Sep 01; 102(5):513-7.Am J Cardiol2008-06-26T00:00:002008Is coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction?18779470Lewis WR, Peterson ED, Cannon CP, Super DM, LaBresh KA, Quealy K, Liang L, Fonarow GCArchives of internal medicineAn organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. Arch Intern Med. 2008 Sep 08; 168(16):1813-9.Arch Intern Med2008-09-08T00:00:002008An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program.Authorship 10684752Authorship 10677759Authorship 1067141429802475Lee S, Cannon CPCurrent cardiology reportsCombination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Curr Cardiol Rep. 2018 05 25; 20(7):55.Curr Cardiol Rep2018-05-25T00:00:002018Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.29779195Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, Letierce A, Bujas-Bobanovic M, Louie MJ, Colhoun HMDiabetes therapy : research, treatment and education of diabetes and related disordersEfficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Ther. 2018 Jun; 9(3):1317-1334.Diabetes Ther2018-05-19T00:00:002018Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.29798783Reynolds MR, Allison JS, Natale A, Weisberg IL, Ellenbogen KA, Richards M, Hsieh WH, Sutherland J, Cannon CPJACC. Clinical electrophysiologyA Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial. JACC Clin Electrophysiol. 2018 05; 4(5):580-588.JACC Clin Electrophysiol2017-12-20T00:00:002017A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.21167342Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MTAmerican heart journalRisk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011 Jan; 161(1):113-122.e2.Am Heart J2011-01-01T00:00:002011Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score.21194870Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin LJournal of the American College of CardiologyTicagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84.J Am Coll Cardiol2010-12-30T00:00:002010Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.21517644Cannon CP, Stecker ECThe American journal of managed careNew options for stroke prevention in atrial fibrillation. Am J Manag Care. 2010 11; 16(10 Suppl):S291-7.Am J Manag Care2010-11-01T00:00:002010New options for stroke prevention in atrial fibrillation.Authorship 104715112040337Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJAmerican heart journalCritical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J. 2002 May; 143(5):777-89.Am Heart J2002-05-01T00:00:002002Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program.Authorship 1069809329848776Jarolim P, White WB, Cannon CP, Gao Q, Morrow DADiabetes careSerial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. Diabetes Care. 2018 07; 41(7):1510-1515.Diabetes Care2018-05-30T00:00:002018Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.21804104Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin LEuropean heart journalCharacterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53.Eur Heart J2011-07-30T00:00:002011Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.21884017Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CPCardiovascular therapeuticsBlood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012 Dec; 30(6):342-50.Cardiovasc Ther2011-05-25T00:00:002011Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.Authorship 1074795Cannon CPOptimizing fibrinolytic therapy in acute myocardial infarctionOptimizing fibrinolytic therapy in acute myocardial infarction. 2000.2000-01-01T00:00:002000Optimizing fibrinolytic therapy in acute myocardial infarction14760314Gelfand EV, Cannon CPAmerican heart journalAntibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004 Feb; 147(2):202-9.Am Heart J2004-02-01T00:00:002004Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT.15007110Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AMThe New England journal of medicineIntensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 08; 350(15):1495-504.N Engl J Med2004-03-08T00:00:002004Intensive versus moderate lipid lowering with statins after acute coronary syndromes.Authorship 10717531629859968Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF, Steg PG, Held C, Himmelmann A, Mahaffey KW, Wallentin L, Cannon CPAmerican heart journalSafety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. Am Heart J. 2018 08; 202:54-60.Am Heart J2018-05-07T00:00:002018Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis.15231372Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Michael Gibson C, McCabe CH, Barron HV, Van De Werf F, Braunwald EEuropean heart journalThe Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.Eur Heart J2004-07-01T00:00:002004The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies.15289215Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald EAnnals of internal medicineThe effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 03; 141(3):186-95.Ann Intern Med2004-08-03T00:00:002004The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes.Kloner RA, Gibson CM, Cannon CP, Braunwald EN Engl J MedPreinfarction antina. N Engl J Med. 1996; 335:59-60.1996-01-01T00:00:001996Preinfarction antina16442899Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald EAmerican heart journalPredicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6.Am Heart J2006-02-01T00:00:002006Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.16473257Cannon CPClinical cornerstoneThe endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone. 2005; 7(2-3):17-26.Clin Cornerstone2005-01-01T00:00:002005The endocannabinoid system: a new approach to control cardiovascular disease.Gelfand CV, Cannon CPGelfand CV, Cannon CP, editors. Management of Acute Coronary SyndromesST-segment-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 79-121.2009-01-01T00:00:002009ST-segment-elevation myocardial infarctionEricsson CD, Cannon CP, Deutsch EUnstable angina: Diagnosis and managementUnstable angina: Diagnosis and management. 1998.1998-01-01T00:00:001998Unstable angina: Diagnosis and managementCannon CPCurr Pract MedAggrastat to treat unstable angina. Curr Pract Med. 1998; 1:55-58.1998-01-01T00:00:001998Aggrastat to treat unstable anginaCannon CPWhat is the difference between stable and unstable angina. Is it safe to fly when you have stable angina?What is the difference between stable and unstable angina. Is it safe to fly when you have stable angina?. 2008.2008-02-01T00:00:002008What is the difference between stable and unstable angina. Is it safe to fly when you have stable angina?Cannon CP, Ganz LI, Stone PHIrwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care MedicineComplicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000.2000-01-01T00:00:002000Complicated myocardial infarctionBoden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Pepine CJ, Ferry DR, Chow BK, Lavori PW, for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators (CP Cannon, Chairman, Endpoints Committee) N Engl J MedOutcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative strategy. N Engl J Med. 1998; 338:1785-92..1998-01-01T00:00:001998Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative strategyKaur A, Curtis S, Cannon CP, Griffin M, Connors LG, Laine LGastroenterologyPhysicians fail to provide protective co-therapy for high GI risk patients taking NSAIDS--even with direct interactive communication and free PPI: Results of a prospective outcomes trial. Gastroenterology. 2008.2008-01-01T00:00:002008Physicians fail to provide protective co-therapy for high GI risk patients taking NSAIDS--even with direct interactive communication and free PPI: Results of a prospective outcomes trial17452919Normand AN, Cannon CP, Lewis VO, Lin PP, Yasko AWClinical orthopaedics and related researchCurettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma. Clin Orthop Relat Res. 2007 Jun; 459:146-9.Clin Orthop Relat Res2007-06-01T00:00:002007Curettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma.17630410Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AHCirculationNational Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007 Jul 31; 116(5):e99-109.Circulation2007-07-14T00:00:002007National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure.17950785Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GCThe American journal of cardiologyMedical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol. 2007 Nov 01; 100(9):1331-5.Am J Cardiol2007-08-13T00:00:002007Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database.18048022Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RHClinical biochemistryNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem. 2008 Mar; 41(4-5):210-21.Clin Biochem2007-11-28T00:00:002007National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure.18222355Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald EJournal of the American College of CardiologyPolymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008 Jan 29; 51(4):449-55.J Am Coll Cardiol2008-01-29T00:00:002008Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.10575552Cannon CPCurrent problems in cardiologyDiagnosis and management of patients with unstable angina. Curr Probl Cardiol. 1999 Nov; 24(11):681-744.Curr Probl Cardiol1999-11-01T00:00:001999Diagnosis and management of patients with unstable angina.12529735Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RHThrombosis and haemostasisAcute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost. 2002 Dec; 88(6):892-7.Thromb Haemost2002-12-01T00:00:002002Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.Authorship 10725436Authorship 10740313Authorship 1073695929903515Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RPInternational journal of cardiologyThe nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.Int J Cardiol2018-05-26T00:00:002018The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.29891625Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald ECirculationResponse by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 06 12; 137(24):2662-2663.Circulation2018-06-12T00:00:002018Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".29909156Vardeny O, Udell JA, Joseph J, Farkouh ME, Hernandez AF, McGeer AJ, Talbot HK, Bhatt DL, Cannon CP, Goodman SG, Anand I, DeMets DL, Temte J, Wittes J, Nichol K, Yancy CW, Gaziano JM, Cooper LS, Kim K, Solomon SDAmerican heart journalHigh-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. Am Heart J. 2018 08; 202:97-103.Am Heart J2018-05-23T00:00:002018High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.20394040Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CPClinical cardiologyChanges in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol. 2010 Apr; 33(4):206-12.Clin Cardiol2010-04-01T00:00:002010Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.20558431Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald EEuropean heart journalPatients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005.Eur Heart J2010-06-17T00:00:002010Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.22615345Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GCCirculationTrends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 03; 126(1):65-75.Circulation2012-05-21T00:00:002012Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.Becker RC, Hebert J, Hurley T, Ma Y, Cannon CP, for the TIMI 5 Hemostasis and Thrombosis Study GroupJ Am Coll CardiolEarly PTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. J Am Coll Cardiol. 1996; 27(Suppl A):11-12.1996-01-01T00:00:001996Early PTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulationRose E, McCabe CH, Cairns R, Cannon CP, Braunwald EJ Am Coll CardiolDramatic benefit of intensive statin therapy in women: Results from PROVE IT - TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):12.2005-01-01T00:00:002005Dramatic benefit of intensive statin therapy in women: Results from PROVE IT - TIMI 22Sharis P, Cannon CP, McCabe CH, Charlesworth AJ Am Coll CardiolPrior aspirin use is a univariate, but NOT a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2000; 35(Suppl A):391.2000-01-01T00:00:002000Prior aspirin use is a univariate, but NOT a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16Ray KK, Cannon CP, Gibson CM, Cairns R, Kirtane AJ, McCabe CH, Braunwald EEur Heart JWhat are the future targets of therapy beyond intensive statin therapy? An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.2005-01-01T00:00:002005What are the future targets of therapy beyond intensive statin therapy? An analysis from PROVE IT-TIMI 22Storey RF, Harrington RA, Husted S, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Wickens M, Peters G, Emanuelsson H, Cannon CPJ Am Coll CardiolAZD6140 suppresses platelet aggregation in clopidogrel-treated patients even in those with high aggregation levels. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):208A.2007-03-06T00:00:002007AZD6140 suppresses platelet aggregation in clopidogrel-treated patients even in those with high aggregation levelsKwong RY, editorCannon CP, series editor. Contemporary CardiologyCardiovascular magnetic resonance imaging. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-01-01T00:00:002008Cardiovascular magnetic resonance imagingAhmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM, the TIMI Study GroupJ Am Coll CardiolImpact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. J Am Coll Cardiol. 2006; 47(4):159A.2006-02-21T00:00:002006Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28Cannon, CPThe Johns Hopkins distinguished author series for cardiology: Acute coronary syndromesThe Johns Hopkins distinguished author series for cardiology: Acute coronary syndromes. 2005.2005-12-01T00:00:002005The Johns Hopkins distinguished author series for cardiology: Acute coronary syndromesQuality of Care and Outcomes Research in CVD and Stroke Working Groups (Cannon CP, Member, Acute Myocardial Infarction Working Group)CirculationMeasuring and improving quality of care. A report for the AHA/ACC First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. Circulation. 2000; 101:1483-93.2000-01-01T00:00:002000Measuring and improving quality of care. A report for the AHA/ACC First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and StrokeCannon CPWhat symptoms are suggestive of heart disease?What symptoms are suggestive of heart disease?. 2008.2008-01-30T00:00:002008What symptoms are suggestive of heart disease?Giugliano RP, Cannon CPAntman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart DiseaseAntiplatelet therapy. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 601-54.2002-01-01T00:00:002002Antiplatelet therapyde Lemos JA, Cannon CPSirtori C, editor. Clinical PharmacologyAngina and coronary heart disease. Sirtori C, editor. Clinical Pharmacology. 2000; 269-85.2000-01-01T00:00:002000Angina and coronary heart diseaseWiviott SD, Cannon CP, Morrow DA, Scirica BM, McCabe CH, Braunwald EJ Am Coll CardiolElevations in creatine kinase (CK) with intensive statin treatment: a PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):413.2005-01-01T00:00:002005Elevations in creatine kinase (CK) with intensive statin treatment: a PROVE IT-TIMI 22 SubstudyCannon CP, Rizzo MJ, Antman EM, McCabe CH, Gibson CM, Braunwald EJ Am Coll CardiolValidation of a multivariate model for risk stratification in acute MI: Results from TIMI 9B. J Am Coll Cardiol. 1999; 33(Suppl A):396.1999-01-01T00:00:001999Validation of a multivariate model for risk stratification in acute MI: Results from TIMI 9BCannon CPImplications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: A comparison of TIMI IIIB and TACTICS-TIMI 18Implications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: A comparison of TIMI IIIB and TACTICS-TIMI 18. 2002.2002-01-01T00:00:002002Implications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: A comparison of TIMI IIIB and TACTICS-TIMI 18Steg PG, Dabbous O, Cohen-Solal A, Aumont M, Cannon CP, Lopez-Sendon J, Budaj A, Klein WJ Am Coll CardiolDeterminants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary events. J Am Coll Cardiol. 2002; 39:154A.2002-01-01T00:00:002002Determinants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary eventsThrombolysis in myocardial infarction (TIMI) 11A Trial InvestigatorsJ Am Coll CardiolDose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol. 1997; 29:1474-82..1997-01-01T00:00:001997Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11ACannon CPJ Respiratory DiseasesC-reactive protein: A marker for assessing and managing cardiac risk. J Respiratory Diseases. 2005; 26(7):290-4.2005-01-01T00:00:002005C-reactive protein: A marker for assessing and managing cardiac riskDeo R, Cannon CP, de Lemos JAEssential CardiologyRosendorf C, editor. ST segment elevation myocardial infarction. Essential Cardiology. 2005; 489-520.2005-01-01T00:00:002005Rosendorf C, editor. ST segment elevation myocardial infarctionCannon CPThrombolysis and medication errorsThrombolysis and medication errors. 1999.1999-01-01T00:00:001999Thrombolysis and medication errorsStone GW, Cannon CP, Chronos NA, Ferguson JJ, Gibson CM, King SB, Yeung ACTherapeutic strategies in acute coronary syndromes: An integrated approachTherapeutic strategies in acute coronary syndromes: An integrated approach. 2001.2001-01-01T00:00:002001Therapeutic strategies in acute coronary syndromes: An integrated approachCannon CPI recently had a heart attack treated with a stent. Can I drive my car?I recently had a heart attack treated with a stent. Can I drive my car?. 2008.2008-02-01T00:00:002008I recently had a heart attack treated with a stent. Can I drive my car?Truong QA, Singh JP, Hoffmann U, Cannon CPCase studiesCase studies. 2007.2007-10-01T00:00:002007Case studiesGibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, van de Werf F, Braunwald ECirculationIs the corrected TIMI frame count an independent predictor of adverse outcome?. Circulation. 2000; 102:e19.2000-01-01T00:00:002000Is the corrected TIMI frame count an independent predictor of adverse outcome?Mega JL, Cannon CP, Sabatine MSJACCInfluence of the Xbal polymorphism in the APOB gene on lipids, statin response, and recurrent cardiovascular events. JACC. 2008; 51(10):A331.2008-03-11T00:00:002008Influence of the Xbal polymorphism in the APOB gene on lipids, statin response, and recurrent cardiovascular eventsAuthorship 1171462Cannon CPPharmacology overview platelet glycoprotein IIb/IIIa inhibitorsPharmacology overview platelet glycoprotein IIb/IIIa inhibitors. 2000.2000-01-01T00:00:002000Pharmacology overview platelet glycoprotein IIb/IIIa inhibitorsMcLean DS, Cannon CPCritical Pathways Cardiol.The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Critical Pathways Cardiol. 2006; 5(2):103-13.2006-01-01T00:00:002006The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrelPride YB, Buros JL, Lord E, Harrigan CJ, Lew M, Abraham J, Murphy SA, Cannon CP, Sabatine MS, Gibson CMCirculationAngiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. Circulation. 2007; 116(16):II-352.2007-10-16T00:00:002007Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 daysCannon CP, Herrmann H, Ohman EM, Coussement PK, Moliterno DJ, Topol EJMedi-FaxBolus thrombolytics erduce medication errors. Medi-Fax. 1999.1999-01-01T00:00:001999Bolus thrombolytics erduce medication errorsCannon CP, O'Gara PTCannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine.Cardiac catheterization and percutaneous coronary intervention. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 155--9..2007-01-01T00:00:002007Cardiac catheterization and percutaneous coronary interventionCannon CP, O'Gara PTCannon CP, O'Gara PT, editors. Critical Pathways in CardiologyGoals, design and implementation of critical pathways in cardiology. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 3-6.2001-01-01T00:00:002001Goals, design and implementation of critical pathways in cardiologyBombardier C, Cannon CPPlacing the evidence in perspective: Cardiovascular and renal risks with pharmacologic therapy in osteoarthritisPlacing the evidence in perspective: Cardiovascular and renal risks with pharmacologic therapy in osteoarthritis. 2002.2002-01-01T00:00:002002Placing the evidence in perspective: Cardiovascular and renal risks with pharmacologic therapy in osteoarthritisCannon CP, Giugliano RPPfeffer MA, series editor. Cardiology Scientific UpdateTNK-tPA (tenecteplase): The single bolus thrombolytic agent for the new millenium. Pfeffer MA, series editor. Cardiology Scientific Update. 2000.2000-01-01T00:00:002000TNK-tPA (tenecteplase): The single bolus thrombolytic agent for the new milleniumWolfe ML, Shui A, Harris M, Cannon CP, Rader DJCirculationOn-treatment cholesteryl ester transfer protein mass and risk for MI in the PROVE-IT study. Circulation. 2006; 114(18):II-461.2006-01-01T00:00:002006On-treatment cholesteryl ester transfer protein mass and risk for MI in the PROVE-IT studyCannon CPWhat's hot in acute coronary syndromes?What's hot in acute coronary syndromes?. 2001.2001-01-01T00:00:002001What's hot in acute coronary syndromes?Weintraub WS, editorCannon CP, series editor. Contemporary CardiologyCardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2005; 436.2005-01-01T00:00:002005Cardiovascular health care economicsCannon CPCardiologyLogging in at Cardiosource 2.0. Cardiology. 2007; 36(7):18-9.2007-07-01T00:00:002007Logging in at Cardiosource 2.0Cannon CP, O'Gara PT, editorsCritical Pathways in CardiologyCritical Pathways in Cardiology. 2001; 259.2001-01-01T00:00:002001Critical Pathways in CardiologyStein RA, Oz MC, editorsCannon CP, series editor. Contemporary CardiologyComplementary and alternative cardiovascular medicine. Cannon CP, series editor. Contemporary Cardiology. 2004; 286.2004-01-01T00:00:002004Complementary and alternative cardiovascular medicine20946994Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald EJournal of the American College of CardiologyPrior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85.J Am Coll Cardiol2010-10-19T00:00:002010Prior aspirin use and outcomes in acute coronary syndromes.21404720Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez A, Peterson ED, Fonarow GCAmerican heart journalUse of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3.Am Heart J2011-02-01T00:00:002011Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG).22089271Stowell SA, Cannon CP, Hoekstra JW, Peterson ED, Miller SCCritical pathways in cardiologyTake heart: a one-on-one peer-based strategy to improve acute coronary syndrome patient care. Crit Pathw Cardiol. 2011 Dec; 10(4):164-8.Crit Pathw Cardiol2011-12-01T00:00:002011Take heart: a one-on-one peer-based strategy to improve acute coronary syndrome patient care.22110019Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DAClinical chemistryGalectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012 Jan; 58(1):267-73.Clin Chem2011-11-22T00:00:002011Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.Authorship 106275123130159Boyer NM, Laskey WK, Cox M, Hernandez AF, Peterson ED, Bhatt DL, Cannon CP, Fonarow GCJournal of the American Heart AssociationTrends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206.J Am Heart Assoc2012-08-24T00:00:002012Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program.Fuster V, Cannon CP, Ferguson J, Weber MOpening doors to new therapies: Clinical trials at AHAOpening doors to new therapies: Clinical trials at AHA. 2001.2001-01-01T00:00:002001Opening doors to new therapies: Clinical trials at AHACannon CP, Denard SJ, Ferguson J, Gibson CM, Harrington R, Peterson ED, Popma J, Roe M, Tcheng JEGP IIb/IIIa inhibitors: Examining the evidenceGP IIb/IIIa inhibitors: Examining the evidence. 2003.2003-01-01T00:00:002003GP IIb/IIIa inhibitors: Examining the evidence14739628Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EMJournal of thrombosis and thrombolysisDistance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96.J Thromb Thrombolysis2003-06-01T00:00:002003Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture.15173053Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa FCirculationThe clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Circulation. 2004 Jun 01; 109(21):e305-7.Circulation2004-06-01T00:00:002004The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.15277787Cannon CPJournal of thrombosis and thrombolysisUtilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease. J Thromb Thrombolysis. 2004 Feb; 17(1):45-9.J Thromb Thrombolysis2004-02-01T00:00:002004Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease.15566912Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, Gibson CMThe American journal of cardiologyAssociation of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.Am J Cardiol2004-12-01T00:00:002004Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction.17075010Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, Gibson CMCirculationHospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 07; 114(19):2019-25.Circulation2006-10-30T00:00:002006Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy.17292766Laine L, Curtis SP, Cryer B, Kaur A, Cannon CPLancet (London, England)Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10; 369(9560):465-73.Lancet2007-02-10T00:00:002007Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.17378975Ray KK, Cannon CPCurrent treatment options in cardiovascular medicineLipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. Curr Treat Options Cardiovasc Med. 2007 Feb; 9(1):46-51.Curr Treat Options Cardiovasc Med2007-02-01T00:00:002007Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes.Cannon CP, Braunwald ECannon CP, editor. Management of Acute Coronary SyndromesThe spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 3-18.1999-01-01T00:00:001999The spectrum of myocardial ischemia: The paradigm of acute coronary syndromesCoulter SA, McCabe CH, Giugliano RP, Cutler SS, Charlesworth A, Chew PH, Cannon CPCirculationDosing errors and outcomes in patients receiving single bolus compared to bolus + infusion thrombolytic regimens: An InTIME-II Study. Circulation. 1999; 100(Suppl I):791.1999-01-01T00:00:001999Dosing errors and outcomes in patients receiving single bolus compared to bolus + infusion thrombolytic regimens: An InTIME-II StudyCannon CPStatin use in acute coronary syndromes: The next step in cardiovascular protectionStatin use in acute coronary syndromes: The next step in cardiovascular protection. 2003.2003-01-01T00:00:002003Statin use in acute coronary syndromes: The next step in cardiovascular protectionCannon CPA 1999 approach to unstable anginaA 1999 approach to unstable angina. 2000.2000-01-01T00:00:002000A 1999 approach to unstable anginaHarkness JR, Scirica BM, Sabatine MS, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Cannon CP, Braunwald EJACCExtent of ST segment resolution after fibrinolysis adds dynamic risk stratification to the TIMI rick score for STEMI. JACC. 2008; 51(10):A221.2008-03-11T00:00:002008Extent of ST segment resolution after fibrinolysis adds dynamic risk stratification to the TIMI rick score for STEMIFoody JM, editorCannon CP, series editor. Contemporary Cardiology.Preventive Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2006.2006-01-01T00:00:002006Preventive CardiologyCannon CPMeeting today's treatment goals in lipid loweringMeeting today's treatment goals in lipid lowering. 2005.2005-01-01T00:00:002005Meeting today's treatment goals in lipid lowering17917707Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DAJournal of thrombosis and thrombolysisLack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84.J Thromb Thrombolysis2007-10-05T00:00:002007Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.18187215Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CMInternational journal of cardiologyThe independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.Int J Cardiol2008-01-09T00:00:002008The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.18237589Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CMThe American journal of cardiologyAssociation of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol. 2008 Feb 01; 101(3):303-7.Am J Cardiol2007-12-20T00:00:002007Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study).18378613Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RTCirculationComplementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15; 117(15):1936-44.Circulation2008-03-31T00:00:002008Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.19174782Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CPThe American journal of gastroenterologyHow common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb; 104(2):356-62.Am J Gastroenterol2009-01-27T00:00:002009How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.19637098Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S, Armstrong MPlateletsTicagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009 Aug; 20(5):341-8.Platelets2009-08-01T00:00:002009Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.Authorship 1097086Authorship 1079995430012326Rosenson RS, Hegele RA, Fazio S, Cannon CPJournal of the American College of CardiologyThe Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018 07 17; 72(3):314-329.J Am Coll Cardiol2018-07-09T00:00:002018The Evolving Future of PCSK9 Inhibitors.21709065Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin LCirculationTicagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54.Circulation2011-06-27T00:00:002011Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.Authorship 112256716728216Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, Gibson CM, Cannon CP, Braunwald EThe American journal of cardiologyAssociation between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006 Jun 01; 97(11):1573-7.Am J Cardiol2006-04-04T00:00:002006Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial.17113426Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine LLancet (London, England)Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18; 368(9549):1771-81.Lancet2006-11-18T00:00:002006Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.17917618Cannon CPReviews in cardiovascular medicineClopidogrel: who, when, and how? Rev Cardiovasc Med. 2007; 8 Suppl 3:S27-34.Rev Cardiovasc Med2007-01-01T00:00:002007Clopidogrel: who, when, and how?17948363Cannon CPClinical cornerstoneHigh-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007; 8 Suppl 6:S14-23.Clin Cornerstone2007-01-01T00:00:002007High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.18279736Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald EJournal of the American College of CardiologyImpact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008 Feb 19; 51(7):724-30.J Am Coll Cardiol2008-02-19T00:00:002008Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.18481815Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyAntiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.Clin Cardiol2008-03-01T00:00:002008Antiplatelet therapy and platelet function testing. Introduction.22182956Kohli P, Cannon CPNature reviews. CardiologyAcute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol. 2011 Dec 20; 9(2):69-71.Nat Rev Cardiol2011-12-20T00:00:002011Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.22497674Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumenthal RSThe American journal of cardiologyWaiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012 Jul 15; 110(2):307-13.Am J Cardiol2012-04-10T00:00:002012Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations.22674150Joshi PH, Chaudhari S, Blaha MJ, Jones SR, Martin SS, Post WS, Cannon CP, Fonarow GC, Wong ND, Amsterdam E, Hirshfeld JW, Blumenthal RSClinical cardiologyA point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology. Clin Cardiol. 2012; 35(7):404-9.Clin Cardiol2012-06-06T00:00:002012A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology.Cannon CPWhat other symptoms besides angina can signal a heart attack?What other symptoms besides angina can signal a heart attack?. 2008.2008-01-31T00:00:002008What other symptoms besides angina can signal a heart attack?Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical IssuesNon-ST-Segment Elevation ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007.2007-01-01T00:00:002007Non-ST-Segment Elevation ACSAkoum FH, Boxer R, Cannon CP, Pina IL, Scirica BMImproving management of high-risk cardiovascular patientsImproving management of high-risk cardiovascular patients. 2006.2006-07-17T00:00:002006Improving management of high-risk cardiovascular patientsForman DE, Cannon CP, Albert NM, Fonarow GC, Yancy CW, Liang L, Hernandez AF, JACCAre guideline recommended therapies being applied to elderly patients hospitalized with heart failure?. JACC. 2008; 51(10):A239.2008-03-11T00:00:002008Are guideline recommended therapies being applied to elderly patients hospitalized with heart failure?Topol EJ, Cannon CP, Van de Werf F, Ferguson JJ, Califf RMAcute coronary syndromes: The 360 degree viewAcute coronary syndromes: The 360 degree view. 2001.2001-01-01T00:00:002001Acute coronary syndromes: The 360 degree viewCannon CPCardiovasc Fellows ForumParticipating in clinical trials after fellowship ends. Cardiovasc Fellows Forum. 2001; 2:12-3.2001-01-01T00:00:002001Participating in clinical trials after fellowship endsCannon CP, Stone PHCarruthers SG, Hoffman BB, Melmon KL, Nierenberg, DW, editors. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in TherapeuticsAcute myocardial infarction. Carruthers SG, Hoffman BB, Melmon KL, Nierenberg, DW, editors. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. 2000; 131-56.2000-01-01T00:00:002000Acute myocardial infarctionCannon CP, O'Gara PTCannon CP, O'Gara PT, editors. Critical Pathways in CardiologyCritical pathway for unstable angina. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 131-41.2001-01-01T00:00:002001Critical pathway for unstable anginaAuthorship 1197683Quinn M, Fitzgerald G, editorsCannon CP, series editor. Contemporary CardiologyPlatelet function. Cannon CP, series editor. Contemporary Cardiology. 2005; 397.2005-01-01T00:00:002005Platelet functionFuster V, Cannon CP, Ferguson J, Weber MConfirming knowledgeConfirming knowledge. 2003.2003-01-01T00:00:002003Confirming knowledgeCannon CPEfficacy of percutaneous coronary intervention after thrombolysis for acute ST elevation (Q wave) myocardial infarctionEfficacy of percutaneous coronary intervention after thrombolysis for acute ST elevation (Q wave) myocardial infarction. 2002.2002-01-01T00:00:002002Efficacy of percutaneous coronary intervention after thrombolysis for acute ST elevation (Q wave) myocardial infarctionSabatine MS, Morrow DA, Jiang S, Rifai N, Cannon CP, Gerszten RECirculationElevated levels of the atherosclerotic lesion metalloproteinase PAPPA are an independent predictor of cardiovascular death of CHF in STEMI: Results from the CLARITY-TIMI 28 biomarker study. Circulation. 2007; 116(16):II-363.2007-10-16T00:00:002007Elevated levels of the atherosclerotic lesion metalloproteinase PAPPA are an independent predictor of cardiovascular death of CHF in STEMI: Results from the CLARITY-TIMI 28 biomarker studyScirica BM, Sabatine MS, Cannon CP, McCabe CH, Braunwald E, Stone PHJ Am Coll CardiolClopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY - TIMI 28. J Am Coll Cardiol. 2006; 47(4):213A.2006-02-21T00:00:002006Clopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY - TIMI 28Cannon CPMedical RoundtableBolus thrombolysis: r-PA, t-PA, n-PA. Medical Roundtable. 1998; 4-5.1998-05-01T00:00:001998Bolus thrombolysis: r-PA, t-PA, n-PACannon CPCardiac Surgery: State of the Art Reviews.Pharmacology of anticoagulation. Cardiac Surgery: State of the Art Reviews. 1993; 1-20.1993-01-01T00:00:001993Pharmacology of anticoagulationCannon CP, Weintraub WS, Demopoulos L, DiBattiste P, Robertson DH, DeLucca PT, McCabe CH, Antman EM, Braunwald E, for the TACTICS-TIMI 18 InvestigatorsJ Am Coll CardiolTIMI risk score to predict 6 month mortality, recurrent cardiac events, and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Results from TACTICS-TIMI 18. J Am Coll Cardiol. 2001; 37(Suppl A):335.2001-01-01T00:00:002001TIMI risk score to predict 6 month mortality, recurrent cardiac events, and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Results from TACTICS-TIMI 188018004Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CPArchives of internal medicineUse of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction. Arch Intern Med. 1994 Jul 11; 154(13):1492-6.Arch Intern Med1994-07-11T00:00:001994Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction.8637553Kloner RA, Gibson M, Cannon C, Braunwald EThe New England journal of medicinePreinfarction angina. N Engl J Med. 1996 Jul 04; 335(1):59-60; author reply 60-1.N Engl J Med1996-07-04T00:00:001996Preinfarction angina.The TIMI IIIB InvestigatorsCirculationEffects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. Circulation. 1994; 89:1545-56..1994-01-01T00:00:001994Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB TrialAmbardekar AV, Pan W, Peterson SL, Fonarow GC, Webb LE, Hernandez AF, Cannon CP, Peterson ED, Krantz MJScientific Meeting Heart Failure Society of AmericaFeatures and hospital outcomes for nonadherent patients with heart failure: Findings from GWTG-HF. Scientific Meeting Heart Failure Society of America. 2008.2008-09-21T00:00:002008Features and hospital outcomes for nonadherent patients with heart failure: Findings from GWTG-HFDuckers HJ, Nabel EG, Serruys PW, editorsCannon CP, series editor. Contemporary Cardiology.Essentials of Restenosis for the interventional cardiologist. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Essentials of Restenosis for the interventional cardiologistRoe MT, Cannon CP, Chen AY, Rao SV, Rumsfield JS, Klein LW, Ohman EM, Gibler WB, Peterson EDJACCDecline in the use of drug-eluting stents for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Results from the CRUSADE and ACTION Registries. JACC. 2008; 51(10):A211.2008-03-11T00:00:002008Decline in the use of drug-eluting stents for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Results from the CRUSADE and ACTION RegistriesWackers F J Th, Bruni W, Zaret BLCannon CP, series editor. Contemporary CardiologyNuclear cardiology: The basics. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-01-01T00:00:002008Nuclear cardiology: The basicsCannon CP, O'Gara P, editors. Critical Pathways In Cardiovascular Medicine. Cannon CP, O'Gara P, editors. Critical Pathways In Cardiovascular Medicine. 2007.2007-01-01T00:00:002007Cannon CP, O'Gara P, editors. Critical Pathways In Cardiovascular MedicineMahoney EM, Jurkovitz C, Chu H, Alexander C, Demopoulos L, DiBattiste P, Robertson D, Cannon C, Weintraub WSEur Heart JLength of stay for the treatment of acute coronary syndromes: international experience from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):223.2001-01-01T00:00:002001Length of stay for the treatment of acute coronary syndromes: international experience from the TACTICS-TIMI 18 trialCannon CPACS: Tiroban study shows routine catheterization bestACS: Tiroban study shows routine catheterization best. 2001.2001-01-01T00:00:002001ACS: Tiroban study shows routine catheterization bestCannon CP, Granger CB, Armstrong PW, Roe MImplementing a critical pathway based on the ACC/AHA guidelinesImplementing a critical pathway based on the ACC/AHA guidelines. 2002.2002-01-01T00:00:002002Implementing a critical pathway based on the ACC/AHA guidelinesMehta RH, Montoye CK, Gallogly M, Baker P, Lount A, Faul J, Roychoudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E, Lalonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sabotka P, Winston S, Roiba AA, Eagle KA, on behalf of the GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member)JAMAImproving quality of care of acute myocardial infarction: The guideline applied in practice (GAP) initiative in Southeast Michigan. JAMA. 2002; 287:1269-1276..2002-01-01T00:00:002002Improving quality of care of acute myocardial infarction: The guideline applied in practice (GAP) initiative in Southeast MichiganTopol EJ, Cannon CP, Moliterno DLatest clinical updates: Long-term outcome following contemporary PCILatest clinical updates: Long-term outcome following contemporary PCI. 2001.2001-01-01T00:00:002001Latest clinical updates: Long-term outcome following contemporary PCICannon CP, Braunwald ECannon CP, editor. Contemporary Cardiology: Management of Acute Coronary SyndromesThe spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 3-18.2003-01-01T00:00:002003The spectrum of myocardial ischemia: The paradigm of acute coronary syndromesAntman EM, McCabe CH, Cannon CP, Barbash GI, Mueller HS, Gallo PCirculationPrevention of Q-wave development with thrombolytic therapy does not predict better short-term prognosis. Circulation. 1996; 94(Suppl I):381.1996-01-01T00:00:001996Prevention of Q-wave development with thrombolytic therapy does not predict better short-term prognosis18340140Moyer P, Feldman J, Levine J, Beshansky J, Selker HP, Barnewolt B, Brown DF, Cardoza JP, Grossman SA, Jacobs A, Kerman BJ, Kimmelstiel C, Larson R, Losordo D, Pearlmutter M, Pozner C, Ramirez A, Rosenfield K, Ryan TJ, Zane RD, Cannon CPCritical pathways in cardiologyImplications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience. Crit Pathw Cardiol. 2004 Jun; 3(2):53-61.Crit Pathw Cardiol2004-06-01T00:00:002004Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience.18340145Cannon CPCritical pathways in cardiologyRisk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy. Crit Pathw Cardiol. 2004 Jun; 3(2):83-6.Crit Pathw Cardiol2004-06-01T00:00:002004Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy.Authorship 113250119464411Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GCAmerican heart journalInfluence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). Am Heart J. 2009 Jun; 157(6):1010-7.Am Heart J2009-04-25T00:00:002009Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF).8279357Braunwald E, Cannon CP, McCabe CHThe American journal of cardiologyUse of composite endpoints in thrombolysis trials of acute myocardial infarction. Am J Cardiol. 1993 Dec 16; 72(19):3G-12G.Am J Cardiol1993-12-16T00:00:001993Use of composite endpoints in thrombolysis trials of acute myocardial infarction.2541617Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, al-Awqati QThe American journal of physiologyIsolation and culture of HCO3- -secreting intercalated cells. Am J Physiol. 1989 May; 256(5 Pt 1):C1004-11.Am J Physiol1989-05-01T00:00:001989Isolation and culture of HCO3- -secreting intercalated cells.18594042O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MSJAMAEarly invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 02; 300(1):71-80.JAMA2008-07-02T00:00:002008Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.8604620Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, Randall AM, Knatternud G, Braunwald EAmerican heart journalRelation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J. 1996 Mar; 131(3):421-33.Am Heart J1996-03-01T00:00:001996Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.18722187Cannon CP, Greenberg BHThe American journal of cardiologyRisk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol. 2008 Sep 08; 102(5A):13G-20G.Am J Cardiol2008-09-08T00:00:002008Risk stratification and prognostic factors in the post-myocardial infarction patient.19417637Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DLCritical pathways in cardiologyCardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7.Crit Pathw Cardiol2009-06-01T00:00:002009Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry.19898284Cannon CP, Waheed SReviews in cardiovascular medicineEvaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines. Rev Cardiovasc Med. 2009; 10 Suppl 1:S21-9.Rev Cardiovasc Med2009-01-01T00:00:002009Evaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines.20955443Laine L, Curtis SP, Cryer B, Kaur A, Cannon CPAlimentary pharmacology & therapeuticsRisk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov; 32(10):1240-8.Aliment Pharmacol Ther2010-09-23T00:00:002010Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.Authorship 1248492Dracup KA, Cannon CPCrit Care NurCombination treatment strategies for management of acute myocardial infarction: New directions with current therapies. Crit Care Nur. 1999; Suppl:3-15.1999-04-01T00:00:001999Combination treatment strategies for management of acute myocardial infarction: New directions with current therapiesCannon CP, Schwartz SISPORCost-effectiveness of intensive therapy compared to moderate statin therapy in patients with acute coronary syndrome: Analysis from Canada, Germany and the UK. ISPOR. 2006.2006-01-01T00:00:002006Cost-effectiveness of intensive therapy compared to moderate statin therapy in patients with acute coronary syndrome: Analysis from Canada, Germany and the UKCannon CPNew Era of ReperfusionExpanding the treatment paradigm for acute myocardial infarction with GP IIb/IIIa inhibitors. New Era of Reperfusion. 1999; 3:1-12.1999-01-01T00:00:001999Expanding the treatment paradigm for acute myocardial infarction with GP IIb/IIIa inhibitorsBhadriraju S, Defranco AC, Barber K, Murphy S, Gibson CM, DiBattiste P, Cannon CPJ Am Coll CardiolMajor bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-ST elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI 18. J Am Coll Cardiol. 2003; 41:374A.2003-01-01T00:00:002003Major bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-ST elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI 18Krum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CPJACCDifferential effect of baseline antihypertensive medications on blood pressure changes in patients with osteoarthritis long-term (MEDAL) study: A multivariate analysis. JACC. 2008; 51(10):A380.2008-03-11T00:00:002008Differential effect of baseline antihypertensive medications on blood pressure changes in patients with osteoarthritis long-term (MEDAL) study: A multivariate analysisCannon CPThe success and failure of glycoprotein IIb/IIIa receptor blockersThe success and failure of glycoprotein IIb/IIIa receptor blockers. 2000.2000-01-01T00:00:002000The success and failure of glycoprotein IIb/IIIa receptor blockersBrikakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, banerjee S, Blazing MA, Califf RM, Braunwald ECirculationOutcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting. Results from the Pravastatin or Atorvastatin evaluation and infection therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. Circulation. 2007; 116(16):II-314.2007-10-16T00:00:002007Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting. Results from the Pravastatin or Atorvastatin evaluation and infection therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trialsCannon CPAntithrombotic therapy within three months of acute coronary syndromesAntithrombotic therapy within three months of acute coronary syndromes. 2001.2001-01-01T00:00:002001Antithrombotic therapy within three months of acute coronary syndromesHarrington R, Ferguson J, Tcheng JE, Cannon CP, Denardo S, Gibson CM, Peterson EInterventionalInterventional. 2003.2003-01-01T00:00:002003InterventionalCannon CPNews in ACS from AHANews in ACS from AHA. 2002.2002-01-01T00:00:002002News in ACS from AHACannon CPACC 2004 PROVE ITACC 2004 PROVE IT. 2004.2004-01-01T00:00:002004ACC 2004 PROVE ITKumar A, Cannon CPMehta S, editor. Textbook of STEMI InterventionsThe Role of Thrombolysis in the Era of STEMI Interventions. Mehta S, editor. Textbook of STEMI Interventions. 2008.2008-01-01T00:00:002008The Role of Thrombolysis in the Era of STEMI InterventionsCannon CPAngioplasty for Sir Paul? Docs say possibleAngioplasty for Sir Paul? Docs say possible. 2008.2008-01-02T00:00:002008Angioplasty for Sir Paul? Docs say possibleRay KK, Cannon CPCefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk.Traditional metabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 69-86..2007-01-01T00:00:002007Traditional metabolic risk factorsCannon CPAcute coronary syndrome: A new paradigm for emergency managementAcute coronary syndrome: A new paradigm for emergency management. 2002.2002-01-01T00:00:002002Acute coronary syndrome: A new paradigm for emergency managementRidker PM, Cannon CP, Pasternak R, Sacks F"How low can you go? Pearls from the pros.""How low can you go? Pearls from the pros.". 2004.2004-01-01T00:00:002004"How low can you go? Pearls from the pros."Cannon CPI have angina. Is it safe for me to drive my car?I have angina. Is it safe for me to drive my car?. 2008.2008-01-31T00:00:002008I have angina. Is it safe for me to drive my car?Cannon CPPfeffer MA, series editor. Cardiology Scientific UpdateLate-breaking trial of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: ESPRIT, PARAGON B, and Second Symphony Series. Pfeffer MA, series editor. Cardiology Scientific Update. 2000.2000-01-01T00:00:002000Late-breaking trial of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: ESPRIT, PARAGON B, and Second Symphony SeriesMurphy S, Guigliano RP, Wong G, Cannon CP, Antman E, Gibson CMJ Am Coll CardiolComparison of frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudy. J Am Coll Cardiol. 2002; 39:279A.2002-01-01T00:00:002002Comparison of frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudyWang T, Hernandez A, Fonarow G, Liang L, Ellrodt G, Cannon CP, Peterson EQCORConsistency of acute myocardial infarction (AMI) hospital quality performance improvement with efforts to improve door to balloon times. QCOR. 2008.2008-01-01T00:00:002008Consistency of acute myocardial infarction (AMI) hospital quality performance improvement with efforts to improve door to balloon timesSharis PJ, Cannon CPEvidence-based CardiologyEvidence-based Cardiology. 2003; 370.2003-01-01T00:00:002003Evidence-based CardiologyCannon CPLincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in Cardiovascular MedicinePlatelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in Cardiovascular Medicine. 2003; 263-73.2003-01-01T00:00:002003Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategyLaine L, Curtis SP, Cryer B, Zhang Y, Cannon CPEur League Against RheumRisk factors for NSAID-associated upper GI clinical events in a long-term double-blind study of 34, 701 arthritis patients. Eur League Against Rheum. 2007.2007-01-01T00:00:002007Risk factors for NSAID-associated upper GI clinical events in a long-term double-blind study of 34, 701 arthritis patientsAuthorship 1091122830180960Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovec AM, Roe MT, Blazing MAThe American journal of cardiologyNatural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. Am J Cardiol. 2018 11 01; 122(9):1451-1458.Am J Cardiol2018-08-04T00:00:002018Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.7805217Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CPCirculationPrevious angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995 Jan 01; 91(1):37-45.Circulation1995-01-01T00:00:001995Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?8456753Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald EThe American journal of cardiologyAnticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993 Apr 01; 71(10):778-82.Am J Cardiol1993-04-01T00:00:001993Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.Authorship 11981038598078Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald ECirculationTIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar 01; 93(5):879-88.Circulation1996-03-01T00:00:001996TIMI frame count: a quantitative method of assessing coronary artery flow.22261200Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin LCirculationAssociation of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86.Circulation2012-01-18T00:00:002012Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.18340127Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MACritical pathways in cardiologyRole of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Crit Pathw Cardiol. 2003 Dec; 2(4):239-46.Crit Pathw Cardiol2003-12-01T00:00:002003Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.18340294Bahit MC, Murphy SA, Gibson CM, Cannon CPCritical pathways in cardiologyCritical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry. Crit Pathw Cardiol. 2002 Jun; 1(2):107-12.Crit Pathw Cardiol2002-06-01T00:00:002002Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry.18452839Cannon CPClinical cornerstoneCardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007; 8(3):11-28.Clin Cornerstone2007-01-01T00:00:002007Cardiovascular disease and modifiable cardiometabolic risk factors.19339264Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MTEuropean heart journalPrior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.Eur Heart J2009-04-01T00:00:002009Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.20031902Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, Pan W, Fonarow GCCirculation. Cardiovascular quality and outcomesTrends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):633-41.Circ Cardiovasc Qual Outcomes2009-10-27T00:00:002009Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.20065168Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SDCirculationUse of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26; 121(3):357-65.Circulation2010-01-11T00:00:002010Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.20569716Vidovich MI, Vasaiwala S, Cannon CP, Peterson ED, Dai D, Hernandez AF, Fonarow GCAmerican heart journalAssociation of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program. Am Heart J. 2010 Jun; 159(6):1026-36.Am Heart J2010-06-01T00:00:002010Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program.20700096Kumar A, Cannon CPReviews in cardiovascular medicineNews and views from the literature. Antiplatelet therapy. Ticagrelor in acute coronary syndrome: a new frontier in platelet inhibition. Rev Cardiovasc Med. 2010; 11(2):117-20.Rev Cardiovasc Med2010-01-01T00:00:002010News and views from the literature. Antiplatelet therapy. Ticagrelor in acute coronary syndrome: a new frontier in platelet inhibition.Authorship 1094324830239711Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RPEuropean heart journalModes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.Eur Heart J2018-11-07T00:00:002018Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.21228357Vaughan-Shaw PG, Cannon CPhlebologyVenous thromboembolism prevention in medical patients: a framework for improving practice. Phlebology. 2011 Mar; 26(2):62-8.Phlebology2011-01-12T00:00:002011Venous thromboembolism prevention in medical patients: a framework for improving practice.21420059Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SDThe American journal of cardiologyEffect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6.Am J Cardiol2011-03-21T00:00:002011Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry).21517641Cannon CPThe American journal of managed careAn overview of stroke and the impact of atrial fibrillation. Am J Manag Care. 2010 Nov; 16(10 Suppl):S273-7.Am J Manag Care2010-11-01T00:00:002010An overview of stroke and the impact of atrial fibrillation.22991347Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin LCirculation. Cardiovascular quality and outcomesTicagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):680-8.Circ Cardiovasc Qual Outcomes2012-09-01T00:00:002012Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.Cannon CPNew approaches to the prevention on atherothrombotic events in patients with vascular diseaseNew approaches to the prevention on atherothrombotic events in patients with vascular disease. 2002.2002-01-01T00:00:002002New approaches to the prevention on atherothrombotic events in patients with vascular diseaseLincoff AM, editorCannon CP, series editor. Contemporary CardiologyPlatelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2003; 476.2003-01-01T00:00:002003Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease23573652Fonarow G, Cannon C, Epstein AThe Journal of invasive cardiologyQuestions and answers. J Invasive Cardiol. 2004 Sep; 16 Suppl E:16E-17E.J Invasive Cardiol2004-09-01T00:00:002004Questions and answers.Simon DI, Rogers C, editorsCannon CP, series editor. Contemporary CardiologyVascular disease and injury: Preclinical research. Cannon CP, series editor. Contemporary Cardiology. 2001; 347.2001-01-01T00:00:002001Vascular disease and injury: Preclinical researchHusted S, Cannon CPClinical guide to the use of antithrombotic drugs in coronary artery diseaseDirect oral P2Y12 inhibition: AZD6140 (Ticagrelor). Clinical guide to the use of antithrombotic drugs in coronary artery disease. 2008; 85-97.2008-01-01T00:00:002008Direct oral P2Y12 inhibition: AZD6140 (Ticagrelor)Cannon CPOptimizing care of the post-myocardial infarction low-ef patientOptimizing care of the post-myocardial infarction low-ef patient. 2003.2003-01-01T00:00:002003Optimizing care of the post-myocardial infarction low-ef patientWackers FJT, Bruni W, Zaret BLCannon CP, series editor. Contemporary CardiologyNuclear cardiology, The basics: How to set up and maintain a laboratory. Cannon CP, series editor. Contemporary Cardiology. 2004; 293.2004-01-01T00:00:002004Nuclear cardiology, The basics: How to set up and maintain a laboratoryCannon CP.Early invasive vs conservative strategies in non-ST-elevation acute coronary syndromes: What has been learned from recent trials?Early invasive vs conservative strategies in non-ST-elevation acute coronary syndromes: What has been learned from recent trials?. 2005.2005-08-01T00:00:002005Early invasive vs conservative strategies in non-ST-elevation acute coronary syndromes: What has been learned from recent trials?Cannon CP, Feske SKTen-year survival after first-ever stroke in the perth community stroke studyTen-year survival after first-ever stroke in the perth community stroke study. 2004.2004-01-01T00:00:002004Ten-year survival after first-ever stroke in the perth community stroke studyMoliterno DJ, Aguirre FV, Cannon CP, Every NR, Granger CB, Sapp SK, Booth JE, Ferguson JJ, forthe GUARANTEE InvestigatorsCirculationThe global unstable angina registry and treatment evaluation (GUARANTEE) study. Circulation. 1996; 94(Suppl I):195.1996-01-01T00:00:001996The global unstable angina registry and treatment evaluation (GUARANTEE) studySolomon SDCannon CP, series editor. Contemporary CardiologyEssential Echocardiography. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Essential EchocardiographyCannon CPNew thrombolytic and antithrombotic approaches: TNK, hirudin, low molecular weight heparinNew thrombolytic and antithrombotic approaches: TNK, hirudin, low molecular weight heparin. 1996.1996-01-01T00:00:001996New thrombolytic and antithrombotic approaches: TNK, hirudin, low molecular weight heparinJordan M, Dotani MI, Dumaine R, Wong G, Aroesty JM, Cannon CP, McCabe C, Braunwald E, Gibson CMCirculationAssociation of multivessel disease, inflammatory markers and impaired tissue level perfusion in the setting of acute coronary syndromes: A TACTICS-TIMI 18 substudy. Circulation. 2003; 108(Suppl I):2157.2003-01-01T00:00:002003Association of multivessel disease, inflammatory markers and impaired tissue level perfusion in the setting of acute coronary syndromes: A TACTICS-TIMI 18 substudyWong SA, Kraimer N, Pai R, James D, Murphy SA, Cannon CP, Gibson CM for the TACTICS-TIMI 18 Study GroupCirculationElevations in Troponin T are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 Substudy. Circulation. 2002; 106:202-7..2002-01-01T00:00:002002Elevations in Troponin T are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 SubstudyFuster V, Cannon CP, Ferguson J, Weber MAspirin, ICDs, and MRAAspirin, ICDs, and MRA. 2002.2002-01-01T00:00:002002Aspirin, ICDs, and MRACannon C, Van Adelsberg J, Kelly S, Al-Awqati QNatureCarbon dioxide-induced exocytotic insertion of H+ pumps in the turtle-bladder membrane: Role of cell pH and cell calcium. Nature. 1985; 314:443-6..1985-01-01T00:00:001985Carbon dioxide-induced exocytotic insertion of H+ pumps in the turtle-bladder membrane: Role of cell pH and cell calciumCannon CPC-reactive ProteinC-reactive Protein. 2005.2005-01-01T00:00:002005C-reactive ProteinSharis PJ, Cannon DP, editorsEvidence-based CardiologyEvidence-based Cardiology. 2000; 368.2000-01-01T00:00:002000Evidence-based CardiologyGibson CM, Murphy S, Cannon C, Braunwald EEur Heart JBalloon size in percutaneous intervention is associated with abnormal myocardial perfusion: A TACTICS-TIMI 18 angiographic substudy. Eur Heart J. 2001; 22(Suppl):285.2001-01-01T00:00:002001Balloon size in percutaneous intervention is associated with abnormal myocardial perfusion: A TACTICS-TIMI 18 angiographic substudyWiviott SD, Cannon CP, Ray KK, Murphy S, Darius H, Castaigne A, Velasco JA, McCabe CH, Gibson CMJ Am Coll CardiolSeasonal variations in lipid values in patients following acs: PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):394.2005-01-01T00:00:002005Seasonal variations in lipid values in patients following acs: PROVE IT-TIMI 22Braunwald E, Cannon CPThrombolytic Therapy: New Standards of Care. Califf RM, editor.Predictive survival markers as surrogate end points in thrombolytic trials of acute myocardial infarction. Thrombolytic Therapy: New Standards of Care. Califf RM, editor. 1997; 3-10.1997-01-01T00:00:001997Predictive survival markers as surrogate end points in thrombolytic trials of acute myocardial infarctionDeedwania PC, Fonarow GC, Cannon CP, Dai DCirculationAre contemporary patients hospitalized with acute coronary syndrome being discharged on intensive lipid lowering therapy?: An analysis of 22,807 hospitalizations in GWTG-CAD. Circulation. 2007; 116(16):II-315.2007-10-16T00:00:002007Are contemporary patients hospitalized with acute coronary syndrome being discharged on intensive lipid lowering therapy?: An analysis of 22,807 hospitalizations in GWTG-CADAuthorship 1096602130290289Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SGAmerican heart journalDesign and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018 12; 206:11-23.Am Heart J2018-09-05T00:00:002018Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).15789175Ray KK, Cannon CPJournal of thrombosis and thrombolysisPathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis. 2004 Oct; 18(2):89-101.J Thromb Thrombolysis2004-10-01T00:00:002004Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation.15876006Cannon CPPharmacoEconomicsCost-effectiveness of clopidogrel. Pharmacoeconomics. 2004; 22 Suppl 4:1-3.Pharmacoeconomics2004-01-01T00:00:002004Cost-effectiveness of clopidogrel.15893181Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald EJournal of the American College of CardiologyRelative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17; 45(10):1644-8.J Am Coll Cardiol2005-04-25T00:00:002005Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.16143698Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald EJAMAEffect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224-32.JAMA2005-09-04T00:00:002005Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.16287961Cannon CPJAMAThe IDEAL cholesterol: lower is better. JAMA. 2005 Nov 16; 294(19):2492-4.JAMA2005-11-16T00:00:002005The IDEAL cholesterol: lower is better.17036354Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PWCancerComplications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006 Nov 15; 107(10):2455-61.Cancer2006-11-15T00:00:002006Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas.Ray KK, Cannon CP, Morrow DA, Cairns R, Braunwald EEur Heart JPercutaneous intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.2005-01-01T00:00:002005Percutaneous intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT-TIMI 22Cannon CPLewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment ProgramUnstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.2002-01-01T00:00:002002Unstable angina: Medical treatmentCannon CPQuality of care in atherothrombosis: From acute to long-term careQuality of care in atherothrombosis: From acute to long-term care. 2003.2003-01-01T00:00:002003Quality of care in atherothrombosis: From acute to long-term carePiazza G, Cannon CPCefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk.Clinical outcomes of patients with cardiometabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 105-136..2007-01-01T00:00:002007Clinical outcomes of patients with cardiometabolic risk factorsCannon CPI have been taking one of the statins. I heard that other brands of statins may be betters. Is this true?I have been taking one of the statins. I heard that other brands of statins may be betters. Is this true?. 2008.2008-01-31T00:00:002008I have been taking one of the statins. I heard that other brands of statins may be betters. Is this true?Cannon CPOral platelet glycoprotein IIb/IIIa receptor inhibitors: Why have they failed so far?Oral platelet glycoprotein IIb/IIIa receptor inhibitors: Why have they failed so far?. 2000.2000-01-01T00:00:002000Oral platelet glycoprotein IIb/IIIa receptor inhibitors: Why have they failed so far?Cannon CPACSTargeting high-risk patient subsets in acute coronary syndromes: Greater benefit from antithrombotic and interventional therapies. ACS. 2000; 3:42-50.2000-01-01T00:00:002000Targeting high-risk patient subsets in acute coronary syndromes: Greater benefit from antithrombotic and interventional therapiesCannon CPIn: Messerli FH, editor. Cardiovascular Drug Therapy.Hirulog. In: Messerli FH, editor. Cardiovascular Drug Therapy. 1996; 1498-505.1996-01-01T00:00:001996Hirulog18340193Cannon CPCritical pathways in cardiologyImplementation of critical pathways in the "real world". Crit Pathw Cardiol. 2005 Jun; 4(2):110-4.Crit Pathw Cardiol2005-06-01T00:00:002005Implementation of critical pathways in the "real world".18340203Steinberg BA, Braganza AJ, Eminowicz G, Dibattiste PM, Flaker GC, Murphy SA, Cannon CPCritical pathways in cardiologyAre statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. Crit Pathw Cardiol. 2005 Dec; 4(4):169-73.Crit Pathw Cardiol2005-12-01T00:00:002005Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18.Authorship 1104126330301542Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MSThe American journal of cardiologyWITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. Am J Cardiol. 2018 Aug 16.Am J Cardiol2018-08-16T00:00:002018WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.9527073Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald EThe American journal of cardiologyEffects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998 Mar 15; 81(6):678-81.Am J Cardiol1998-03-15T00:00:001998Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.7641350Fuchs J, Cannon CPCirculationHirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995 Aug 15; 92(4):727-33.Circulation1995-08-15T00:00:001995Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.8626940Braunwald E, Cannon CPJournal of the American College of CardiologyNon-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy? J Am Coll Cardiol. 1996 May; 27(6):1333-4.J Am Coll Cardiol1996-05-01T00:00:001996Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy?19166678Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CPThe American journal of cardiologyCurrent use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009 Feb 01; 103(3):295-300.Am J Cardiol2008-11-19T00:00:002008Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes.19557957Hartwig KA, Burich D, Cannon C, Massari L, Mueller L, Dembry LMPrehospital and disaster medicineCritical challenges ahead in bioterrorism preparedness training for clinicians. Prehosp Disaster Med. 2009 Jan-Feb; 24(1):47-53.Prehosp Disaster Med2009-01-01T00:00:002009Critical challenges ahead in bioterrorism preparedness training for clinicians.19720978Smith EE, Liang L, Hernandez A, Reeves MJ, Cannon CP, Fonarow GC, Schwamm LHNeurologyInfluence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology. 2009 Sep 01; 73(9):709-16.Neurology2009-09-01T00:00:002009Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program.19843900Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GCJAMAUse of aldosterone antagonists in heart failure. JAMA. 2009 Oct 21; 302(15):1658-65.JAMA2009-10-21T00:00:002009Use of aldosterone antagonists in heart failure.20194881Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RWCirculationEffect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 Mar 16; 121(10):1176-87.Circulation2010-03-01T00:00:002010Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.20338488Natarajan P, Ray KK, Cannon CPJournal of the American College of CardiologyHigh-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010 Mar 30; 55(13):1283-99.J Am Coll Cardiol2010-03-30T00:00:002010High-density lipoprotein and coronary heart disease: current and future therapies.20802270Acharjee S, Cannon CPCritical pathways in cardiologyOffice-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. Crit Pathw Cardiol. 2010 Sep; 9(3):156-9.Crit Pathw Cardiol2010-09-01T00:00:002010Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.21060068Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CPCirculationWhat is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010 Nov 23; 122(21):2142-51.Circulation2010-11-08T00:00:002010What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial.21487089Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CPCirculation. Cardiovascular quality and outcomesBenefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):328-36.Circ Cardiovasc Qual Outcomes2011-04-12T00:00:002011Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.2858819Cannon C, van Adelsberg J, Kelly S, Al-Awqati QNatureCarbon-dioxide-induced exocytotic insertion of H+ pumps in turtle-bladder luminal membrane: role of cell pH and calcium. Nature. 1985 Apr 4-10; 314(6010):443-6.Nature1985-04-01T00:00:001985Carbon-dioxide-induced exocytotic insertion of H+ pumps in turtle-bladder luminal membrane: role of cell pH and calcium.22235068Qian F, Ling FS, Deedwania P, Hernandez AF, Fonarow GC, Cannon CP, Peterson ED, Peacock WF, Kaltenbach LA, Laskey WK, Schwamm LH, Bhatt DLCirculation. Cardiovascular quality and outcomesCare and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33.Circ Cardiovasc Qual Outcomes2012-01-10T00:00:002012Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program.22744797Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DLClinical cardiologyQuality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7.Clin Cardiol2012-06-28T00:00:002012Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program.Cannon CPFocus on fragminFocus on fragmin. 1999.1999-01-01T00:00:001999Focus on fragminCannon CPTeaching case of acute myocardial infarctionTeaching case of acute myocardial infarction. 1997.1997-01-01T00:00:001997Teaching case of acute myocardial infarctionCannon CPClinical CourierTime as an adjunctive agent to thrombolysis. Clinical Courier. 1996; 14:4-5.1996-01-01T00:00:001996Time as an adjunctive agent to thrombolysisWiviott SD, Sabatine MS, Morrow D, Dumaine R, Murphy S, Boundy KE, Cannon CP, Gibson CMJ Am Coll CardiolDistinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarction. J Am Coll Cardiol. 2004; 43(Suppl A):290.2004-01-01T00:00:002004Distinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarctionCannon CPCannon Chronicles: The CREDO trialCannon Chronicles: The CREDO trial. 2003.2003-01-01T00:00:002003Cannon Chronicles: The CREDO trialCannon CP, Gruberg LAntiplatelet regimens in NSTEMI: Current and future approaches CMEAntiplatelet regimens in NSTEMI: Current and future approaches CME. 2008.2008-02-29T00:00:002008Antiplatelet regimens in NSTEMI: Current and future approaches CMECannon CPThe international TIMI 14 trial: Final resultsThe international TIMI 14 trial: Final results. 1999.1999-01-01T00:00:001999The international TIMI 14 trial: Final resultsCannon CP, Krakowski FMDiagnosis and therapy of acute myocardial infarction: Today's look at tomorrow's therapies and outcomesDiagnosis and therapy of acute myocardial infarction: Today's look at tomorrow's therapies and outcomes. 1998.1998-01-01T00:00:001998Diagnosis and therapy of acute myocardial infarction: Today's look at tomorrow's therapies and outcomesCannon CP, Vierck EThe Complete Idiot's Guide: The Anti-Inflammation DietThe Complete Idiot's Guide: The Anti-Inflammation Diet. 2006.2006-01-01T00:00:002006The Complete Idiot's Guide: The Anti-Inflammation DietAuthorship 110953310Authorship 11101667Authorship 1110102530371278White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CPJournal of the American Heart AssociationAverage Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.J Am Heart Assoc2018-10-16T00:00:002018Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.30371283Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, Cannon CP, O'Donoghue MLJournal of the American Heart AssociationCystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2018 10 16; 7(20):e009077.J Am Heart Assoc2018-10-16T00:00:002018Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.30371190Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KKJournal of the American Heart AssociationLower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.J Am Heart Assoc2018-09-18T00:00:002018Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.30409566Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL, Scirica BM, Butler J, Cannon CP, Bhatt DLJournal of the American College of CardiologyPrescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.J Am Coll Cardiol2018-12-25T00:00:002018Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.10492851Cannon CPClinical cardiologyIncorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV30-6.Clin Cardiol1999-08-01T00:00:001999Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.Morrow DA, Cannon CPEmerg MedLow-molecular-weight heparin in the treatment of acute coronary syndromes. Emerg Med. 2001; 33.2001-01-01T00:00:002001Low-molecular-weight heparin in the treatment of acute coronary syndromesGussak I, Antzelevitch C, editorsCommerce Series Edition Contemporary CardiologyCardiac repolarization bridging basic and clinical science. Commerce Series Edition Contemporary Cardiology. 2003; 548.2003-01-01T00:00:002003Cardiac repolarization bridging basic and clinical scienceCannon CPClopidogrel continuing education teleconference workbookClopidogrel continuing education teleconference workbook. 2001.2001-01-01T00:00:002001Clopidogrel continuing education teleconference workbookCannon CP, O'Gara PTCritical pathways for acute coronary syndromesCritical pathways for acute coronary syndromes. 1999.1999-01-01T00:00:001999Critical pathways for acute coronary syndromesCannon CP, Cohen DE, Radar DTargeting multiple pathways for optimal cholestrol managementTargeting multiple pathways for optimal cholestrol management. 2002.2002-01-01T00:00:002002Targeting multiple pathways for optimal cholestrol managementAuthorship 11111819Authorship 11110863Authorship 11112892Authorship 1111002230395259Golwala H, Cannon CP, Bhatt DLEuropean heart journalReply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Eur Heart J. 2019 01 07; 40(2):218-219.Eur Heart J2019-01-07T00:00:002019Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.30412009Spitzer E, Cannon CP, Serruys PWExpert opinion on drug safetyShould real-world evidence be incorporated into regulatory approvals? Expert Opin Drug Saf. 2018 12; 17(12):1155-1159.Expert Opin Drug Saf2018-11-14T00:00:002018Should real-world evidence be incorporated into regulatory approvals?30396865Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald EThe lancet. Diabetes & endocrinologyPolyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.Lancet Diabetes Endocrinol2018-11-02T00:00:002018Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.McLean DS, Cannon CPFuture MedicineA point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):1-13.2006-01-01T00:00:002006A point-of-care assay to measure platelet aggregation in patients taking clopidogrelKirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CMCirculationDifferences between streptokinase and fibrin-specific fibrinolytic therapy with co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudy. Circulation. 2005; 112(17):II-567.2005-01-01T00:00:002005Differences between streptokinase and fibrin-specific fibrinolytic therapy with co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudyCannon CP, McCabe CH, Antman EM, Bentley J, Rifai N, Braunwald EJ Am Coll CardiolAre there high-risk patients who are troponin negative? Further risk stratification with the TIMI risk score in patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2001; 37(Suppl A):326.2001-01-01T00:00:002001Are there high-risk patients who are troponin negative? Further risk stratification with the TIMI risk score in patients with acute coronary syndromes: Results from OPUS-TIMI 16Cannon CPTheroux P, editor. Acute Coronary Syndromes Companion to Braunwald's Heart DiseaseAdvantages and hazards of early revascularization. Theroux P, editor. Acute Coronary Syndromes Companion to Braunwald's Heart Disease. 2003; 752.2003-01-01T00:00:002003Advantages and hazards of early revascularizationCannon CP, Richards CFCannon CP, O'Gara PT, editors. Critical Pathways in CardiologyEmergency department critical pathways for acute coronary syndromes. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 15-22.2001-01-01T00:00:002001Emergency department critical pathways for acute coronary syndromesKumar A, Cannon CPFonarow GC, editor. Heart Failure ClinicsThe role of statins in the prevention of heart failure after acute coronary syndrome. Fonarow GC, editor. Heart Failure Clinics. 2008; 4(2):129-39.2008-04-01T00:00:002008The role of statins in the prevention of heart failure after acute coronary syndromeCannon CP, Ganz LI, Stone PHRippe JM, Irwin RS, Fink MP, Cerra FB, editors. Intensive Care Medicine.Complicated myocardial infarction. Rippe JM, Irwin RS, Fink MP, Cerra FB, editors. Intensive Care Medicine. 1995; 477-99.1995-01-01T00:00:001995Complicated myocardial infarctionCallas PW, Tracy RP, Bovill EG, Cannon CP, Braunwald EJ Thromb ThrombolysisThe association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis In Myocardial Infarction Phase II (TIMI II) Trial. J Thromb Thrombolysis. 1998; 5:53-60..1998-01-01T00:00:001998The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis In Myocardial Infarction Phase II (TIMI II) TrialCannon CP, Golden WEConsultantSecondary prevention in patients with unstable angina and non-ST-segment elevation myocardial infarction: Which drugs are mandatory?. Consultant. 2004; 44:1053-6.2004-01-01T00:00:002004Secondary prevention in patients with unstable angina and non-ST-segment elevation myocardial infarction: Which drugs are mandatory?Cannon CPIntegrating GP IIb/IIIa inhibition and an early invasive strategy for optimal management of acute coronary syndromesIntegrating GP IIb/IIIa inhibition and an early invasive strategy for optimal management of acute coronary syndromes. 2002.2002-01-01T00:00:002002Integrating GP IIb/IIIa inhibition and an early invasive strategy for optimal management of acute coronary syndromesCannon CP, Topol EJGetting it right from the start: Unlocking the ER and CCUGetting it right from the start: Unlocking the ER and CCU. 2001.2001-01-01T00:00:002001Getting it right from the start: Unlocking the ER and CCU10889124Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald ECirculationOral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 Jul 11; 102(2):149-56.Circulation2000-07-11T00:00:002000Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.Cannon CPCardiosource 2.0-An editorial from Chris Cannon, MD, FACC, new cardiosouce editor-in-chiefCardiosource 2.0-An editorial from Chris Cannon, MD, FACC, new cardiosouce editor-in-chief. 2007.2007-07-05T00:00:002007Cardiosource 2.0-An editorial from Chris Cannon, MD, FACC, new cardiosouce editor-in-chiefde Lemos JA, Cannon CP, Stone PHRosendorff E, editor. Essential CardiologyAcute myocardial infarction. Rosendorff E, editor. Essential Cardiology. 2001; 463-504.2001-01-01T00:00:002001Acute myocardial infarctionRay KK, Cannon CPCefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk.Non-traditional risk factors of cardiometabolic risk. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 87-103..2007-01-01T00:00:002007Non-traditional risk factors of cardiometabolic riskCannon CPEvidence-based Cardiovascular MedicineCommentary on early post-thrombolysis catherization may be preferable to a conservative strategy for people with myocardial infarction. Evidence-based Cardiovascular Medicine. 2005; 9:55-6.2005-01-01T00:00:002005Commentary on early post-thrombolysis catherization may be preferable to a conservative strategy for people with myocardial infarctionBallantyne CM, Feldman T, Ricker PM, Stone NJ, Cannon CPMedical Crossfire Special EditionLower is better (on LDL and CRP). Medical Crossfire Special Edition. 2005; 6:121.2005-01-01T00:00:002005Lower is better (on LDL and CRP)7874923Cannon CP, Goldhaber SZChestThe importance of rapidly treating patients with acute myocardial infarction. Chest. 1995 Mar; 107(3):598-600.Chest1995-03-01T00:00:001995The importance of rapidly treating patients with acute myocardial infarction.Cannon CPACS at the 2005 ACCACS at the 2005 ACC. 2005.2005-01-01T00:00:002005ACS at the 2005 ACCCannon CPIncorporating IIb/IIIa inhibitors into today's critical pathwaysIncorporating IIb/IIIa inhibitors into today's critical pathways. 1998.1998-01-01T00:00:001998Incorporating IIb/IIIa inhibitors into today's critical pathwaysCannon CPEvid Based Cardiovasc MedCommentary on SYMPHONY II. Evid Based Cardiovasc Med. 2002.2002-01-01T00:00:002002Commentary on SYMPHONY IICannon CPNew antiplatelet therapiesNew antiplatelet therapies. 2000.2000-01-01T00:00:002000New antiplatelet therapiesCannon CP, Alharethi R, O'Gara PTBecker RC, Alpert JS, editors. Cardiovascular Medicine: Practice and ManagementCritical pathways for acute coronary syndromes. Becker RC, Alpert JS, editors. Cardiovascular Medicine: Practice and Management. 2001; 263-74.2001-01-01T00:00:002001Critical pathways for acute coronary syndromesAuthorship 1166183Cannon CP, Antman EACardiology Clinics: Annual of Drug Therpay. Crawford MH, editor.Heparin and low molecular weight heparin in acute coronary syndromes and angioplasty. Cardiology Clinics: Annual of Drug Therpay. Crawford MH, editor. 1997; 105-19.1997-01-01T00:00:001997Heparin and low molecular weight heparin in acute coronary syndromes and angioplastyCannon CP, Kuntz RESirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary arterySirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. 2003.2003-01-01T00:00:002003Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary arteryBhatt D, Cannon CP, Peacock F, Reiner J AMI 2002: Discovering optimal treatment pathwaysAMI 2002: Discovering optimal treatment pathways. 2002.2002-01-01T00:00:002002AMI 2002: Discovering optimal treatment pathwaysBugiardini R, Manfrini O, Murphy SA, De Ferrari GM, Cannon CPJ Am Coll CardiolLong-term prognosis of nonobstructive coronary artery disease in the setting of acute coronary syndrome: A TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):208.2005-01-01T00:00:002005Long-term prognosis of nonobstructive coronary artery disease in the setting of acute coronary syndrome: A TIMI 22 SubstudyCannon CP, McCallister BDIntegrating IIb/IIIa inhibition and early invasive strategy for optimal management of ACSIntegrating IIb/IIIa inhibition and early invasive strategy for optimal management of ACS. 2001.2001-01-01T00:00:002001Integrating IIb/IIIa inhibition and early invasive strategy for optimal management of ACSCannon CP, Roe MT, Chen AY, Rumsfeld JS, Brindis RG, Ohman EM, Gibler WB, Fonarow GC, Lambrew CT, Penney J, Peterson EDTemporal improvements in door-to-balloon times for primary percutaneous coronary intervention. Results from the CRUSADE and ACTION RegistriesTemporal improvements in door-to-balloon times for primary percutaneous coronary intervention. Results from the CRUSADE and ACTION Registries. 2008.2008-03-01T00:00:002008Temporal improvements in door-to-balloon times for primary percutaneous coronary intervention. Results from the CRUSADE and ACTION RegistriesCannon CPCirculationReview of Textbook of Cardiovascular Medicine. Circulation. 1999; 100:566-7.1999-01-01T00:00:001999Review of Textbook of Cardiovascular MedicineCannon CP, Fuster VAntman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart DiseaseAnticoagulant and fibrinolytic therapy for acute coronary syndromes. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 669-93.2002-01-01T00:00:002002Anticoagulant and fibrinolytic therapy for acute coronary syndromesRay KK, Cannon CPTopol EJ, editor. Textbook of Interventional Cardiology.Lipid lowering in coronary artery disease. Topol EJ, editor. Textbook of Interventional Cardiology. 2008; 183-201.2008-01-01T00:00:002008Lipid lowering in coronary artery diseaseCannon CPClinical value of the troponins in acute coronary syndromesClinical value of the troponins in acute coronary syndromes. 1999.1999-01-01T00:00:001999Clinical value of the troponins in acute coronary syndromesSteinberg BA, Cannon CP, Bhatt DL, Montalescot G, Mehta S, O'Hagan, Poole-Wilson PA, Ballantyne CMEur Heart JContemporary Therapies for Diabetes in the Cardiovascular Populations of the US and Europe. Eur Heart J. 2007.2007-01-01T00:00:002007Contemporary Therapies for Diabetes in the Cardiovascular Populations of the US and EuropeCannon CP, Creager MACritical issues in peripheral arterial disease detection managementCritical issues in peripheral arterial disease detection management. 2003.2003-01-01T00:00:002003Critical issues in peripheral arterial disease detection managementAuthorship 1112066630427997Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin LJAMA cardiologyAssociation of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiol. 2018 12 01; 3(12):1160-1166.JAMA Cardiol2018-12-01T00:00:002018Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.Rizzo MJ, Ryan K, Cannon CP, Braunwald ECirculationOnset of chest pain between 6PM and 6AM is associated with poorer outcomes following thrombolysis. Circulation. 1998; 98(Suppl I):764.1998-01-01T00:00:001998Onset of chest pain between 6PM and 6AM is associated with poorer outcomes following thrombolysisCannon CPWhat are right TACTICS for treatment acute coronary syndromes?What are right TACTICS for treatment acute coronary syndromes?. 2001.2001-01-01T00:00:002001What are right TACTICS for treatment acute coronary syndromes?Cannon CP, Hawkins D, Wallace-Hixson JPharmacy Practice News Special EditionGuide to antithrombotic agents. Pharmacy Practice News Special Edition. 2004; 57-62.2004-01-01T00:00:002004Guide to antithrombotic agents11704000Kloner RA, Das S, Poole WK, Perrit R, Muller J, Cannon CP, Braunwald EThe American journal of cardiologySeasonal variation of myocardial infarct size. Am J Cardiol. 2001 Nov 01; 88(9):1021-4.Am J Cardiol2001-11-01T00:00:002001Seasonal variation of myocardial infarct size.12088781Murphy SA, Gibson CM, Van de Werf F, McCabe CH, Cannon CPThe American journal of cardiologyComparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002 Jul 01; 90(1):51-4.Am J Cardiol2002-07-01T00:00:002002Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I).14757697Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald ECirculationImplications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.Circulation2004-02-02T00:00:002004Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.15173050Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa FCirculationThe clinician as investigator: participating in clinical trials in the practice setting. Circulation. 2004 Jun 01; 109(21):2672-9.Circulation2004-06-01T00:00:002004The clinician as investigator: participating in clinical trials in the practice setting.15353915Kirtane AJ, Bui A, Murphy SA, Karmpaliotis D, Kosmidou I, Boundy K, Rahman A, Pinto DS, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, Gibson CMJournal of thrombosis and thrombolysisAssociation of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J Thromb Thrombolysis. 2004 Jun; 17(3):177-84.J Thromb Thrombolysis2004-06-01T00:00:002004Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction.16379781Cannon CPEvidence-based cardiovascular medicineDouble-bolus alteplase was not equivalent to accelerated infusion in patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7.Evid Based Cardiovasc Med1998-03-01T00:00:001998Double-bolus alteplase was not equivalent to accelerated infusion in patients with acute MI.Authorship 1116556730477800Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GLThe American journal of cardiologyRelation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391.Am J Cardiol2018-11-06T00:00:002018Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).Dawson B, Browning SR, Dai D, Hernandez AF, Cannon CP, Steinhub IQCORQuality improvement in patients with coronary artery disease from Rural America: Insightsfrom the AHA's GWTG-CAD Database [aka](Comparing the quality of cardiovascular care in rural and urban hospitals: Insights from the American Heart Association Get With the Guidelines CAD Program). QCOR. 2008.2008-01-01T00:00:002008Quality improvement in patients with coronary artery disease from Rural America: Insightsfrom the AHA's GWTG-CAD Database [aka](Comparing the quality of cardiovascular care in rural and urban hospitals: Insights from the American Heart Association Get With the Guidelines CAD Program)7594098Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald EJournal of the American College of CardiologyOne-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995 Dec; 26(7):1643-50.J Am Coll Cardiol1995-12-01T00:00:001995One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.17980251Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CPJournal of the American College of CardiologyInhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 06; 50(19):1852-6.J Am Coll Cardiol2007-10-23T00:00:002007Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.18340119Cannon CP, Braunwald ECritical pathways in cardiologyStrategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit. Crit Pathw Cardiol. 2003 Sep; 2(3):153-77.Crit Pathw Cardiol2003-09-01T00:00:002003Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit.18340286Sharayeva ML, Tcheng JE, Cannon CPCritical pathways in cardiologyAssessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit. Crit Pathw Cardiol. 2002 Mar; 1(1):22-5.Crit Pathw Cardiol2002-03-01T00:00:002002Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit.18340289Cannon CP, Ornato JPCritical pathways in cardiologyHow to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program. Crit Pathw Cardiol. 2002 Mar; 1(1):53-60.Crit Pathw Cardiol2002-03-01T00:00:002002How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program.2390969Liaw CW, Cannon C, Power MD, Kiboneka PK, Rubin LLThe EMBO journalIdentification and cloning of two species of cadherins in bovine endothelial cells. EMBO J. 1990 Sep; 9(9):2701-8.EMBO J1990-09-01T00:00:001990Identification and cloning of two species of cadherins in bovine endothelial cells.19033001Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJAmerican heart journalAssessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J. 2008 Dec; 156(6):1074-9.Am Heart J2008-10-11T00:00:002008Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.19056001Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TPJournal of the American College of CardiologyACC/AHA 2008 statement on Performance Measurement and Reperfusion Therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of Performance Measurement and Reperfusion Therapy). J Am Coll Cardiol. 2008 Dec 09; 52(24):2100-12.J Am Coll Cardiol2008-12-09T00:00:002008ACC/AHA 2008 statement on Performance Measurement and Reperfusion Therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of Performance Measurement and Reperfusion Therapy).Authorship 126160419258835Pollack CV, Hollander JE, Chen AY, Peterson ED, Bangalore S, Peacock FW, Cannon CP, Canto JG, Gibler BW, Ohman ME, Roe MTCritical pathways in cardiologyNon-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):29-33.Crit Pathw Cardiol2009-03-01T00:00:002009Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.19958964Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CPJournal of the American College of CardiologyEffect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 08; 54(24):2290-5.J Am Coll Cardiol2009-12-08T00:00:002009Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.Authorship 106910420691300Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJThe American journal of cardiologyOn-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010 Aug 15; 106(4):451-6.Am J Cardiol2010-08-15T00:00:002010On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).Authorship 107585621082868Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter PThe New England journal of medicineSafety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.N Engl J Med2010-11-17T00:00:002010Safety of anacetrapib in patients with or at high risk for coronary heart disease.21406438Natarajan P, Cannon CPEuropean heart journalMyocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. Eur Heart J. 2011 Jul; 32(14):1701-3.Eur Heart J2011-03-15T00:00:002011Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention.21685437James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RABMJ (Clinical research ed.)Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527.BMJ2011-06-17T00:00:002011Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.Authorship 11368610Authorship 1121357730571525Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DPCirculationAntithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation. 2018 07 31; 138(5):527-536.Circulation2018-07-31T00:00:002018Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.Authorship 109250223369353Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WSJournal of the American College of Cardiology2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). J Am Coll Cardiol. 2013 Mar 05; 61(9):992-1025.J Am Coll Cardiol2013-01-28T00:00:0020132013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards).Cannon CPST depression V1-V2: Anterior ischemia of posterior infarction?ST depression V1-V2: Anterior ischemia of posterior infarction?. 1998.1998-01-01T00:00:001998ST depression V1-V2: Anterior ischemia of posterior infarction?Steinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CPJ Am Coll CardiolStatin use and low-density lipoprotein cholsterol goals in 2004: How are we doing applying national cholesterol education program III guidelines. J Am Coll Cardiol. 2006; 47(4):209A.2006-02-21T00:00:002006Statin use and low-density lipoprotein cholsterol goals in 2004: How are we doing applying national cholesterol education program III guidelinesCannon CPAdjunctive agents for myocardial infarction thrombolysisAdjunctive agents for myocardial infarction thrombolysis. 1994.1994-01-01T00:00:001994Adjunctive agents for myocardial infarction thrombolysisGreenbaum AB, Kleiman NS, Berger PB, Cohen DJ, Cannon CP, Brindis R, Li Y, Roe MT, Harrington RA, Peterson E, Gibler WB, Ohman EMTranscatheter Cardiovascular TherapeuticsClinical trials in acute myocardial infarction and acute coronary syndrome. Transcatheter Cardiovascular Therapeutics. 2003.2003-01-01T00:00:002003Clinical trials in acute myocardial infarction and acute coronary syndromede Lemos JA, Cannon CPImproving reperfusion in acute myocardial infarction: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapyImproving reperfusion in acute myocardial infarction: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. 1999.1999-01-01T00:00:001999Improving reperfusion in acute myocardial infarction: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapyHusted S, Storey RF, Harrington RA, Sanders N, Peters G, Emanuelsson H, Cannon CPJ Am Coll CardiolThe effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). J Am Coll Cardiol. 2006; 47(4):200A.2006-02-21T00:00:002006The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS)The Occluded Artery Trial (OAT) Research Group (Cannon CP, Morbidity and Mortality Committee, Member OAT)Am Heart JDesign and methodology of the occcluded artery trial (OAT). Am Heart J. 2005; 150:627-42.2005-01-01T00:00:002005Design and methodology of the occcluded artery trial (OAT)Cannon CPCase study: "The heart attack" or "A midsummer's night drive"Case study: "The heart attack" or "A midsummer's night drive". 1999.1999-01-01T00:00:001999Case study: "The heart attack" or "A midsummer's night drive"Cannon CP, Ganz LI, Stone PH, Becker RCIrwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care MedicineComplicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000; 185-93.2000-01-01T00:00:002000Complicated myocardial infarctionArmani A, Qin J, Murphy SA, McCabe CH, Cannon CPJ Am Coll CardiolEffects of intensive vs standard statin therapy on lipids and inflammation in racial/ethnic groups. An analysis from PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):408A.2007-03-06T00:00:002007Effects of intensive vs standard statin therapy on lipids and inflammation in racial/ethnic groups. An analysis from PROVE-IT-TIMI 22Casey M, Fornari C, Bozovich GE, Iglesias Varela ML, Mautner B, Cannon CPCirculationIncreased expression of platelet p-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 Study. Circulation. 1999; 100(Suppl I):681.1999-01-01T00:00:001999Increased expression of platelet p-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 StudyCannon CPCase study: A woman with rest chest discomfort: What is the optimal treatment?Case study: A woman with rest chest discomfort: What is the optimal treatment?. 2003.2003-01-01T00:00:002003Case study: A woman with rest chest discomfort: What is the optimal treatment?Cannon CPInnovative directions in the future role of antiplatelet agentsInnovative directions in the future role of antiplatelet agents. 2004.2004-01-01T00:00:002004Innovative directions in the future role of antiplatelet agentsCannon CP, Barnathan E, Fowles R, Jordan RReoPro: A powerful and versatile agent in ACSReoPro: A powerful and versatile agent in ACS. 1999.1999-01-01T00:00:001999ReoPro: A powerful and versatile agent in ACSCannon CP, Ferguson J, Kereiakes D, Roe MTaking ACS to the bedsideTaking ACS to the bedside. 2003.2003-01-01T00:00:002003Taking ACS to the bedsideCannon CPAntithrombostic therapyAntithrombostic therapy. 2003.2003-01-01T00:00:002003Antithrombostic therapyKociol RD, Cannon CPLiterature ReviewTime to treatment in acute myocardial infarction. Literature Review. 2006; 1-8.2006-01-01T00:00:002006Time to treatment in acute myocardial infarctionCannon CP, Ornato JACS ACTION: Acute cardiac team to improve optimal treatment nowACS ACTION: Acute cardiac team to improve optimal treatment now. 2001.2001-01-01T00:00:002001ACS ACTION: Acute cardiac team to improve optimal treatment nowCannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald ECirculationPIA2 polymorphism of the platelet IIb/IIIa receptor: Increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12. Circulation. 1998; 98(Suppl I):171.1998-01-01T00:00:001998PIA2 polymorphism of the platelet IIb/IIIa receptor: Increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12Authorship 11222276Authorship 1122265330586757Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman BCirculationEmpagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 03 12; 139(11):1384-1395.Circulation2019-03-12T00:00:002019Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.30582177Contreras JP, Hong KN, Castillo J, Marzec LN, Hsu JC, Cannon CP, Yang S, Maddox TMClinical cardiologyAnticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. Clin Cardiol. 2019 Mar; 42(3):339-345.Clin Cardiol2019-01-30T00:00:002019Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry.Morrow DA, editorCannon CP, series editor. Contemporary Cardiology.Cardiovascular Biomarkers, Pathophysiology and Disease Management. Cannon CP, series editor. Contemporary Cardiology. 2006.2006-01-01T00:00:002006Cardiovascular Biomarkers, Pathophysiology and Disease ManagementCannon CPJ Crit IllnessManaging ST-segment elevation MI: An update on the alternatives. J Crit Illness. 2007; 5-6.2007-06-01T00:00:002007Managing ST-segment elevation MI: An update on the alternativesCannon CPMultinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes following long-term treatment with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritisMultinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes following long-term treatment with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. 2007.2007-03-01T00:00:002007Multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes following long-term treatment with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis7775712Cannon CP, Braunwald EJournal of the American College of CardiologyHirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995 Jun; 25(7 Suppl):30S-37S.J Am Coll Cardiol1995-06-01T00:00:001995Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty.9207635Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald EJournal of the American College of CardiologyOutcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997 Jul; 30(1):141-8.J Am Coll Cardiol1997-07-01T00:00:001997Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction.Authorship 1123390530609214Fan W, Song Y, Inzucchi SE, Sperling L, Cannon CP, Arnold SV, Kosiborod M, Wong NDDiabetes, obesity & metabolismComposite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes Obes Metab. 2019 05; 21(5):1121-1127.Diabetes Obes Metab2019-02-14T00:00:002019Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.10520778Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, Cannon CP, Antman EM, Braunwald EJournal of the American College of CardiologyImpaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.J Am Coll Cardiol1999-10-01T00:00:001999Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction.10637197Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald ECirculationRelationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18; 101(2):125-30.Circulation2000-01-18T00:00:002000Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.10751789Kloner RA, Przyklenk K, Shook T, Cannon CPJournal of thrombosis and thrombolysisProtection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial. J Thromb Thrombolysis. 1998 Sep; 6(2):89-92.J Thromb Thrombolysis1998-09-01T00:00:001998Protection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial.11129681Cannon CPClinical cardiologyLearning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol. 2000 Nov; 23 Suppl 6:VI-14-7.Clin Cardiol2000-11-01T00:00:002000Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.11157653Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JWChestIntravenous thrombolysis in acute myocardial infarction. Chest. 2001 Jan; 119(1 Suppl):253S-277S.Chest2001-01-01T00:00:002001Intravenous thrombolysis in acute myocardial infarction.11416578Cannon CPThe American journal of geriatric cardiologyElderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional Therapies. Am J Geriatr Cardiol. 2000 Oct; 9(5):265-270.Am J Geriatr Cardiol2000-10-01T00:00:002000Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional Therapies.12495392Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald EJAMABenefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002 Dec 25; 288(24):3124-9.JAMA2002-12-25T00:00:002002Benefit of an early invasive management strategy in women with acute coronary syndromes.12514662Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald EAmerican heart journalDirect comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan; 145(1):109-17.Am Heart J2003-01-01T00:00:002003Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.12849652Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald EJournal of the American College of CardiologyEarly and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.J Am Coll Cardiol2003-07-02T00:00:002003Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.15171792Byrne CE, Fitzgerald A, Cannon CP, Fitzgerald DJ, Shields DCBMC medical geneticsElevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet. 2004 Jun 01; 5:13.BMC Med Genet2004-06-01T00:00:002004Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes.15337207Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald EJournal of the American College of CardiologyAssociation of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.J Am Coll Cardiol2004-09-01T00:00:002004Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction.15936606Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CMJournal of the American College of CardiologySerum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 07; 45(11):1781-6.J Am Coll Cardiol2005-06-07T00:00:002005Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates.16814646Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyThe role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.J Am Coll Cardiol2006-06-12T00:00:002006The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.16952046Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PWAnnals of surgical oncologyThe effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol. 2006 Sep; 13(9):1209-15.Ann Surg Oncol2006-09-03T00:00:002006The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas.17097416Cannon CP, McLean DSThe American journal of cardiologyCritical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. Am J Cardiol. 2006 Nov 20; 98(10A):33N-38N.Am J Cardiol2006-10-02T00:00:002006Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy.Authorship 11265974Authorship 1127094330620370Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, Cohen DJ, Bhandary D, Khan ND, Anstrom KJ, Peterson EDJAMAEffect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. JAMA. 2019 01 01; 321(1):44-55.JAMA2019-01-01T00:00:002019Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.30630361Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MACirculation. Cardiovascular quality and outcomesMedication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e005041.Circ Cardiovasc Qual Outcomes2019-01-01T00:00:002019Medication Discontinuation in the IMPROVE-IT Trial.18481818Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyAntiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.Clin Cardiol2008-03-01T00:00:002008Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.19084083Cannon CPThe American journal of cardiologyMixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008 Dec 22; 102(12A):5L-9L.Am J Cardiol2008-12-22T00:00:002008Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.19166680Syed Z, Scirica BM, Mohanavelu S, Sung P, Michelson EL, Cannon CP, Stone PH, Stultz CM, Guttag JVThe American journal of cardiologyRelation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am J Cardiol. 2009 Feb 01; 103(3):307-11.Am J Cardiol2008-11-19T00:00:002008Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology.19361589Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CMThe American journal of cardiologySeasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Am J Cardiol. 2009 Apr 15; 103(8):1056-60.Am J Cardiol2009-02-21T00:00:002009Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).19643312Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Piña IL, Safford MM, Fonarow GCJournal of the American College of CardiologyPredictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. J Am Coll Cardiol. 2009 Aug 04; 54(6):515-21.J Am Coll Cardiol2009-08-04T00:00:002009Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program.Authorship 111787320185006Acharjee S, Qin J, Murphy SA, McCabe C, Cannon CPThe American journal of cardiologyDistribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). Am J Cardiol. 2010 Mar 01; 105(5):619-23.Am J Cardiol2010-03-01T00:00:002010Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).20215909Krishnaswamy A, Lincoff AM, Cannon CPCritical pathways in cardiologyThe use and limitations of unfractionated heparin. Crit Pathw Cardiol. 2010 Mar; 9(1):35-40.Crit Pathw Cardiol2010-03-01T00:00:002010The use and limitations of unfractionated heparin.Authorship 107284121982652White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad FAmerican heart journalEXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.Am Heart J2011-09-14T00:00:002011EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.22740361Kohli P, Cannon CPEvidence-based medicineDabigatran associated with increased risk of acute coronary events. Evid Based Med. 2013 Feb; 18(1):e9.Evid Based Med2012-06-27T00:00:002012Dabigatran associated with increased risk of acute coronary events.Cannon CP, Peacock WF, Reiner JSIMPACT: Optimal management of the AMI patient: Medical decision pointIMPACT: Optimal management of the AMI patient: Medical decision point. 2004.2004-01-01T00:00:002004IMPACT: Optimal management of the AMI patient: Medical decision pointKumar A, Cannon CPCardiology InternationalEfficacy and safety of cholesterol-lowering treatment. Cardiology International. 2007; 128-36.2007-12-01T00:00:002007Efficacy and safety of cholesterol-lowering treatmentSteinberg BA, Ballantyne CM, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Cannon CPEur Heart JInternational comparisons of the prevalence of obesity in patients with overt cardiovascular disease. Eur Heart J. 2006; P1509.2006-01-01T00:00:002006International comparisons of the prevalence of obesity in patients with overt cardiovascular diseaseCannon CPCardiology RoundsNew guidelines for the management of unstable angina and non-ST-elevation myocardial infarction. Cardiology Rounds. 2003; 1-7.2003-01-01T00:00:002003New guidelines for the management of unstable angina and non-ST-elevation myocardial infarctionCannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues.Epidemiology, Physiopathology and Diagnosis of ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007.2007-01-01T00:00:002007Epidemiology, Physiopathology and Diagnosis of ACSMehta RH, Montoye CK, Faul J, Nagle DJ, Kure J, Raj E, Fattal P, Sharriff S, Amlani M, Changezi H, Skorcz S, Bailey N, La Tarte M, McLean D, Savoy S, Werner P, Baker PL, Defranco A, Eagle K, Cannon CP on behalf of GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member)J Am Coll CardiolEnhancing quality of care for acute myocardial infraction: Shifting the focus of improvement from key indicators to process of care and tool use. J Am Coll Cardiol. 2004; 43:2167-73..2004-01-01T00:00:002004Enhancing quality of care for acute myocardial infraction: Shifting the focus of improvement from key indicators to process of care and tool useCannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, DiBattiste PMArchives Drug InformationA comparison of cardiovascular biomarkers in patients treated for three months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives Drug Information. 2008; 1:4-13.2008-01-01T00:00:002008A comparison of cardiovascular biomarkers in patients treated for three months with Etoricoxib, Celecoxib, Ibuprofen, and PlaceboCannon CPCase history: Non-ST elevation myocardial infarctionCase history: Non-ST elevation myocardial infarction. 2000.2000-01-01T00:00:002000Case history: Non-ST elevation myocardial infarctionLackland DT, Cannon CP, Egan BM, Fonarow G, Yu Y, Hernandez AF, Robertson RM, Jones DWCirculationHypertension treatment and control among patients hospitalized with heart failure: An analysis of get with the guidelines heart failure. Circulation. 2007; 116(16):II-784.2007-10-16T00:00:002007Hypertension treatment and control among patients hospitalized with heart failure: An analysis of get with the guidelines heart failureCannon CPCardiology RoundsPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Cardiology Rounds. 1998; 2:1-8.1998-01-01T00:00:001998Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromesCannon CP, Fuster VFuster V, Alexander RW, O'Rourke R, Roberts RA, King SB III, Wellens HJJ, editors. Hurst's the HeartThrombogenesis, antithrombotic and thrombolytic therapy. Fuster V, Alexander RW, O'Rourke R, Roberts RA, King SB III, Wellens HJJ, editors. Hurst's the Heart. 2001; 1373-436.2001-01-01T00:00:002001Thrombogenesis, antithrombotic and thrombolytic therapyAntman EM, for the TIMI 9B InvestigatorsCirculationHirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation. 1996; 94:911-21..1996-01-01T00:00:001996Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B TrialCannon CPNew Era ReperfusionEvidence points to role of bolus fibrinolytic agents in reducing medication errors. New Era Reperfusion. 2000; 4:1-7.2000-01-01T00:00:002000Evidence points to role of bolus fibrinolytic agents in reducing medication errorsMartinezclark P, Karmpaliotis D, Murphy S, Wiviott SD, Bigelow B, Kosmidou I, Chang A, Cannon CP, Giugliano R, Gibson CMJ Am Coll CardiolThe association of race with angiographic and clinical outcomes following fibrinolytic administration. J Am Coll Cardiol. 2004; 43(Suppl A):305.2004-01-01T00:00:002004The association of race with angiographic and clinical outcomes following fibrinolytic administrationWhite WB, editorCannon CP, series editor. Contemporary CardiologyBlood pressure monitoring in cardiovascular medicine and therapeutics. Cannon CP, series editor. Contemporary Cardiology. 2001; 308.2001-01-01T00:00:002001Blood pressure monitoring in cardiovascular medicine and therapeuticsCannon CPTopol EJ, editor. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology.Prehospital management of acute myocardial infarction. Topol EJ, editor. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 1998; 485-98.1998-01-01T00:00:001998Prehospital management of acute myocardial infarctionBlock PC, Cannon CP, Hochman JSThrombolytic strategy in myocardial infarctionThrombolytic strategy in myocardial infarction. 1997.1997-01-01T00:00:001997Thrombolytic strategy in myocardial infarctionCannon CPAdv Stud MedACS and antiplatelet management: Updated guidelines and current trials. Adv Stud Med. 2007; 7(17):540-5.2007-01-01T00:00:002007ACS and antiplatelet management: Updated guidelines and current trialsGelfand EV, Cannon CPColman RW, Marder VJ, Clowes AW, George JN, Goldhaber SW, editors. Hemostasis and Thrombosis.Acute coronary syndromes. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SW, editors. Hemostasis and Thrombosis. 2006; 1387-404..2006-01-01T00:00:002006Acute coronary syndromesGelfand EV, Cannon CPIrwin RS, Rippe JM, editors. Manual of Intensive Care Medicine.Management of unstable angina and non-ST-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 190-4.2006-01-01T00:00:002006Management of unstable angina and non-ST-elevation myocardial infarctionCannon CP, Januzzi JLPeripheral arterial disease in people with diabetesPeripheral arterial disease in people with diabetes. 2004.2004-01-01T00:00:002004Peripheral arterial disease in people with diabetesCannon CPRole of newer antiplatelet and antithrombotic agentsRole of newer antiplatelet and antithrombotic agents. 2003.2003-01-01T00:00:002003Role of newer antiplatelet and antithrombotic agentsCannon CP, Ballantyne CM, Feldman T, Ridker PM, Stone NJLower is better (on LDL and CRP) but how can we meet the challenge?. 2005.2005-01-01T00:00:002005Lower is better (on LDL and CRP) but how can we meet the challenge?Cannon CPIntensive Care MedicineUnstable angina/non-ST-elevation myocardial infarction. Intensive Care Medicine. 2002; 377-99.2002-01-01T00:00:002002Unstable angina/non-ST-elevation myocardial infarctionAuthorship 1083887Authorship 1257302Authorship 1110032Authorship 1109502Authorship 1173334Authorship 1197519Authorship 11355081130793734Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CPEuropean heart journalDabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019 05 14; 40(19):1553-1562.Eur Heart J2019-05-14T00:00:002019Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.30922481Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL, Scirica BM, Butler J, Cannon CP, Bhatt DLJournal of the American College of CardiologyPrescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.J Am Coll Cardiol2019-04-02T00:00:002019Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.D008078Chemicals & Drugs64123340.491911Cholesterol, LDLD009203Disorders1626116680.217433Myocardial InfarctionAuthorship 1176832Authorship 1143231D054058Disorders39823310.371624Acute Coronary SyndromeAuthorship 1303311D010975Chemicals & Drugs66430660.390528Platelet Aggregation InhibitorsD000789Disorders1929260.691062Angina, UnstableAuthorship 11407119Authorship 114204016Authorship 114381011Authorship 11427721Authorship 114753014Authorship 114765413Authorship 1144834130990260Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KWThe New England journal of medicineCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.N Engl J Med2019-04-14T00:00:002019Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.30736965Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RSThe American journal of cardiologySimulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019 04 15; 123(8):1202-1207.Am J Cardiol2019-01-25T00:00:002019Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.30928824Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CPAmerican heart journalRelationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. Am Heart J. 2019 06; 212:13-22.Am Heart J2019-03-01T00:00:002019Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.18352170Abbasi RU, Abu-Zayyad T, Allen M, Amman JF, Archbold G, Belov K, Belz JW, Ben Zvi SY, Bergman DR, Blake SA, Brusova OA, Burt GW, Cannon C, Cao Z, Connolly BC, Deng W, Fedorova Y, Finley CB, Gray RC, Hanlon WF, Hoffman CM, Holzscheiter MH, Hughes G, Hüntemeyer P, Jones BF, Jui CC, Kim K, Kirn MA, Loh EC, Maestas MM, Manago N, Marek LJ, Martens K, Matthews JA, Matthews JN, Moore SA, O'Neill A, Painter CA, Perera L, Reil K, Riehle R, Roberts M, Rodriguez D, Sasaki N, Schnetzer SR, Scott LM, Sinnis G, Smith JD, Sokolsky P, Song C, Springer RW, Stokes BT, Thomas SB, Thomas JR, Thomson GB, Tupa D, Westerhoff S, Wiencke LR, Zhang X, Zech APhysical review lettersFirst observation of the Greisen-Zatsepin-Kuzmin suppression. Phys Rev Lett. 2008 Mar 14; 100(10):101101.Phys Rev Lett2008-03-10T00:00:002008First observation of the Greisen-Zatsepin-Kuzmin suppression.20482038Abbasi RU, Abu-Zayyad T, Al-Seady M, Allen M, Amman JF, Anderson RJ, Archbold G, Belov K, Belz JW, Bergman DR, Blake SA, Brusova OA, Burt GW, Cannon C, Cao Z, Deng W, Fedorova Y, Finley CB, Gray RC, Hanlon WF, Hoffman CM, Holzscheiter MH, Ivanov D, Hughes G, Hüntemeyer P, Ivanov D, Jones BF, Jui CC, Kim K, Kirn MA, Loh EC, Liu J, Lundquist JP, Maestas MM, Manago N, Marek LJ, Martens K, Matthews JA, Matthews JN, Moore SA, O'Neill A, Painter CA, Perera L, Reil K, Riehle R, Roberts M, Rodriguez D, Sasaki N, Schnetzer SR, Scott LM, Sinnis G, Smith JD, Sokolsky P, Song C, Springer RW, Stokes BT, Stratton S, Thomas SB, Thomas JR, Thomson GB, Tupa D, Zech A, Zhang XPhysical review lettersIndications of proton-dominated cosmic-ray composition above 1.6 EeV. Phys Rev Lett. 2010 Apr 23; 104(16):161101.Phys Rev Lett2010-04-20T00:00:002010Indications of proton-dominated cosmic-ray composition above 1.6 EeV.8649706Cannon C, Dildy GA, Ward R, Varner MW, Dudley DJObstetrics and gynecologyA population-based study of congenital diaphragmatic hernia in Utah: 1988-1994. Obstet Gynecol. 1996 Jun; 87(6):959-63.Obstet Gynecol1996-06-01T00:00:001996A population-based study of congenital diaphragmatic hernia in Utah: 1988-1994.Authorship 1183027Authorship 1151041731076261Bruckert E, Kereiakes DJ, Koren MJ, Louie MJ, Letierce A, Miller K, Cannon CPJournal of clinical lipidologyPCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. J Clin Lipidol. 2019 May - Jun; 13(3):443-454.J Clin Lipidol2019-04-10T00:00:002019PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.MedicineCardiologyBrigham and Women's HospitalAuthorship 11544071031097165Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, Lopez JAG, de Ferranti SD, Plutzky J, Cannon CP, Januzzi JL, Di Carli MF, Nasir K, Bhatt DL, Blankstein RJournal of the American College of CardiologyFamilial Hypercholesterolemia Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2019 05 21; 73(19):2439-2450.J Am Coll Cardiol2019-05-21T00:00:002019Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction.DLB20DeepakBhattDeepak L. Bhatt, M.D.42.33510370000000-71.1061649000000081016Bhatt, DeepakVisiting Professor of MedicineYS25Yee-PingSunYee-Ping Sun, M.D.42.33510370000000-71.1061649000000052737Sun, Yee-PingAssistant Professor of MedicineAuthorship 1155959731108273Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RDAmerican heart journalTicagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2019 07; 213:57-65.Am Heart J2019-04-18T00:00:002019Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.DAM6DavidMorrowDavid Andrew Morrow, M.D.42.33510370000000-71.106164900000008518Morrow, DavidProfessor of MedicinePMR3PaulRidkerPaul M. Ridker, M.D.42.35195210000000-71.1243705000000041982Ridker, PaulEugene Braunwald Professor of MedicineAuthorship 13934710MDG4MarieGerhard-HermanMarie Denise Gerhard-Herman, M.D.42.33510370000000-71.1061649000000035273Gerhard-Herman, MarieAssociate Professor of MedicineAuthorship 1221665PVF1PeterFinnPeter Vincent Finn, M.D.42.33510370000000-71.1061649000000042332Finn, PeterInstructor in MedicineMSS7MarcSabatineMarc Steven Sabatine, M.D.42.33510370000000-71.106164900000001849Sabatine, MarcProfessor of MedicineAuthorship 1317172SZG1SamuelGoldhaberSamuel Zachary Goldhaber, M.D.42.33510370000000-71.106164900000004477Goldhaber, SamuelProfessor of MedicineAuthorship 116315410Authorship 1163289631174429Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod MCirculationUse of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 08 13; 140(7):618-620.Circulation2019-06-07T00:00:002019Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.31215979Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JHJAMA cardiologySafety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol. 2019 08 01; 4(8):747-755.JAMA Cardiol2019-08-01T00:00:002019Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.BMS1BenjaminSciricaBenjamin Morgan Scirica, M.D.42.33510370000000-71.1061649000000063097Scirica, BenjaminAssociate Professor of MedicineRPG1RobertGiuglianoRobert Patrick Giugliano, M.D.42.33864350000000-71.1068662000000065551Giugliano, RobertProfessor of Medicine111565selected publications13.09960.002128711093research areas14.79190.00893173161coauthor of2472.32146.42560similar toEB3EugeneBraunwaldEugene Braunwald, M.D.42.33864350000000-71.1068662000000062123Braunwald, EugeneHersey Distinguished Professor of the Theory and Practice of PhysicAuthorship 116666510Authorship 116820216Authorship 11692763Authorship 11689569Authorship 1168691331268631Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JLESC heart failureHeart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019 08; 6(4):784-792.ESC Heart Fail2019-07-03T00:00:002019Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®.31258990Wagholikar KB, Ainsworth L, Vernekar VP, Pathak A, Glynn C, Zelle D, Zagade A, Karipineni N, Herrick CD, McPartlin M, Bui TV, Mendis M, Klann J, Oates M, Gordon W, Cannon C, Patel R, Aronson SJ, MacRae CA, Scirica BM, Murphy SNAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational ScienceExtending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. AMIA Jt Summits Transl Sci Proc. 2019; 2019:370-378.AMIA Jt Summits Transl Sci Proc2019-05-06T00:00:002019Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications.31268222Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JLESC heart failureAlteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC Heart Fail. 2019 10; 6(5):1085-1087.ESC Heart Fail2019-07-03T00:00:002019Alteration of medical therapy in patients with heart failure relative to change in symptom severity.31272556Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJJournal of the American College of CardiologyManagement of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 07 09; 74(1):83-99.J Am Coll Cardiol2019-07-09T00:00:002019Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.31253441Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CPAtherosclerosisLipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.Atherosclerosis2019-06-08T00:00:002019Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.Authorship 11717684Authorship 1171599231314050Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MAJAMA cardiologyEffect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 09 01; 4(9):846-854.JAMA Cardiol2019-09-01T00:00:002019Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.31291786Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic VCirculationCanagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750.Circulation2019-07-11T00:00:002019Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.Authorship 11756571031349086Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CPAtherosclerosisAssociations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.Atherosclerosis2019-07-12T00:00:002019Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.Authorship 13492313Authorship 1442891Authorship 14489510Authorship 1178969131386936Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D'Agostino RB, Reynolds MRAmerican heart journalSimulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. Am Heart J. 2019 10; 216:30-41.Am Heart J2019-06-12T00:00:002019Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.Authorship 11860469Authorship 11847281431439336Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CPJACC. Cardiovascular interventionsRenal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC Cardiovasc Interv. 2019 08 26; 12(16):1553-1561.JACC Cardiovasc Interv2019-08-26T00:00:002019Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.31439215Qamar A, Giugliano RP, Bohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DAJournal of the American College of CardiologyBiomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.J Am Coll Cardiol2019-08-27T00:00:002019Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.Authorship 115524Authorship 1190178131495878Cannon CPEuropean heart journalDon't stop the statin! Eur Heart J. 2019 11 14; 40(43):3526-3528.Eur Heart J2019-11-14T00:00:002019Don't stop the statin!31548242Divakaran S, Singh A, Biery D, Yang J, DeFilippis EM, Collins BL, Ramsis M, Qamar A, Hainer J, Klein J, Cannon CP, Polk DM, Plutzky J, Nasir K, Januzzi JL, Di Carli MF, Bhatt DL, Blankstein RDiabetes careDiabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care. 2020 08; 43(8):1843-1850.Diabetes Care2019-09-23T00:00:002019Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry.Authorship 119343011Authorship 1167362Authorship 1638682Authorship 1198349531596518Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, Himmelmann A, Katus HA, Storey RF, Wallentin L, Weaver WD, Siegbahn AClinical cardiologyInterleukin-18 in patients with acute coronary syndromes. Clin Cardiol. 2019 Dec; 42(12):1202-1209.Clin Cardiol2019-10-09T00:00:002019Interleukin-18 in patients with acute coronary syndromes.Authorship 1523222Authorship 1115781Authorship 1563381Authorship 12022571031699285Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CPJournal of the American College of CardiologyDabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range. J Am Coll Cardiol. 2019 11 12; 74(19):2431-2433.J Am Coll Cardiol2019-11-12T00:00:002019Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.Authorship 1200502Authorship 12050461Authorship 12043434Authorship 12047097Authorship 120588812Authorship 1206126131707795Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KWCirculationEvaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.Circulation2019-11-11T00:00:002019Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.31721978Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, Anstrom KJ, Cohen DJ, Fonseca E, Khan ND, Fonarow GC, Wang TYJAMA cardiologyAssociation of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. JAMA Cardiol. 2020 01 01; 5(1):38-46.JAMA Cardiol2020-01-01T00:00:002020Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.31708410Robinson JG, Farnier M, Kastelein JJP, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CPJournal of clinical lipidologyRelationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. J Clin Lipidol. 2019 Nov - Dec; 13(6):979-988.e10.J Clin Lipidol2019-10-14T00:00:002019Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.31263998Rosen JG, Malik M, Cooney EE, Wirtz AL, Yamanis T, Lujan M, Cannon C, Hardy D, Poteat TAIDS and behaviorAntiretroviral Treatment Interruptions Among Black and Latina Transgender Women Living with HIV: Characterizing Co-occurring, Multilevel Factors Using the Gender Affirmation Framework. AIDS Behav. 2019 Sep; 23(9):2588-2599.AIDS Behav2019-09-01T00:00:002019Antiretroviral Treatment Interruptions Among Black and Latina Transgender Women Living with HIV: Characterizing Co-occurring, Multilevel Factors Using the Gender Affirmation Framework.31726422Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Yazdi D, Elliott-Davey M, Mues KE, Bhatt DL, Kosiborod MNAmerican heart journalGetting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.Am Heart J2019-10-31T00:00:002019Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.Authorship 1302546true1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Instructor in MedicineInstructor in Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of MedicineAuthorship 12620113Authorship 1560141Authorship 1292402Authorship 1456131Authorship 1602536Authorship 1283949Authorship 120667113Authorship 12065711131806216Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CPJACC. Cardiovascular interventionsDabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. JACC Cardiovasc Interv. 2019 12 09; 12(23):2346-2355.JACC Cardiovasc Interv2019-12-09T00:00:002019Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.31806214Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CPJACC. Cardiovascular interventionsSwitching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis. JACC Cardiovasc Interv. 2019 12 09; 12(23):2331-2341.JACC Cardiovasc Interv2019-12-09T00:00:002019Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.Authorship 1283191Authorship 1432782Authorship 1384866Authorship 12135303Authorship 1214167631868508Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF, Wallentin LEuropean heart journal. Acute cardiovascular carePrognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. Eur Heart J Acute Cardiovasc Care. 2019 12 23.Eur Heart J Acute Cardiovasc Care2019-12-23T00:00:002019Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.31865968Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue MLJournal of the American College of CardiologyOutcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.J Am Coll Cardiol2019-12-09T00:00:002019Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.Authorship 1215566231895449Bach RG, Cannon CP, Blazing MAJAMA cardiologyInterpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply. JAMA Cardiol. 2020 02 01; 5(2):235-236.JAMA Cardiol2020-02-01T00:00:002020Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.Authorship 1174492Authorship 1191671Authorship 121746711Authorship 1216988631924322Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CPThe American journal of cardiologyComparison of the Effect of Age (< 75 Versus = 75) on the Efficacy and Safety of Dual Therapy (Dabigatran?+?Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin?+?Aspirin?+?Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). Am J Cardiol. 2020 03 01; 125(5):735-743.Am J Cardiol2019-12-09T00:00:002019Comparison of the Effect of Age (< 75 Versus = 75) on the Efficacy and Safety of Dual Therapy (Dabigatran?+?Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin?+?Aspirin?+?Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).31902327Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad FJournal of the American Heart AssociationClinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.J Am Heart Assoc2020-01-04T00:00:002020Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.Authorship 12190801031948654Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CPJournal of the American College of CardiologyDabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020 01 21; 75(2):238-240.J Am Coll Cardiol2020-01-21T00:00:002020Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.Authorship 1631082Authorship 1559912Authorship 1222249931992158Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal BJournal of the American Heart AssociationSodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020 02 04; 9(3):e014908.J Am Heart Assoc2020-01-29T00:00:002020Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Authorship 1220355Authorship 1225655832081289Nanna MG, Navar AM, Giugliano RP, White JA, Lokhnygina Y, Mitchel YB, Musliner TA, Cannon CP, Blazing MAJournal of the American College of CardiologyMuscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. J Am Coll Cardiol. 2020 02 25; 75(7):835-837.J Am Coll Cardiol2020-02-25T00:00:002020Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin.Authorship 1229146632101251Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Vranckx P, Goette A, Gibson CM, Alexander JHJAMA cardiologyOptimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020 05 01; 5(5):582-589.JAMA Cardiol2020-05-01T00:00:002020Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.Authorship 1303385Authorship 1309152Authorship 1709873Authorship 12343425Authorship 12319543Authorship 1232321432139229Maeng M, Bhatt DL, Nordaby M, Miede C, Cannon CPJACC. Cardiovascular interventionsReply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes. JACC Cardiovasc Interv. 2020 03 09; 13(5):658-659.JACC Cardiovasc Interv2020-03-09T00:00:002020Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes.32129795Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, Anstrom KJ, Cohen DJ, Fonseca E, Khan ND, Fonarow GC, Wang TYJAMA cardiologyAgreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial. JAMA Cardiol. 2020 05 01; 5(5):532-539.JAMA Cardiol2020-05-01T00:00:002020Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.32192644Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy RJournal of clinical lipidologyEfficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol. 2020 Jan - Feb; 14(1):88-97.e2.J Clin Lipidol2020-01-13T00:00:002020Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.Authorship 1234957132209335Cannon CPJournal of the American College of CardiologyLow-Density Lipoprotein Cholesterol: Lower Is Totally Better. J Am Coll Cardiol. 2020 05 05; 75(17):2119-2121.J Am Coll Cardiol2020-03-21T00:00:002020Low-Density Lipoprotein Cholesterol: Lower Is Totally Better.Authorship 1287574Authorship 1237084932245636Vaduganathan M, Singh A, Sharma A, Januzzi JL, Scirica BM, Butler J, Zannad F, McGuire DK, Cannon CP, Bhatt DLThe American journal of cardiologyContemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Am J Cardiol. 2020 05 15; 125(10):1577-1581.Am J Cardiol2020-03-04T00:00:002020Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.Authorship 1269676Authorship 12382301232252548Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CPCirculation. Cardiovascular interventionsEffect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ Cardiovasc Interv. 2020 04; 13(4):e008349.Circ Cardiovasc Interv2020-04-07T00:00:002020Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.Authorship 1725102Authorship 173953332327085Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin LJACC. Cardiovascular interventionsNo Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.JACC Cardiovasc Interv2020-04-27T00:00:002020No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.31180995Poteat T, Wirtz A, Malik M, Cooney E, Cannon C, Hardy WD, Arrington-Sanders R, Lujan M, Yamanis TJournal of acquired immune deficiency syndromes (1999)A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):131-140.J Acquir Immune Defic Syndr2019-10-01T00:00:002019A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women.32299284Doll JA, Kaltenbach LA, Anstrom KJ, Cannon CP, Henry TD, Fonarow GC, Choudhry NK, Fonseca E, Bhalla N, Eudicone JM, Peterson ED, Wang TYJournal of the American Heart AssociationImpact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs. J Am Heart Assoc. 2020 04 21; 9(8):e014975.J Am Heart Assoc2020-04-17T00:00:002020Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs.32281542Rich AJ, Williams J, Malik M, Wirtz A, Reisner S, DuBois LZ, Juster RP, Lesko CR, Davis N, Althoff KN, Cannon C, Mayer K, Elliott A, Poteat TJMIR research protocolsBiopsychosocial Mechanisms Linking Gender Minority Stress to HIV Comorbidities Among Black and Latina Transgender Women (LITE Plus): Protocol for a Mixed Methods Longitudinal Study. JMIR Res Protoc. 2020 Apr 13; 9(4):e17076.JMIR Res Protoc2020-04-13T00:00:002020Biopsychosocial Mechanisms Linking Gender Minority Stress to HIV Comorbidities Among Black and Latina Transgender Women (LITE Plus): Protocol for a Mixed Methods Longitudinal Study.32027622Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RBThe Journal of clinical investigationBCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J Clin Invest. 2020 05 01; 130(5):2542-2559.J Clin Invest2020-05-01T00:00:002020BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.32301989Arnold SV, de Lemos JA, Liu Y, Mues KE, Bhatt DL, Cannon CP, Kosiborod MJAMA network openAdherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction. JAMA Netw Open. 2020 04 01; 3(4):e203032.JAMA Netw Open2020-04-01T00:00:002020Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction.Authorship 12405095Authorship 124131811Authorship 12419998Authorship 12414586Authorship 124171118Authorship 12421414Authorship 1243723932354987Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic VJournal of the American Society of Nephrology : JASNRenal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.J Am Soc Nephrol2020-05-01T00:00:002020Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.Authorship 1333281Authorship 12449391632378265Sciria CT, Maddox TM, Marzec L, Rodwin B, Virani SS, Annapureddy A, Freeman JV, O'Hare A, Liu Y, Song Y, Doros G, Zheng Y, Lee JJ, Daggubati R, Vadlamani L, Cannon C, Desai NRClinical cardiologySwitching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clin Cardiol. 2020 Jul; 43(7):743-751.Clin Cardiol2020-05-06T00:00:002020Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry.Authorship 124882117Authorship 12475995Authorship 1247472732389658De Caterina R, Procopio A, Lopez Sendon JL, Raev D, Mehta SR, Opolski G, Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Kleine E, Ten Berg JM, Bhatt DL, Miede C, Nordaby M, Cannon CPThe American journal of medicineComparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. Am J Med. 2020 11; 133(11):1302-1312.Am J Med2020-05-07T00:00:002020Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.32393129Fanaroff AC, Peterson ED, Kaltenbach LA, Anstrom KJ, Fonarow GC, Henry TD, Cannon CP, Choudhry NK, Cohen DJ, Atreja N, Bhalla N, Eudicone JM, Wang TYCirculation. Cardiovascular quality and outcomesCopayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial. Circ Cardiovasc Qual Outcomes. 2020 05; 13(5):e006182.Circ Cardiovasc Qual Outcomes2020-05-12T00:00:002020Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial.32436638Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, Edwards R, Kavalam M, Rosenthal N, Perkovic V, Jardine MJ, Mahaffey K, Neal BDiabetes, obesity & metabolismThe effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020 10; 22(10):1753-1766.Diabetes Obes Metab2020-06-24T00:00:002020The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.Authorship 12514716Authorship 1250519632466892Khalid U, Marzec LN, Mantini N, Manson SM, Doros G, Cannon CP, Song Y, Dong L, Hsu JC, Jeong MY, Virani SS, Maddox TMJournal of the American College of CardiologyTreatment of AF in American Indians and Alaska Natives: Insights From the NCDR PINNACLE-AF Registry. J Am Coll Cardiol. 2020 06 02; 75(21):2749-2750.J Am Coll Cardiol2020-06-02T00:00:002020Treatment of AF in American Indians and Alaska Natives: Insights From the NCDR PINNACLE-AF Registry.32468837Navarese EP, Khan SU, Kolodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James SCirculationComparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation. 2020 07 14; 142(2):150-160.Circulation2020-05-29T00:00:002020Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.Authorship 1252226532480059White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin LAmerican heart journalIn patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <?7% are associated with lower major cardiovascular events. Am Heart J. 2020 07; 225:97-107.Am Heart J2020-04-18T00:00:002020In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <?7% are associated with lower major cardiovascular events.32539451Berman AN, Biery DW, Singh A, Wu WY, Divakaran S, DeFilippis EM, Hainer J, Blaha MJ, Cannon C, Polk DM, Plutzky J, Natarajan P, Nasir K, Di Carli MF, Bhatt DL, Blankstein REuropean journal of preventive cardiologyAtherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2021 07 23; 28(8):e12-e14.Eur J Prev Cardiol2021-07-23T00:00:002021Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry.Authorship 1256396932562206Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CPDrugsDabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020 Jul; 80(10):995-1005.Drugs2020-07-01T00:00:002020Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.Authorship 1547372Authorship 1258441732569700Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, Cannon CP, Rosenthal N, Shaw W, Mahaffey KW, Jardine MJ, Perkovic V, Neal BInternational journal of cardiologyThe effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020 11 01; 318:126-129.Int J Cardiol2020-06-20T00:00:002020The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.Authorship 1438366Authorship 1538131Authorship 1511061Authorship 2115114Authorship 12689172Authorship 1268606632673510Abadie BQ, Cannon CP, Cavender MACirculation. Cardiovascular interventionsNovel Oral Anticoagulants Following Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2020 07; 13(7):e008465.Circ Cardiovasc Interv2020-07-15T00:00:002020Novel Oral Anticoagulants Following Percutaneous Coronary Intervention.32688097Sambola A, Rello P, Soriano T, Bhatt DL, Pasupuleti V, Cannon CP, Gibson CM, Dewilde WJM, Lip GYH, Peterson ED, Airaksinen KEJ, Kiviniemi T, Fauchier L, Räber L, Ruiz-Nodar JM, Banach M, Bueno H, Hernandez AVThrombosis researchSafety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thromb Res. 2020 11; 195:128-135.Thromb Res2020-07-09T00:00:002020Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis.Authorship 1271823332720582Khan I, Peterson ED, Cannon CP, Sedita LE, Edelberg JM, Ray KKJournal of the American Heart AssociationTime-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. J Am Heart Assoc. 2020 08 04; 9(15):e016506.J Am Heart Assoc2020-07-28T00:00:002020Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies.Authorship 16975412Authorship 1897785Authorship 1278916132820336Cannon CPEuropean heart journalChronic kidney disease: a high-risk group that deserves intensive lipid lowering. Eur Heart J. 2020 11 07; 41(42):4124-4126.Eur Heart J2020-11-07T00:00:002020Chronic kidney disease: a high-risk group that deserves intensive lipid lowering.Authorship 1385671Authorship 140190732893370Berman AN, Biery DW, Ginder C, Hulme OL, Marcusa D, Leiva O, Wu WY, Singh A, Divakaran S, Hainer J, Turchin A, Januzzi JL, Natarajan P, Cannon CP, Di Carli MF, Bhatt DL, Blankstein RClinical cardiologyStudy of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clin Cardiol. 2020 Nov; 43(11):1209-1215.Clin Cardiol2020-09-06T00:00:002020Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry.Authorship 2040792Authorship 128444414Authorship 1288339332928709Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, Brunet A, Manvelian G, Sasiela WJ, Baccara-Dinet MT, Zhao J, Robinson JGJournal of clinical lipidologyPharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020 Sep - Oct; 14(5):707-719.J Clin Lipidol2020-07-25T00:00:002020Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.Authorship 1346747Authorship 1289800132966714Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DKThe New England journal of medicineCardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020 10 08; 383(15):1425-1435.N Engl J Med2020-09-23T00:00:002020Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.Authorship 2083356Authorship 1383996Authorship 129429814Authorship 12931342Authorship 1293304233026243Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DKCirculationEfficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020 12 08; 142(23):2205-2215.Circulation2020-10-07T00:00:002020Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.33023859Underberg JA, Cannon CP, Larrey D, Makris L, Blom D, Phillips HJournal of clinical lipidologyLong-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J Clin Lipidol. 2020 Nov - Dec; 14(6):807-817.J Clin Lipidol2020-08-19T00:00:002020Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER).33031522McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CPJAMA cardiologyAssociation of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021 02 01; 6(2):148-158.JAMA Cardiol2021-02-01T00:00:002021Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.33164896Zeymer U, Leiva O, Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Gabor Kiss R, Ongen Z, Navarro Estrada J, Oude Ophuis T, Lip GYH, Nordaby M, Miede C, Ten Berg JM, Bhatt DL, Cannon CPEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of CardiologyDual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention. 2021 Aug 27; 17(6):474-480.EuroIntervention2021-08-27T00:00:002021Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.Authorship 1299624233119069Gargiulo G, Cannon CP, Gibson CM, Goette A, Lopes RD, Oldgren J, Korjian S, Windecker S, Esposito G, Vranckx P, Valgimigli MEuropean heart journal. Cardiovascular pharmacotherapySafety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J Cardiovasc Pharmacother. 2021 04 09; 7(FI1):f50-f60.Eur Heart J Cardiovasc Pharmacother2021-04-09T00:00:002021Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.33185476Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CTCirculationClinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.Circulation2020-11-13T00:00:002020Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.Authorship 13025842Authorship 13024615Authorship 130246312Authorship 13025374Authorship 13035344Authorship 13035324Authorship 13039323Authorship 13063065Authorship 130394916Authorship 130548413Authorship 13067654Authorship 1304587833200892Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt BThe New England journal of medicineSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 01 14; 384(2):117-128.N Engl J Med2020-11-16T00:00:002020Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.33200891Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PGThe New England journal of medicineSotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 01 14; 384(2):129-139.N Engl J Med2020-11-16T00:00:002020Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.33201729Scirica BM, Cannon CP, Fisher NDL, Gaziano TA, Zelle D, Chaney K, Miller A, Nichols H, Matta L, Gordon WJ, Murphy S, Wagholikar KB, Plutzky J, MacRae CACirculationDigital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. Circulation. 2021 02 02; 143(5):507-509.Circulation2020-11-17T00:00:002020Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control.33214158Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic VClinical journal of the American Society of Nephrology : CJASNEffects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.Clin J Am Soc Nephrol2020-11-19T00:00:002020Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.32801105Goldsmith K, Roux C, Cannon CCurrent opinion in psychologyUnderstanding the relationship between resource scarcity and object attachment. Curr Opin Psychol. 2021 06; 39:26-30.Curr Opin Psychol2020-07-18T00:00:002020Understanding the relationship between resource scarcity and object attachment.33185670Marcusa DP, Giugliano RP, Park JG, de Lemos JA, Cannon CP, Sabatine MSJAMA cardiologyAssociation of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2020 Nov 13.JAMA Cardiol2020-11-13T00:00:002020Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.33186063Cherney DZI, McGuire DK, Charbonnel B, Cosentino F, Pratley R, Dagogo-Jack S, Frederich R, Maldonado M, Liu J, Pong A, Liu CC, Cannon CPCirculationGradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV. Circulation. 2021 02 09; 143(6):602-605.Circulation2020-11-13T00:00:002020Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.33186535Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MSLancet (London, England)Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.Lancet2020-11-10T00:00:002020Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.16295165Arnold JL, Dembry LM, Tsai MC, Dainiak N, Rodoplu U, Schonfeld DJ, Paturas J, Cannon C, Selig SPrehospital and disaster medicineRecommended modifications and applications of the Hospital Emergency Incident Command System for hospital emergency management. Prehosp Disaster Med. 2005 Sep-Oct; 20(5):290-300.Prehosp Disaster Med2005-09-01T00:00:002005Recommended modifications and applications of the Hospital Emergency Incident Command System for hospital emergency management.7129567Verma SK, Dooley L, Verma K, Cannon CIndian journal of pediatricsMeasurement of reverse triiodothyronine in maternal serum and amniotic fluid and its correlation with fetal lung maturity. Indian J Pediatr. 1982 Mar-Apr; 49(397):181-3.Indian J Pediatr1982-03-01T00:00:001982Measurement of reverse triiodothyronine in maternal serum and amniotic fluid and its correlation with fetal lung maturity.Authorship 13079672Authorship 130856311Authorship 13089121333258897Costa F, Valgimigli M, Steg PG, Bhatt DL, Hohnloser SH, Ten Berg JM, Miede C, Nordaby M, Lip GYH, Oldgren J, Cannon CPEuropean heart journal. Cardiovascular pharmacotherapyAntithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. Eur Heart J Cardiovasc Pharmacother. 2022 05 05; 8(3):216-226.Eur Heart J Cardiovasc Pharmacother2022-05-05T00:00:002022Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.33275134Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, Hegde SM, Hernandez AF, McGeer A, Talbot HK, Anand I, Bhatt DL, Cannon CP, DeMets D, Gaziano JM, Goodman SG, Nichol K, Tattersall MC, Temte JL, Wittes J, Yancy C, Claggett B, Chen Y, Mao L, Havighurst TC, Cooper LS, Solomon SDJAMAEffect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 01 05; 325(1):39-49.JAMA2021-01-05T00:00:002021Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.33250267Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VHJournal of the American College of Cardiology2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 02 09; 77(5):629-658.J Am Coll Cardiol2020-11-26T00:00:0020202020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.33340322Gargiulo G, Cannon CP, Gibson CM, Lopes RD, Vranckx P, Valgimigli MEuropean heart journal. Cardiovascular pharmacotherapyThe multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? Eur Heart J Cardiovasc Pharmacother. 2021 05 23; 7(3):e29-e30.Eur Heart J Cardiovasc Pharmacother2021-05-23T00:00:002021The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?33316282Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJLKidney internationalInsights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 04; 99(4):999-1009.Kidney Int2020-12-11T00:00:002020Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.Authorship 13121965Authorship 13117802Authorship 1314454333358942Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KWAmerican heart journalEffects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.Am Heart J2020-12-22T00:00:002020Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.Authorship 1500671Authorship 1507221Authorship 13176208Authorship 153797633400910Tomasdottir M, Held C, Hadziosmanovic N, Westerbergh J, Lindbäck J, Aylward PE, Budaj A, Cannon CP, Engdahl J, Granger CB, Koenig W, Manolis AJ, Oldgren J, Stewart RAH, Svennberg E, Vinereanu D, White HD, Siegbahn A, Wallentin L, Hijazi ZAmerican heart journalRisk markers of incident atrial fibrillation in patients with coronary heart disease. Am Heart J. 2021 03; 233:92-101.Am Heart J2021-01-02T00:00:002021Risk markers of incident atrial fibrillation in patients with coronary heart disease.Authorship 1461191Authorship 206106Authorship 132759012Authorship 13278373Authorship 13279641233555916Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, Granger CB, Holmes DR, Lopes RD, Mehran R, Moliterno DJ, Price MJ, Saw J, Tanguay JF, Faxon DPCirculationAntithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation. 2021 02 09; 143(6):583-596.Circulation2021-02-08T00:00:002021Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.33554616Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Górriz JL, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BLCirculationBlood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749.Circulation2021-02-08T00:00:002021Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.Authorship 13319166Authorship 133160512Authorship 1331330633587654Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O'Donoghue MLCirculationSex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.Circulation2021-02-15T00:00:002021Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.33609104Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF, Wallentin LEuropean heart journal. Acute cardiovascular carePrognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. Eur Heart J Acute Cardiovasc Care. 2019 Dec 23.Eur Heart J Acute Cardiovasc Care2019-12-23T00:00:002019Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.33595905Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MDESC heart failureCardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021 04; 8(2):1482-1493.ESC Heart Fail2021-02-17T00:00:002021Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.Authorship 13334919Authorship 1333263833619120Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic VClinical journal of the American Society of Nephrology : CJASNKidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.Clin J Am Soc Nephrol2021-02-22T00:00:002021Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.33611447Berman AN, Biery DW, Singh A, Wu WY, Divakaran S, DeFilippis EM, Hainer J, Blaha MJ, Cannon C, Polk DM, Plutzky J, Natarajan P, Nasir K, Di Carli MF, Bhatt DL, Blankstein REuropean journal of preventive cardiologyAtherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur J Prev Cardiol. 2020 Jun 23.Eur J Prev Cardiol2020-06-23T00:00:002020Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry.Authorship 2265751Authorship 13367191133665685Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CPDiabetologiaEffects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021 06; 64(6):1256-1267.Diabetologia2021-03-04T00:00:002021Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.Authorship 2480521Authorship 1337307133706988Cannon CPThe American journal of cardiologyRole and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. Am J Cardiol. 2021 04 01; 144 Suppl 1:S32-S39.Am J Cardiol2021-04-01T00:00:002021Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation.Authorship 1972315Authorship 1973846Authorship 1595216Authorship 13420571Authorship 1342242333752228Cannon CPThe Journal of family practiceAn Update on Aspirin for Cardioprevention: Implications for Patient Care. J Fam Pract. 2021 Jan-Feb; 70(1 suppl [i]):S1-S10.J Fam Pract2021-01-01T00:00:002021An Update on Aspirin for Cardioprevention: Implications for Patient Care.33769679Arnott C, Li JW, Cannon CP, de Zeeuw D, Neuen BL, Heerspink HJL, Charytan DM, Agarwal A, Huffman MD, Figtree GA, Bakris G, Chang TI, Feng K, Rosenthal N, Zinman B, Jardine MJ, Perkovic V, Neal B, Mahaffey KWDiabetes, obesity & metabolismThe effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659.Diabetes Obes Metab2021-04-16T00:00:002021The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.Authorship 13452201533826497Peterson BE, Bhatt DL, Gabriel Steg P, Oldgren J, Maeng M, Zeymer U, Halvorsen S, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Miede C, Kleine E, Ten Berg JM, Cannon CPJACC. Cardiovascular interventionsEvaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC Cardiovasc Interv. 2021 04 12; 14(7):768-780.JACC Cardiovasc Interv2021-04-12T00:00:002021Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.Authorship 13469225Authorship 1349837833874750Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RIStrokeEffect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke. 2021 05; 52(5):1545-1556.Stroke2021-04-20T00:00:002021Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.33929598Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, Bakris G, Cannon CP, White WB, Zannad FClinical research in cardiology : official journal of the German Cardiac SocietyInfluence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624.Clin Res Cardiol2021-04-30T00:00:002021Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.34009238Berman AN, Biery DW, Ginder C, Singh A, Baek J, Wadhera RK, Wu WY, Divakaran S, DeFilippis EM, Hainer J, Cannon CP, Plutzky J, Polk DM, Nasir K, Di Carli MF, Ash AS, Bhatt DL, Blankstein RJAMA cardiologyAssociation of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol. 2021 08 01; 6(8):880-888.JAMA Cardiol2021-08-01T00:00:002021Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry.Authorship 13557731134042199Eccleston DS, Kim JM, Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CPClinical cardiologyThe effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). Clin Cardiol. 2021 Jul; 44(7):1002-1010.Clin Cardiol2021-05-27T00:00:002021The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).Authorship 135857913Authorship 13639911Authorship 13644932Authorship 13638061134140105Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, Mues KE, Orroth KK, Shannon E, Bonaca MPJournal of the American College of CardiologyEffectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021 06 22; 77(24):3016-3027.J Am Coll Cardiol2021-06-22T00:00:002021Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.34132735Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, Palagashvilli T, Alam S, Mues KE, Bhatt DL, Kosiborod MNJAMA cardiologyUse of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021 Jun 16.JAMA Cardiol2021-06-16T00:00:002021Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.34129237Cherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CPClinical cardiologyKidney outcomes using a sustained =40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug; 44(8):1139-1143.Clin Cardiol2021-06-15T00:00:002021Kidney outcomes using a sustained =40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.Authorship 1807824Authorship 1373063434152828Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt BAnnals of internal medicineEffect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021 08; 174(8):1065-1072.Ann Intern Med2021-06-22T00:00:002021Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.Authorship 1940855Authorship 19922110Authorship 1384651234369165Arnold SV, Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Alam S, Mues KE, Bhatt DL, Kosiborod MJournal of the American Heart AssociationWhat Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.J Am Heart Assoc2021-08-07T00:00:002021What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.Authorship 1670649Authorship 13866301134396246Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald EJACC. CardioOncologyProspective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol. 2020 Sep; 2(3):385-396.JACC CardioOncol2020-09-15T00:00:002020Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT.Authorship 13880258Authorship 1389119734431970Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin LJAMA cardiologyInterleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021 12 01; 6(12):1440-1445.JAMA Cardiol2021-12-01T00:00:002021Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.34423370Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJLEuropean heart journalEffects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901.Eur Heart J2021-12-21T00:00:002021Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.Authorship 1710901Authorship 13919479Authorship 13918591134497110Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CPClinical journal of the American Society of Nephrology : CJASNErtugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. Clin J Am Soc Nephrol. 2021 09; 16(9):1345-1354.Clin J Am Soc Nephrol2021-06-18T00:00:002021Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.34481756Plutzky J, Benson MD, Chaney K, Bui TV, Kraft M, Matta L, McPartlin M, Zelle D, Cannon CP, Dodek A, Gaziano TA, Desai AS, MacRae CA, Scirica BMAmerican heart journalPopulation health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. Am Heart J. 2022 01; 243:15-27.Am Heart J2021-09-03T00:00:002021Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.Authorship 1804886Authorship 1399354734620406Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald EJournal of the American College of CardiologyBaseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1499-1507.J Am Coll Cardiol2021-10-12T00:00:002021Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.Authorship 193678Authorship 218742Authorship 1412543734774485Ginsberg HN, Rosenson RS, Hovingh GK, Letierce A, Samuel R, Poulouin Y, Cannon CPJournal of lipid researchLDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. J Lipid Res. 2022 01; 63(1):100148.J Lipid Res2021-11-11T00:00:002021LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials.true1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 14203064634910136Sammons E, Hopewell JC, Chen F, Stevens W, Wallendszus K, Valdes-Marquez E, Dayanandan R, Knott C, Murphy K, Wincott E, Baxter A, Goodenough R, Lay M, Hill M, Macdonnell S, Fabbri G, Lucci D, Fajardo-Moser M, Brenner S, Hao D, Zhang H, Liu J, Wuhan B, Mosegaard S, Herrington W, Wanner C, Angermann C, Ertl G, Maggioni A, Barter P, Mihaylova B, Mitchel Y, Blaustein R, Goto S, Tobert J, DeLucca P, Chen Y, Chen Z, Gray A, Haynes R, Armitage J, Baigent C, Wiviott S, Cannon C, Braunwald E, Collins R, Bowman L, Landray MEuropean heart journalLong-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022 04 06; 43(14):1416-1424.Eur Heart J2022-04-06T00:00:002022Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.34998708Wu WY, Biery DW, Berman AN, Hsieh G, Divakaran S, Gupta S, Steigner ML, Aghayev A, Skali H, Polk DM, Plutzky J, Cannon CP, Di Carli MF, Blankstein RJournal of cardiovascular computed tomographyImpact of coronary artery calcium testing on patient management. J Cardiovasc Comput Tomogr. 2022 Jul-Aug; 16(4):303-308.J Cardiovasc Comput Tomogr2021-12-17T00:00:002021Impact of coronary artery calcium testing on patient management.Authorship 1423525434988471Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DLJACC. CardioOncologyCommon Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Dec; 3(5):619-634.JACC CardioOncol2021-11-16T00:00:002021Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review.Authorship 20251714Authorship 165053435063969Charytan DM, Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, Mahaffey KWClinical journal of the American Society of Nephrology : CJASNPotential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373.Clin J Am Soc Nephrol2022-01-21T00:00:002022Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.Authorship 14268274Authorship 142611812Authorship 1428696435086664Oyama K, Giugliano RP, Sabatine MS, Cannon CP, Braunwald EJournal of the American College of CardiologyReply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 02 01; 79(4):e153.J Am Coll Cardiol2022-02-01T00:00:002022Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol.Authorship 2207627Authorship 14322783Authorship 1430992835112882Fordyce CB, Giugliano RP, Cannon CP, Roe MT, Sharma A, Page C, White JA, Lokhnygina Y, Braunwald E, Blazing MAJournal of the American Heart AssociationCardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. J Am Heart Assoc. 2022 02 15; 11(4):e022733.J Am Heart Assoc2022-02-03T00:00:002022Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.35105533Zwart B, Bor WL, de Veer AJWM, Mahmoodi BK, Kelder JC, Lip GYH, Bhatt DL, Cannon CP, Ten Berg JMEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of CardiologyA novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention. 2022 Jul 22; 18(4):e292-e302.EuroIntervention2022-07-22T00:00:002022A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial.Authorship 14382631Authorship 14409417Authorship 144146810Authorship 1440490235233908Cherney DZI, Cosentino F, Pratley RE, Dagogo-Jack S, Frederich R, Maldonado M, Liu J, Pong A, Liu CC, Cannon CPDiabetes, obesity & metabolismThe differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. Diabetes Obes Metab. 2022 06; 24(6):1114-1122.Diabetes Obes Metab2022-03-28T00:00:002022The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.35166429Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, Cannon CP, Mahaffey KW, Schutte AE, Neal B, Arnott CDiabetes, obesity & metabolismCardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022 06; 24(6):1072-1083.Diabetes Obes Metab2022-03-07T00:00:002022Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.35266296Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Liu J, Pong A, Gantz I, Frederich R, Mancuso JP, Pratley REDiabetes, obesity & metabolismCardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes Obes Metab. 2022 07; 24(7):1245-1254.Diabetes Obes Metab2022-03-29T00:00:002022Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.35325103Cannon CPEuropean heart journalStatin intolerance: how common is it and how do we work with patients to overcome it? Eur Heart J. 2022 09 07; 43(34):3224-3226.Eur Heart J2022-09-07T00:00:002022Statin intolerance: how common is it and how do we work with patients to overcome it?Authorship 14480973Authorship 14463261135238955Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CPDiabetologiaErtugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia. 2022 05; 65(5):908-911.Diabetologia2022-03-03T00:00:002022Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].35486404Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, Udell JAJAMA network openAssociation of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw Open. 2022 04 01; 5(4):e228873.JAMA Netw Open2022-04-01T00:00:002022Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis.Authorship 145104013Authorship 1451056935596030Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HKSleep & breathing = Schlaf & AtmungErtugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath. 2023 05; 27(2):669-672.Sleep Breath2022-05-20T00:00:002022Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.35589614Li C, Yu J, Hockham C, Perkovic V, Neuen BL, Badve SV, Houston L, Lee VYJ, Barraclough JY, Fletcher RA, Mahaffey KW, Heerspink HJL, Cannon CP, Neal B, Arnott CDiabetes, obesity & metabolismCanagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab. 2022 10; 24(10):1927-1938.Diabetes Obes Metab2022-06-09T00:00:002022Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.Authorship 3303693Authorship 3662101Authorship 3870497Authorship 3924649Authorship 14638745Authorship 14651341035603908Segar MW, Kolkailah AA, Frederich R, Pong A, Cannon CP, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Liu CC, Maldonado M, Liu J, Cater NB, Pandey A, Cherney DZIDiabetes, obesity & metabolismMediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2022 09; 24(9):1829-1839.Diabetes Obes Metab2022-06-15T00:00:002022Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.35691283Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Frederich R, Maldonado M, Liu CC, Pong A, Cannon CPAmerican journal of nephrologyInitial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. Am J Nephrol. 2022; 53(7):516-525.Am J Nephrol2022-06-10T00:00:002022Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.Authorship 407728736260325Patel SM, Qamar A, Giugliano RP, Jarolim P, Marston NA, Park JG, Blazing MA, Cannon CP, Braunwald E, Morrow DAJAMA cardiologyAssociation of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. JAMA Cardiol. 2022 12 01; 7(12):1199-1206.JAMA Cardiol2022-12-01T00:00:002022Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.Authorship 14925292Authorship 14909643Authorship 14887115Authorship 14896852Authorship 14913498Authorship 149610410Authorship 14994783Authorship 14840362Authorship 15009142Authorship 14906918Authorship 14895618Authorship 14997938Authorship 1482126836302584Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KWJournal of the American College of CardiologyCardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.J Am Coll Cardiol2022-11-01T00:00:002022Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.36153643Nichols H, Cannon CP, Scirica BM, Fisher NDLClinical cardiologyA remote hypertension management program clinical algorithm. Clin Cardiol. 2022 Sep 24.Clin Cardiol2022-09-24T00:00:002022A remote hypertension management program clinical algorithm.35929472Li JW, Arnott C, Heerspink HJL, MBiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJJournal of the American Heart AssociationEffect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 08 16; 11(16):e025045.J Am Heart Assoc2022-08-05T00:00:002022Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.35967112Cherney DZI, Dagogo-Jack S, Cosentino F, Pratley RE, Frederich R, Maldonado M, Liu CC, Cannon CPKidney international reportsHeart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney Int Rep. 2022 Aug; 7(8):1782-1792.Kidney Int Rep2022-05-13T00:00:002022Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial.35994565Cosentino F, Cannon CP, Frederich R, Cherney DZI, Dagogo-Jack S, Pratley RE, Mancuso JP, Maldonado M, Cater NB, Wang S, McGuire DKCirculationCardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial. Circulation. 2022 Aug 23; 146(8):652-654.Circulation2022-08-22T00:00:002022Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.36124341Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, Bhatt DL, Cannon CP, Ballantyne CM, Rosenson RSClinical cardiologyUse of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Sep 19.Clin Cardiol2022-09-19T00:00:002022Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).36254670Banach M, Cannon CP, Paneni F, Penson PEEuropean heart journalIndividualized therapy in statin intolerance: the key to success. Eur Heart J. 2023 02 14; 44(7):544-546.Eur Heart J2023-02-14T00:00:002023Individualized therapy in statin intolerance: the key to success.36250667Rymer JA, Kaltenbach LA, Peterson ED, Cohen DJ, Fonarow GC, Choudhry NK, Henry TD, Cannon CP, Wang TYJournal of the American Heart AssociationDoes the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS. J Am Heart Assoc. 2022 10 18; 11(20):e026421.J Am Heart Assoc2022-10-17T00:00:002022Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS.36303404Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O'Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MSEuropean heart journalGrowth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 01 21; 44(4):293-300.Eur Heart J2023-01-21T00:00:002023Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.36350612Blood AJ, Cannon CP, Gordon WJ, Mailly C, MacLean T, Subramaniam S, Tucci M, Crossen J, Nichols H, Wagholikar KB, Zelle D, McPartlin M, Matta LS, Oates M, Aronson S, Murphy S, Landman A, Fisher NDL, Gaziano TA, Plutzky J, Scirica BMJAMA cardiologyResults of a Remotely Delivered Hypertension and Lipid Program in More Than 10?000 Patients Across a Diverse Health Care Network. JAMA Cardiol. 2023 01 01; 8(1):12-21.JAMA Cardiol2023-01-01T00:00:002023Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10?000 Patients Across a Diverse Health Care Network.36117951Sabouret P, Angoulvant D, Cannon CP, Banach MEuropean heart journal openLow levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate? Eur Heart J Open. 2022 Jul; 2(4):oeac038.Eur Heart J Open2022-06-07T00:00:002022Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?35980763Marston NA, Garfinkel AC, Kamanu FK, Melloni GM, Roselli C, Jarolim P, Berg DD, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O'Donoghue ML, Raz I, Scirica BM, Braunwald E, Morrow DA, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CTEuropean heart journalA polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023 01 14; 44(3):221-231.Eur Heart J2023-01-14T00:00:002023A polygenic risk score predicts atrial fibrillation in cardiovascular disease.Authorship 4362237Authorship 43944113Authorship 1504299336394384Corbin KD, Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Frederich R, Liu J, Pong A, Lin J, Cater NB, Pratley REDiabetes, obesity & metabolismCardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. Diabetes Obes Metab. 2023 03; 25(3):758-766.Diabetes Obes Metab2022-12-26T00:00:002022Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.Authorship 15076783Authorship 1507294136456073Canonico ME, Hsia J, Cannon CP, Bonaca MPJACC. Heart failureUptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease. JACC Heart Fail. 2022 Dec; 10(12):989-991.JACC Heart Fail2022-11-09T00:00:002022Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease.36440852Cannon CP, Fusco LCritical pathways in cardiology20 Years of Critical Pathways. Crit Pathw Cardiol. 2022 Dec 01; 21(4):161.Crit Pathw Cardiol2022-11-22T00:00:00202220 Years of Critical Pathways.Authorship 1655493Authorship 1953463Authorship 15119111236594154Kim JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, Cosentino F, McGuire DK, Pratley RE, Liu CC, Cater NB, Frederich R, Mancuso JP, Cannon CPDiabetes, obesity & metabolismPotential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. Diabetes Obes Metab. 2023 05; 25(5):1398-1402.Diabetes Obes Metab2023-02-14T00:00:002023Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.Authorship 1518617436702781Dagogo-Jack S, Frederich R, Liu J, Cannon CP, Shi H, Cherney DZI, Cosentino F, Masiukiewicz U, Gantz I, Pratley REThe Journal of clinical endocrinology and metabolismErtugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. J Clin Endocrinol Metab. 2023 Jul 14; 108(8):2042-2051.J Clin Endocrinol Metab2023-07-14T00:00:002023Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.Authorship 2380921Authorship 1743633Authorship 1527918836843558Arnold SV, de Lemos JA, Zheng L, Rosenson RS, Ballantyne CM, Alam S, Bhatt DL, Cannon CP, Kosiborod MDiabetes, obesity & metabolismUse of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.Diabetes Obes Metab2023-03-07T00:00:002023Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.Authorship 179321Authorship 15307493Authorship 15303241536889425Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine MAmerican journal of kidney diseases : the official journal of the National Kidney FoundationKidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.Am J Kidney Dis2023-03-07T00:00:002023Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.36915035Lee SG, Blood AJ, Cannon CP, Gordon WJ, Nichols H, Zelle D, Scirica BM, Fisher NDLJournal of the American Heart AssociationRemote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. J Am Heart Assoc. 2023 03 21; 12(6):e027296.J Am Heart Assoc2023-03-13T00:00:002023Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic.Authorship 193930337093601Cannon CP, Kim JM, Lee JJ, Sutherland J, Bachireddy R, Valentine CM, Hearne S, Trebnick A, Jaffer S, Datta S, Semmel E, Thorpe F, Doros G, Cavender MA, Reynolds MRJAMA network openPatients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant. JAMA Netw Open. 2023 04 03; 6(4):e239638.JAMA Netw Open2023-04-03T00:00:002023Patients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant.Authorship 474416Authorship 4781743Authorship 481901Authorship 4865686Authorship 5085073Authorship 5128954Authorship 207382Authorship 2555566Authorship 2601113Authorship 15706803Authorship 156597610Authorship 15609314Authorship 15645443Authorship 15652401Authorship 15514507Authorship 1557489236972054Peterson BE, Bhatt DL, Ballantyne CM, de Lemos JA, Rosenson RS, Kosiborod MN, Cannon CPJAMA network openIntensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease. JAMA Netw Open. 2023 03 01; 6(3):e234709.JAMA Netw Open2023-03-01T00:00:002023Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease.37311602Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DCBMJ open diabetes research & careCardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3).BMJ Open Diabetes Res Care2023-06-01T00:00:002023Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.37223853Canonico ME, Hess CN, Cannon CPCurrent atherosclerosis reportsIn-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? Curr Atheroscler Rep. 2023 07; 25(7):381-389.Curr Atheroscler Rep2023-05-24T00:00:002023In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?37345760Shah NP, McGuire DK, Cannon CP, Giugliano RP, Lokhnygina Y, Page CB, Tershakovec AM, Braunwald E, Blazing MAJournal of the American Heart AssociationImpact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. J Am Heart Assoc. 2023 07 04; 12(13):e029593.J Am Heart Assoc2023-06-22T00:00:002023Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT.37069970Cherney DZI, Cosentino F, McGuire DK, Kolkailah AA, Dagogo-Jack S, Pratley RE, Frederich R, Maldonado M, Liu CC, Cannon CPKidney international reportsEffects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial. Kidney Int Rep. 2023 Apr; 8(4):746-753.Kidney Int Rep2023-01-20T00:00:002023Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.37003273Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, Lawrence D, Jones PLS, Liu J, Adamsons I, Dagogo-Jack SThe lancet. Healthy longevityCardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023 04; 4(4):e143-e154.Lancet Healthy Longev2023-04-01T00:00:002023Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial.Authorship 2239506Authorship 2256063Authorship 318028337641636Shiyovich A, Berman AN, Besser SA, Biery DW, Huck DM, Weber B, Cannon C, Januzzi JL, Booth JN, Nasir K, Di Carli MF, López JAG, Kent ST, Bhatt DL, Blankstein REuropean heart journal openCardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. Eur Heart J Open. 2023 Jul; 3(4):oead077.Eur Heart J Open2023-08-27T00:00:002023Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.Authorship 3485751Authorship 15841424Authorship 15902009Authorship 1590249737558385Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Ezekowitz JA, Sun F, Davies MJ, Verma S, Kosiborod MN, Steg PGJACC. Heart failureEffect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. JACC Heart Fail. 2023 08; 11(8 Pt 1):879-889.JACC Heart Fail2023-08-01T00:00:002023Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.37640175Jafri SH, Hushcha P, Dorbala P, Bousquet G, Lutfy C, Mellett L, Sonis L, Blankstein R, Cannon C, Plutzky J, Polk D, Skali HCurrent problems in cardiologyUse of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation. Curr Probl Cardiol. 2024 Jan; 49(1 Pt A):102058.Curr Probl Cardiol2023-08-26T00:00:002023Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation.Authorship 3814856Authorship 38214713Authorship 4012931true1Hersey Distinguished Professor of the Theory and Practice of PhysicHersey Distinguished Professor of the Theory and Practice of Physictrue1Visiting Professor of MedicineVisiting Professor of MedicineAuthorship 4170644Authorship 420358637914514Aggarwal R, Bhatt DL, Szarek M, Cannon CP, McGuire DK, Inzucchi SE, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PGJournal of the American College of CardiologyEfficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c. J Am Coll Cardiol. 2023 11 07; 82(19):1842-1851.J Am Coll Cardiol2023-11-07T00:00:002023Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.Authorship 4507696Authorship 16024124Authorship 16027272Authorship 1599199437864578Pandey A, Kolkailah AA, Cosentino F, Cannon CP, Frederich RC, Cherney DZI, Dagogo-Jack S, Pratley RE, Cater NB, Gantz I, Mancuso JP, McGuire DKEuropean heart journalErtugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. Eur Heart J. 2023 Dec 21; 44(48):5163-5166.Eur Heart J2023-12-21T00:00:002023Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.37879804Kim G, Cannon CPJACC. Cardiovascular interventionsTicagrelor-Induced Dyspnea: A Controllable Side Effect. JACC Cardiovasc Interv. 2023 10 23; 16(20):2525-2527.JACC Cardiovasc Interv2023-10-23T00:00:002023Ticagrelor-Induced Dyspnea: A Controllable Side Effect.Authorship 4561010Authorship 5036076Authorship 5363561Authorship 5644381Authorship 16252181738302335Blood AJ, Chang LS, Colling C, Stern G, Gabovitch D, Feldman G, Adan A, Waterman F, Durden E, Hamersky C, Noone J, Aronson SJ, Liberatore P, Gaziano TA, Matta LS, Plutzky J, Cannon CP, Wexler DJ, Scirica BMPrimary care diabetesMethods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk. Prim Care Diabetes. 2024 Jan 31.Prim Care Diabetes2024-01-31T00:00:002024Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.Authorship 579365Authorship 582000Authorship 583179Authorship 587689Authorship 590843Authorship 591149Authorship 592055Authorship 592266Authorship 1744103Authorship 176465138418000Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, Huck DM, Divakaran S, Hainer J, Kaur G, Blaha MJ, Cannon CP, Plutzky J, Januzzi JL, Booth JN, López JAG, Kent ST, Nasir K, Di Carli MF, Bhatt DL, Blankstein RJournal of the American College of CardiologyLipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 Mar 05; 83(9):873-886.J Am Coll Cardiol2024-03-05T00:00:002024Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.Authorship 1632173155Authorship 16299791238373851Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B, Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K, Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S, Clearfield M, Downs JR, Gotto A, Weis S, Fellström B, Holdaas H, Jardine A, Pedersen TR, Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L, Koren M, Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H, Knopp RH, Cobbe S, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Betteridge DJ, Colhoun HM, Durrington PN, Fuller J, Hitman GA, Neil A, Braunwald E, Davis B, Hawkins CM, Moyé L, Pfeffer M, Sacks F, Kjekshus J, Wedel H, Wikstrand J, Wanner C, Krane V, Franzosi MG, Latini R, Lucci D, Maggioni A, Marchioli R, Nicolis EB, Tavazzi L, Tognoni G, Bosch J, Lonn E, Yusuf S, Armitage J, Bowman L, Collins R, Keech A, Landray M, Parish S, Peto R, Sleight P, Kastelein JJ, Pedersen TR, Glynn R, Gotto A, Kastelein JJ, Koenig W, MacFadyen J, Ridker PM, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Simes J, White H, Serruys PW, Knatterud G, Blauw GJ, Cobbe S, Ford I, Macfarlane P, Packard C, Sattar N, Shepherd J, Trompet S, Braunwald E, Cannon CP, Murphy S, Collins R, Armitage J, Bowman L, Bulbulia R, Haynes R, Parish S, Peto R, Sleight P, Amarenco P, Welch KM, Kjekshus J, Pedersen TR, Wilhelmsen L, Barter P, Gotto A, LaRosa J, Kastelein JJ, Shepherd J, Cobbe S, Ford I, Kean S, Macfarlane P, Packard C, Roberston M, Sattar N, Shepherd J, Young R, Arashi H, Clarke R, Flather M, Goto S, Goldbourt U, Hopewell J, Hovingh GK, Kitas G, Newman C, Sabatine MS, Schwartz GG, Smeeth L, Tobert J, Varigos J, Yamamguchi JThe British journal of general practice : the journal of the Royal College of General PractitionersLong-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. Br J Gen Pract. 2024 Feb 19.Br J Gen Pract2024-02-19T00:00:002024Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.Authorship 2243153Authorship 16338592Authorship 16338558Authorship 16344792Authorship 1633873338442294Cosentino F, Cannon CP, Marx NEuropean heart journalThe year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders. Eur Heart J. 2024 Mar 05.Eur Heart J2024-03-05T00:00:002024The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders.37359269Roux C, Goldsmith K, Cannon CJournal of the Academy of Marketing ScienceOn the role of scarcity in marketing: Identifying research opportunities across the 5Ps. J Acad Mark Sci. 2023 Jun 06; 1-6.J Acad Mark Sci2023-06-06T00:00:002023On the role of scarcity in marketing: Identifying research opportunities across the 5Ps.36662568Luderer H, Enman N, Gerwien R, Braun S, McStocker S, Xiong X, Koebele C, Cannon C, Glass J, Maricich YJMIR research protocolsA Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study. JMIR Res Protoc. 2023 Jan 20; 12:e43122.JMIR Res Protoc2023-01-20T00:00:002023A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.9972965Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri MThe Journal of rheumatologyCorrelation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol. 1999 Feb; 26(2):318-24.J Rheumatol1999-02-01T00:00:001999Correlation of serum measures of nitric oxide production with lupus disease activity.Authorship 5351421Authorship 5402222Authorship 540652true1Eugene Braunwald Professor of MedicineEugene Braunwald Professor of MedicineAuthorship 5497452Authorship 5731603Authorship 577748Authorship 579040Authorship 579171Authorship 580165Authorship 588346Authorship 589201Authorship 592128Authorship 592516Authorship 595021Authorship 596055Authorship 604922Authorship 604988Authorship 605830Authorship 611941Authorship 612505Authorship 612958Authorship 617106Authorship 617369Authorship 618182Authorship 593749Authorship 2467285Authorship 2528049Authorship 2582027Authorship 2689904Authorship 2691831Authorship 2771691Authorship 2836362Authorship 3007485Authorship 3068331Authorship 3091071Authorship 338142Authorship 3441693Authorship 3656502Authorship 3822932Authorship 4324142Authorship 4668212Authorship 4671112Authorship 2413891Authorship 2523292Authorship 2688810Authorship 2967003Authorship 3127712Authorship 3153924Authorship 3298719Authorship 4917778Authorship 594527Authorship 601966Authorship 602107Authorship 602909Authorship 603874Authorship 606947Authorship 607303Authorship 6471771Authorship 6428714Authorship 6468601Authorship 6660533Authorship 6521933Authorship 6471711Authorship 644192323144048Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DLEuropean heart journalResistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.Eur Heart J2012-11-09T00:00:002012Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.21597584Cannon CAcute medicineThe NICE Guideline on chest pain of recent onset: what does it mean for the acute physician? Acute Med. 2010; 9(2):98-9.Acute Med2010-01-01T00:00:002010The NICE Guideline on chest pain of recent onset: what does it mean for the acute physician?23800583Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Hoffman E, Goto S, Ohman EM, Bhatt DLThe American journal of medicineAdherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med. 2013 Aug; 126(8):693-700.e1.Am J Med2013-06-22T00:00:002013Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.23910054Cannon C, Ezekowitz MD, Granger CThe American journal of cardiologyApplying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. Am J Cardiol. 2013 Aug 15; 112(4):S3.Am J Cardiol2013-08-15T00:00:002013Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation.23800556James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RAStrokeResponse to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.Stroke2013-06-25T00:00:002013Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".23572474James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RAStrokeTicagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.Stroke2013-04-09T00:00:002013Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.Authorship 362317223680811Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WSCritical pathways in cardiology2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013 Jun; 12(2):65-105.Crit Pathw Cardiol2013-06-01T00:00:0020132013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).Authorship 3675093Authorship 615524Authorship 615682Authorship 617679Authorship 619379Authorship 622155Authorship 622545Authorship 628680Authorship 629337Authorship 786251Authorship 854835Authorship 947864Authorship 622638Authorship 1874055Authorship 1882217Authorship 5133778Authorship 543521Authorship 5569171Authorship 932592Authorship 5611002Authorship 5620672Authorship 5688502Authorship 5700156Authorship 5758862Authorship 580102Authorship 585051Authorship 585716Authorship 590207Authorship 592596Authorship 594790Authorship 2267641Authorship 2268397Authorship 6746224Authorship 674841523212806Nazer B, Ray KK, Murphy SA, Gibson CM, Cannon CPJournal of thrombosis and thrombolysisUrinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. J Thromb Thrombolysis. 2013 Oct; 36(3):233-9.J Thromb Thrombolysis2013-10-01T00:00:002013Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.23892940Peacock WF, Kontos MC, Amsterdam E, Cannon CP, Diercks D, Garvey L, Graff L, Holmes D, Holmes KS, McCord J, Newby K, Roe M, Dadkhah S, Siler-Fisher A, Ross MCritical pathways in cardiologyImpact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis. Crit Pathw Cardiol. 2013 Sep; 12(3):116-20.Crit Pathw Cardiol2013-09-01T00:00:002013Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis.Authorship 252175Authorship 6802582Authorship 680650223873635Reed GW, Cannon CPClinical cardiologyTriple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. Clin Cardiol. 2013 Oct; 36(10):585-94.Clin Cardiol2013-07-19T00:00:002013Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting.23992602White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad FThe New England journal of medicineAlogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.N Engl J Med2013-09-02T00:00:002013Alogliptin after acute coronary syndrome in patients with type 2 diabetes.Authorship 1537682Authorship 2200345Authorship 6811591124150467Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CPJAMAAssociation between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23; 310(16):1711-20.JAMA2013-10-23T00:00:002013Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.Authorship 27269411Authorship 252571Authorship 687935123973702Cannon CPJournal of the American College of CardiologyShould we measure quality by the dose? J Am Coll Cardiol. 2013 Nov 05; 62(19):1802-3.J Am Coll Cardiol2013-08-21T00:00:002013Should we measure quality by the dose?Authorship 3098602Authorship 3108556Authorship 34541424166484Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, Bhatt DLClinical cardiologyPredictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013 Dec; 36(12):721-7.Clin Cardiol2013-10-25T00:00:002013Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.Authorship 3523045Authorship 2025512Authorship 2028402Authorship 692647324064010Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RPJournal of cardiovascular pharmacology and therapeuticsCircadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.J Cardiovasc Pharmacol Ther2013-09-24T00:00:002013Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.Authorship 2103831Authorship 694655624166574Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, Hernandez AF, Hlatky MA, Luepker RV, Peterson PN, Reeves M, Smith EECirculationSynthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013 Nov 26; 128(22):2447-60.Circulation2013-10-28T00:00:002013Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.Authorship 2288042Authorship 3711610Authorship 3765563Authorship 603895Authorship 606324Authorship 2280712Authorship 698560224188894Gotto AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter PThe American journal of cardiologyEvaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.Am J Cardiol2013-10-04T00:00:002013Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.Authorship 1854584Authorship 18719112Authorship 699554324299581Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HS, Mahaffey KW, Pieper KS, Storey RF, Steg PG, Harrington RAInternational journal of cardiologyReview of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 01; 170(3):e59-62.Int J Cardiol2013-11-13T00:00:002013Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.Authorship 700314324280110Kohli P, Steg PG, Cannon CP, Smith SC, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DLThe American journal of medicineNSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014 Jan; 127(1):53-60.e1.Am J Med2013-11-23T00:00:002013NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.Authorship 265269224452727Waks JW, Sabatine MS, Cannon CP, Morrow DA, Gibson CM, Wiviott SD, Giugliano RP, Sloan S, Scirica BMClinical cardiologyClinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.Clin Cardiol2014-01-22T00:00:002014Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.Authorship 7039576Authorship 7050624Authorship 244325424170388Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SKCirculationBiomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303.Circulation2013-10-29T00:00:002013Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.24140678Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SDJournal of the American College of CardiologyDischarge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32.J Am Coll Cardiol2013-10-16T00:00:002013Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).Authorship 2324246Authorship 3930251Authorship 2843922Authorship 608484Authorship 608747Authorship 616593Authorship 616940Authorship 1779117Authorship 4098922Authorship 2070664Authorship 184582Authorship 2676381Authorship 2700773Authorship 619655Authorship 3113546Authorship 620651Authorship 620710Authorship 622040Authorship 623207Authorship 625637Authorship 625790Authorship 626766Authorship 2887067Authorship 38304114Authorship 3839968Authorship 384812Authorship 46223210Authorship 2826858Authorship 2871381Authorship 3215272Authorship 3000197Authorship 4773152Authorship 3273857Authorship 7121123Authorship 71814013Authorship 711166104Authorship 7186179Authorship 7246505Authorship 7177294Authorship 7136091Authorship 7160024Authorship 71805812Authorship 7228243Authorship 7244836Authorship 7164432Authorship 723354822993746Northfield J, Beale A, Cannon C, Gonzalez LAcute medicineEnough to bring a lump to the throat: two emergency presentations to the acute medical take. Acute Med. 2012; 11(3):154-6.Acute Med2012-01-01T00:00:002012Enough to bring a lump to the throat: two emergency presentations to the acute medical take.22958960Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DRJournal of the American College of CardiologyThird universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16; 60(16):1581-98.J Am Coll Cardiol2012-09-05T00:00:002012Third universal definition of myocardial infarction.23178643Cannon PEuropean heart journalStatement on matching language to the type of evidence used in describing observational studies vs. randomized trials. Eur Heart J. 2013 Jan; 34(1):20-1.Eur Heart J2012-11-23T00:00:002012Statement on matching language to the type of evidence used in describing observational studies vs. randomized trials.23726390Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent CLancet (London, England)Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79.Lancet2013-05-30T00:00:002013Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.24161323O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MSJournal of the American College of CardiologyLipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014 Feb 18; 63(6):520-7.J Am Coll Cardiol2013-10-23T00:00:002013Lipoprotein(a) for risk assessment in patients with established coronary artery disease.24122913Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SRClinical cardiologyVery large database of lipids: rationale and design. Clin Cardiol. 2013 Nov; 36(11):641-8.Clin Cardiol2013-10-01T00:00:002013Very large database of lipids: rationale and design.24561148Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin LJournal of the American College of CardiologyTicagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22; 63(15):1493-9.J Am Coll Cardiol2014-02-19T00:00:002014Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.24594548Xian Y, Chen AY, Thomas L, Roe MT, Subherwal S, Cannon CP, Pollack CV, Fonarow GC, Kosiborod M, Peterson ED, Alexander KPCirculation. Cardiovascular quality and outcomesSources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):236-43.Circ Cardiovasc Qual Outcomes2014-03-04T00:00:002014Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR).24672813Vardi M, Debidda M, Bhatt DL, Mauri L, Cannon CPClinical cardiologyEvolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists. Clin Cardiol. 2014 Feb; 37(2):103-7.Clin Cardiol2014-02-01T00:00:002014Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.24569634Bainey KR, Armstrong PW, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Zhao X, Schwamm LH, Bhatt DLCirculation. Cardiovascular quality and outcomesUse of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes. 2014 Mar; 7(2):227-35.Circ Cardiovasc Qual Outcomes2014-02-25T00:00:002014Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program.24085713Cavender MA, Rassi AN, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Schwamm LH, Bhatt DLClinical cardiologyRelationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease. Clin Cardiol. 2013 Dec; 36(12):749-56.Clin Cardiol2013-09-24T00:00:002013Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery Disease.Authorship 2296292Authorship 3250429Authorship 3278211Authorship 3308592Authorship 260802Authorship 852178Authorship 2727322Authorship 2773152Authorship 2774686Authorship 2857971Authorship 2947484Authorship 2948923Authorship 898212Authorship 72849260Authorship 728662224678955White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin LThe New England journal of medicineDarapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 01; 370(18):1702-11.N Engl J Med2014-03-30T00:00:002014Darapladib for preventing ischemic events in stable coronary heart disease.24786143Sarma A, Cannon CP, de Lemos J, Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue MLJournal of the American Heart AssociationThe incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc. 2014 May 01; 3(3):e000784.J Am Heart Assoc2014-05-01T00:00:002014The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.Authorship 2181173Authorship 3082324Authorship 2264741Authorship 7294163Authorship 730667524596074Cavender MA, Rassi AN, Schwamm LH, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, Hernandez AF, Peterson ED, Cox M, Grau-Sepulveda M, Bhatt DLClinical cardiologyResponse to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply. Clin Cardiol. 2014 May; 37(5):323.Clin Cardiol2014-03-04T00:00:002014Response to Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Findings from Get With the Guidelines-Coronary Artery Diseases. Authors' reply.24452828Thukkani AK, Fonarow GC, Cannon CP, Cox M, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Schwamm LH, Bhatt DLClinical cardiologyQuality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD. Clin Cardiol. 2014 May; 37(5):285-92.Clin Cardiol2014-01-22T00:00:002014Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: Insights from get with the guidelines-CAD.Authorship 3550441Authorship 3733649Authorship 2586597Authorship 2408738Authorship 2657977Authorship 2831318Authorship 2846934Authorship 2855253Authorship 738054424952862Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SKAmerican heart journalExtent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2014 Jul; 168(1):68-75.e2.Am Heart J2014-04-13T00:00:002014Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.Authorship 2045475Authorship 3556457Authorship 39270613Authorship 40916710Authorship 4205463Authorship 4274245Authorship 4295861Authorship 4317833Authorship 337928Authorship 2684251Authorship 3013831Authorship 3079201Authorship 3126533Authorship 4390952Authorship 4628702Authorship 4643781Authorship 3768519Authorship 3928961Authorship 3983848Authorship 4056268Authorship 4929102Authorship 7495193Authorship 7488753Authorship 750764325005338Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS, Storey RF, Steg PG, Harrington RAInternational journal of cardiologyNo misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.Int J Cardiol2014-06-27T00:00:002014No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.25066560Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RMAmerican heart journalEvaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug; 168(2):205-12.e1.Am Heart J2014-05-15T00:00:002014Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.24727884Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SKEuropean heart journalTicagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014 Aug 14; 35(31):2083-93.Eur Heart J2014-04-11T00:00:002014Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Authorship 3467552Authorship 3492202Authorship 353911Authorship 5229107Authorship 7566652125173516O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DLJAMAEffect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10; 312(10):1006-15.JAMA2014-09-10T00:00:002014Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.Authorship 5642181Authorship 581935Authorship 583293Authorship 585830Authorship 585889Authorship 587046Authorship 588012Authorship 591014Authorship 591854Authorship 591881Authorship 594584Authorship 594933Authorship 596269Authorship 596768Authorship 598034Authorship 599558Authorship 604937Authorship 611393Authorship 611640Authorship 611823Authorship 612834Authorship 3455155Authorship 3603255Authorship 3662231Authorship 3813542Authorship 3819256Authorship 3919071Authorship 393331Authorship 614291Authorship 4137076Authorship 763684724737712Gotto AM, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter PJournal of cardiovascular pharmacology and therapeuticsLipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther. 2014 Nov; 19(6):543-9.J Cardiovasc Pharmacol Ther2014-04-14T00:00:002014Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.Authorship 45057110Authorship 617496Authorship 617528Authorship 620976Authorship 628538Authorship 670512Authorship 7669288Authorship 765252724127651Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin LPlateletsLower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014; 25(7):517-25.Platelets2013-10-15T00:00:002013Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.24957530Varenhorst C, Alström U, Braun OÖ, Storey RF, Mahaffey KW, Bertilsson M, Cannon CP, Scirica BM, Himmelmann A, James SK, Wallentin L, Held CHeart (British Cardiac Society)Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov; 100(22):1762-9.Heart2014-06-23T00:00:002014Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.Authorship 97841Authorship 768325324585266Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DLEuropean heart journalStatin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014 Nov 01; 35(41):2864-72.Eur Heart J2014-02-28T00:00:002014Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.Authorship 2353889Authorship 4916213Authorship 427553Authorship 4426061Authorship 772278225447629Blankstein R, Cannon C, Udelson JThe American journal of medicineUpdate on pharmacological cardiac stress testing: efficacy, risk stratification and patient selection. Am J Med. 2014 Nov; 127(11):e16-e17.Am J Med2014-10-15T00:00:002014Update on pharmacological cardiac stress testing: efficacy, risk stratification and patient selection.Authorship 4597951Authorship 4707316Authorship 776279725497258Lytle BL, Li S, Lofthus DM, Thomas L, Poteat JL, Bhatt DL, Cannon CP, Fonarow GC, Peterson ED, Wang TY, Alexander KPAmerican heart journalTargeted versus standard feedback: results from a randomized quality improvement trial. Am Heart J. 2015 Jan; 169(1):132-41.e2.Am Heart J2014-10-22T00:00:002014Targeted versus standard feedback: results from a randomized quality improvement trial.Authorship 5177522Authorship 5239174Authorship 5287901Authorship 5355251Authorship 5437551Authorship 777457325227704Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson MHeart (British Cardiac Society)Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2015 Jan; 101(2):119-25.Heart2014-09-16T00:00:002014Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.Authorship 5097112Authorship 5189921Authorship 5202087Authorship 5586671Authorship 579122Authorship 579125Authorship 579148Authorship 581433Authorship 581546Authorship 582625Authorship 585472Authorship 585778Authorship 587038Authorship 5335381Authorship 5604343Authorship 5618965Authorship 5667008Authorship 5676644Authorship 5678779Authorship 5701302Authorship 5705373Authorship 5730072Authorship 577853Authorship 580051Authorship 581026Authorship 588083Authorship 593329Authorship 598380Authorship 602693Authorship 604392Authorship 604461Authorship 604973Authorship 608616Authorship 609074Authorship 611799Authorship 612205Authorship 613919Authorship 617078Authorship 618866Authorship 959422Authorship 972229Authorship 3000041Authorship 591712Authorship 211991Authorship 593602Authorship 594223Authorship 596654Authorship 5641068Authorship 5660624Authorship 577492Authorship 578591Authorship 580193Authorship 582978Authorship 583362Authorship 583439Authorship 586072Authorship 589019Authorship 592905Authorship 595051Authorship 595349Authorship 595591Authorship 595822Authorship 596925Authorship 597429Authorship 602145Authorship 606084Authorship 609265Authorship 612694Authorship 614904Authorship 616007Authorship 627852Authorship 627922Authorship 679611Authorship 941674Authorship 605252Authorship 612026Authorship 612845Authorship 614058Authorship 615995Authorship 625663Authorship 638103Authorship 773173Authorship 418521Authorship 4039853Authorship 4051926Authorship 4126Authorship 428395Authorship 4375072Authorship 44049311Authorship 4520403Authorship 470898Authorship 4430171Authorship 1669077Authorship 219844Authorship 487642Authorship 4633203Authorship 5105022Authorship 5135917Authorship 4678161Authorship 47478312Authorship 4783452Authorship 4798925Authorship 49890610Authorship 4740554Authorship 5321182Authorship 224121Authorship 2352992Authorship 5252413Authorship 4953002Authorship 22397512Authorship 5359783Authorship 54035911Authorship 3982186Authorship 5587931Authorship 56977814Authorship 580324Authorship 580713Authorship 580966Authorship 581255Authorship 584285Authorship 584761Authorship 593508Authorship 593546Authorship 594343Authorship 594583Authorship 595283Authorship 595720Authorship 597534Authorship 598525Authorship 603519Authorship 604325Authorship 607708Authorship 607844Authorship 609694Authorship 610785Authorship 613152Authorship 615236Authorship 618302Authorship 619033Authorship 5681361Authorship 5688933Authorship 581416Authorship 587857Authorship 589883Authorship 590603Authorship 620590Authorship 624195Authorship 594386Authorship 594397Authorship 5196282Authorship 599887Authorship 4162066Authorship 603215Authorship 1807498Authorship 1820042Authorship 72774Authorship 605903Authorship 607551Authorship 608001Authorship 611746Authorship 5317549Authorship 3174772Authorship 619156Authorship 886193Authorship 2551852Authorship 2554523Authorship 4547029Authorship 4554359Authorship 4909748Authorship 4952956Authorship 51790010Authorship 524862Authorship 5263691Authorship 57307911Authorship 577547Authorship 578215Authorship 579812Authorship 579837Authorship 584869Authorship 586249Authorship 587818Authorship 5645672Authorship 619870Authorship 620106Authorship 591294Authorship 591447Authorship 593366Authorship 623267Authorship 594007Authorship 5745419Authorship 625494Authorship 626684Authorship 627632Authorship 578634Authorship 579368Authorship 1837972Authorship 598980Authorship 599219Authorship 599427Authorship 580198Authorship 582631Authorship 586947Authorship 606746Authorship 607413Authorship 588048Authorship 589766Authorship 2210196Authorship 620365Authorship 621238Authorship 591088Authorship 591880Authorship 623631Authorship 596005Authorship 598527Authorship 598832Authorship 603981Authorship 606686Authorship 608186Authorship 611058Authorship 613803Authorship 615491Authorship 616662Authorship 621484Authorship 624828Authorship 625550Authorship 628319Authorship 6465510Authorship 707692Authorship 2623895Authorship 2839617Authorship 3003141Authorship 2465232Authorship 2362298Authorship 2365525Authorship 2716672Authorship 1842787Authorship 2439212Authorship 2000505Authorship 3516151Authorship 3904608Authorship 4146123Authorship 4180136Authorship 2530896Authorship 2537981Authorship 26721110Authorship 2780782Authorship 33257910Authorship 34650612Authorship 1200041Authorship 2006092Authorship 3646671Authorship 2879762Authorship 2944354Authorship 3441111Authorship 3472653Authorship 35271714Authorship 3784289Authorship 3676614Authorship 3776992Authorship 3825695Authorship 4355441Authorship 4977426Authorship 2276016Authorship 20316310Authorship 2332736Authorship 3852552Authorship 2304301Authorship 4458821Authorship 2612451Authorship 2638903Authorship 5310311Authorship 5389081Authorship 5465987Authorship 5678571Authorship 57126114Authorship 578900Authorship 579005Authorship 581251Authorship 581666Authorship 582471Authorship 584215Authorship 586953Authorship 589074Authorship 594143Authorship 594197Authorship 596173Authorship 602210Authorship 602851Authorship 603432Authorship 606517Authorship 607983Authorship 609782Authorship 610062Authorship 615516Authorship 616947Authorship 619117Authorship 621927Authorship 621939Authorship 622589Authorship 624832Authorship 824832Authorship 2441393Authorship 2607571Authorship 262201Authorship 2642801Authorship 26454512Authorship 2737554Authorship 2806712Authorship 2867391Authorship 2947235Authorship 360643Authorship 3650696Authorship 3986183Authorship 415571Authorship 4259222Authorship 4337641Authorship 4361444Authorship 1370882Authorship 1393433Authorship 4432321Authorship 2112097Authorship 4512993Authorship 4603132Authorship 2704594Authorship 2218185Authorship 2260715Authorship 2323321Authorship 2337362Authorship 2873962Authorship 297701Authorship 31929110Authorship 328867Authorship 3299471Authorship 4193653Authorship 4441352Authorship 5581891Authorship 1633041Authorship 16906011Authorship 4557421Authorship 2493961Authorship 40228430Authorship 4641942Authorship 578105Authorship 578775Authorship 581328Authorship 581818Authorship 582855Authorship 4721631Authorship 584866Authorship 584932Authorship 3238434Authorship 3386631Authorship 3689612Authorship 4131966Authorship 4279412Authorship 4556702Authorship 4625558Authorship 4626381Authorship 4794645Authorship 4991381Authorship 520512Authorship 5332597Authorship 5592132Authorship 5624256Authorship 7874933Authorship 8023877Authorship 7984763Authorship 8063077Authorship 7963403Authorship 79818210Authorship 79370010Authorship 8024204Authorship 8020711Authorship 7999604Authorship 7968677Authorship 7972737Authorship 7959982Authorship 57826325829340Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WBCirculationTreatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015 May 12; 131(19):e435-70.Circulation2015-03-31T00:00:002015Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.25828847Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe G, Oparil S, White WBHypertension (Dallas, Tex. : 1979)Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015 Jun; 65(6):1372-407.Hypertension2015-03-31T00:00:002015Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Authorship 57846125765696Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WBLancet (London, England)Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.Lancet2015-03-10T00:00:002015Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.25660925Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LÅ, Cannon CP, Harrington RA, Mark DBJournal of the American College of CardiologyEconomic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76.J Am Coll Cardiol2015-02-10T00:00:002015Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.25687353Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HMEuropean heart journalEfficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 May 14; 36(19):1186-94.Eur Heart J2015-02-16T00:00:002015Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.Authorship 578977Authorship 57901425433302Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Deedwania P, Grau-Sepulveda M, Schwamm LH, Bhatt DLThe American journal of medicineTemporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015 Apr; 128(4):426.e1-9.Am J Med2014-11-26T00:00:002014Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.25733550Patti G, Bennett R, Seshasai SR, Cannon CP, Cavallari I, Chello M, Nusca A, Mega S, Caorsi C, Spadaccio C, Keun On Y, Mannacio V, Berkan O, Yilmaz MB, Katrancioglu N, Ji Q, Kourliouros A, Baran Ç, Pasceri V, Rüçhan Akar A, Carlos Kaski J, Di Sciascio G, Ray KKEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of CardiologyStatin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. Europace. 2015 Jun; 17(6):855-63.Europace2015-03-01T00:00:002015Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials.25655085Reed GW, Kumar A, Guo J, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield K, Cannon CPClinical cardiologyPoint-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. Clin Cardiol. 2015 Feb; 38(2):92-8.Clin Cardiol2015-02-05T00:00:002015Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study.25840695Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WBJournal of the American Society of Hypertension : JASHTreatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015 Jun; 9(6):453-98.J Am Soc Hypertens2015-03-31T00:00:002015Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.25840655Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WBJournal of the American College of CardiologyTreatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015 May 12; 65(18):1998-2038.J Am Coll Cardiol2015-03-31T00:00:002015Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.25670362Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter PJournal of clinical lipidologyEffects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol. 2015 Jan-Feb; 9(1):65-71.J Clin Lipidol2014-11-04T00:00:002014Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.24989125Krygier JE, Lewis VO, Cannon CP, Satcher RL, Moon BS, Lin PPClinical orthopaedics and related researchOperative management of metastatic melanoma in bone may require en bloc resection of disease. Clin Orthop Relat Res. 2014 Oct; 472(10):3196-203.Clin Orthop Relat Res2014-07-03T00:00:002014Operative management of metastatic melanoma in bone may require en bloc resection of disease.Authorship 58020126027630Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HMAmerican heart journalEfficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun; 169(6):906-915.e13.Am Heart J2015-03-13T00:00:002015Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.Authorship 580652Authorship 584488Authorship 584776Authorship 586044Authorship 587354Authorship 588061Authorship 590563Authorship 593597Authorship 594181Authorship 594695Authorship 594931Authorship 595345Authorship 596679Authorship 600074Authorship 600975Authorship 604489Authorship 612612Authorship 613129Authorship 619657Authorship 626646Authorship 626997Authorship 628390Authorship 2440556Authorship 2458421Authorship 28292521Authorship 2843443Authorship 2939143Authorship 3348645Authorship 270526125971287Shimada YJ, Cannon CPEuropean heart journalPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015 Sep 21; 36(36):2415-24.Eur Heart J2015-05-12T00:00:002015PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Authorship 2738905Authorship 290752Authorship 2994375Authorship 3052604Authorship 3127883Authorship 3224777Authorship 349981Authorship 3508551Authorship 3664115Authorship 3677501Authorship 382276Authorship 3825038Authorship 3918667Authorship 4028271Authorship 4116845Authorship 4124201Authorship 419052Authorship 4325811Authorship 435081Authorship 4609636Authorship 4810356Authorship 4868276Authorship 4919891Authorship 5103905Authorship 5116721Authorship 5160015Authorship 5284295Authorship 5303201Authorship 3668182Authorship 4465268Authorship 452353Authorship 507072626119654Khera AV, Qamar A, Murphy SA, Cannon CP, Sabatine MS, Rader DJThe American journal of cardiologyOn-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). Am J Cardiol. 2015 Sep 01; 116(5):694-8.Am J Cardiol2015-06-04T00:00:002015On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).Authorship 5164061Authorship 5181363Authorship 5701215Authorship 582071Authorship 583885Authorship 585541Authorship 586882Authorship 2866255Authorship 8092569Authorship 8086223Authorship 809632126039521Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RMThe New England journal of medicineEzetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97.N Engl J Med2015-06-03T00:00:002015Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.25748612Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MSLancet (London, England)Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271.Lancet2015-03-04T00:00:002015Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.26102848Chilton R, Tikkanen I, Cannon CP, Crowe S, Hach T, Woerle HJ, Broedl UC, Johansen OEJournal of hypertension4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES. J Hypertens. 2015 Jun; 33 Suppl 1:e53.J Hypertens2015-06-01T00:00:0020154B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES.Authorship 4847556Authorship 595193Authorship 587017Authorship 597927Authorship 587860Authorship 598822Authorship 2943326Authorship 599729Authorship 599929Authorship 295281Authorship 3006858Authorship 8136401226032114Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DLAlimentary pharmacology & therapeuticsThe effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Aliment Pharmacol Ther. 2015 Aug; 42(3):365-74.Aliment Pharmacol Ther2015-05-29T00:00:002015The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.Authorship 3174982Authorship 2974244Authorship 3125291Authorship 3447579Authorship 819313326216006Reed GW, Guo J, Cannon CP, Kumar A, Aranki S, Shekar P, Agnihotri A, Maree AO, McLean DS, Rosenfield KClinical cardiologyAuthors' Reply. Clin Cardiol. 2015 Jul; 38(7):444-5.Clin Cardiol2015-07-01T00:00:002015Authors' Reply.Authorship 4149781Authorship 4236234Authorship 4285562Authorship 4310115Authorship 435108Authorship 4484151Authorship 8262024Authorship 4584349Authorship 4714722Authorship 4870051Authorship 4991265Authorship 5155482Authorship 5716272Authorship 577501Authorship 583393Authorship 584637Authorship 585501Authorship 586236Authorship 586725Authorship 594606Authorship 594867Authorship 595537Authorship 596511Authorship 601678Authorship 603008Authorship 603737Authorship 604062Authorship 604703Authorship 609118Authorship 609827Authorship 613553Authorship 614516Authorship 615008Authorship 617337Authorship 618282Authorship 622775Authorship 8354622Authorship 623747Authorship 625585Authorship 625693Authorship 836314326330412Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald ECirculationAchievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33.Circulation2015-09-01T00:00:002015Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.Authorship 993722Authorship 3602563Authorship 3676054Authorship 8401591Authorship 840084326444734Cannon CP, Blazing MA, Braunwald EThe New England journal of medicineEzetimibe plus a Statin after Acute Coronary Syndromes. N Engl J Med. 2015 10 08; 373(15):1476-7.N Engl J Med2015-10-08T00:00:002015Ezetimibe plus a Statin after Acute Coronary Syndromes.26452988Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge DJournal of the American Heart AssociationTicagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015 Oct 09; 4(10):e002490.J Am Heart Assoc2015-10-09T00:00:002015Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Authorship 4124085Authorship 42584510Authorship 436121Authorship 842899326343814Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OEDiabetes, obesity & metabolismEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015 Dec; 17(12):1180-93.Diabetes Obes Metab2015-10-09T00:00:002015Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Authorship 45519510Authorship 4693612Authorship 47360410Authorship 4817854Authorship 848673425254357Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, Wallentin L, Steg PGEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of CardiologyAssociation of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.EuroIntervention2015-11-01T00:00:002015Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.Authorship 5209905Authorship 8526198Authorship 853120326699597Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf F, James SK, Cannon CP, Armstrong PW, White HD, Califf RM, Gibson CM, Giugliano RP, Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini JPAmerican heart journalHigh-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J. 2016 Jan; 171(1):25-32.Am Heart J2015-09-12T00:00:002015High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.26687696Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DAJournal of clinical lipidologyEfficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec; 9(6):758-769.J Clin Lipidol2015-08-29T00:00:002015Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.Authorship 4437272Authorship 8564616Authorship 855900126450011Cannon CPEuropean heart journalShould all surgery patients get statins pre-operatively? Clear or blurry VISION? Eur Heart J. 2016 Jan 07; 37(2):186-8.Eur Heart J2015-10-07T00:00:002015Should all surgery patients get statins pre-operatively? Clear or blurry VISION?26651452Tickoo S, Bhardwaj A, Fonarow GC, Liang L, Bhatt DL, Cannon CPThe American journal of cardiologyRelation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set). Am J Cardiol. 2016 Jan 15; 117(2):201-5.Am J Cardiol2015-11-05T00:00:002015Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines--Coronary Artery Disease Data Set).Authorship 495881Authorship 4971872Authorship 4989121Authorship 5312293Authorship 532628Authorship 5362646Authorship 5551096Authorship 577476Authorship 579460Authorship 583349Authorship 587115Authorship 595250Authorship 598347Authorship 599967Authorship 606047Authorship 608946Authorship 615423Authorship 624307Authorship 629048Authorship 8644242Authorship 865095226810596Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BMCirculation. Arrhythmia and electrophysiologyRelationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016 Feb; 9(2):e002951.Circ Arrhythm Electrophysiol2016-02-01T00:00:002016Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.26821621Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald EJournal of the American College of CardiologyReduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361.J Am Coll Cardiol2016-02-02T00:00:002016Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.Authorship 94191Authorship 600344Authorship 602057Authorship 602167Authorship 606181Authorship 606542Authorship 607312Authorship 607647Authorship 608721Authorship 609231Authorship 611103Authorship 617801Authorship 620659Authorship 621293Authorship 621998Authorship 624875Authorship 625515Authorship 649041Authorship 767056Authorship 811934Authorship 3227726Authorship 3381108Authorship 33925711Authorship 1820372Authorship 8754253Authorship 8756721427022050Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, Tershakovec AM, Blazing MA, Braunwald ECirculationResponse to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463.Circulation2016-03-29T00:00:002016Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".27012778Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CPJournal of the American College of CardiologyProton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71.J Am Coll Cardiol2016-03-21T00:00:002016Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.Authorship 3858032Authorship 3876191Authorship 3981998Authorship 879968526945047Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman ADCirculationIndividualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation. 2016 Apr 19; 133(16):1574-81.Circulation2016-03-04T00:00:002016Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.Authorship 4750021Authorship 5033272Authorship 5114115Authorship 8809722Authorship 8818671027179720Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WBAmerican heart journalIschemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.Am Heart J2016-01-23T00:00:002016Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.27179718Mathews R, Fonarow GC, Li S, Peterson ED, Rumsfeld JS, Heidenreich PA, Roe MT, Oetgen WJ, Jollis JG, Cannon CP, de Lemos JA, Wang TYAmerican heart journalComparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. Am Heart J. 2016 May; 175:1-8.Am Heart J2016-01-22T00:00:002016Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.Authorship 5193031Authorship 883427327207959O'Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, Murphy SA, Gerszten RE, Sabatine MSJournal of the American Heart AssociationMultimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016 05 20; 5(5).J Am Heart Assoc2016-05-20T00:00:002016Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.Authorship 577919Authorship 582315Authorship 8870084Authorship 8869896Authorship 8869741527297843Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CPAmerican heart journalImpact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.Am Heart J2016-04-13T00:00:002016Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.27297847Doll JA, Wang TY, Choudhry NK, Cannon CP, Cohen DJ, Fonarow GC, Henry TD, Bhandary DD, Khan N, Davidson-Ray LD, Anstrom K, Peterson EDAmerican heart journalRationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. Am Heart J. 2016 Jul; 177:33-41.Am Heart J2016-04-19T00:00:002016Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.27287699Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJJournal of the American Heart AssociationRelationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. J Am Heart Assoc. 2016 06 10; 5(6).J Am Heart Assoc2016-06-10T00:00:002016Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.Authorship 587500Authorship 588435Authorship 592689Authorship 594534Authorship 594848Authorship 595389Authorship 598841Authorship 599471Authorship 606274Authorship 609834Authorship 613742Authorship 617425Authorship 617779Authorship 618234Authorship 619750Authorship 621104Authorship 621830Authorship 622474Authorship 623009Authorship 625331Authorship 628803Authorship 5487642Authorship 5496537Authorship 578157Authorship 579484Authorship 8884704Authorship 8895352Authorship 8895931327329448Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HDJournal of the American Heart AssociationLipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 06 21; 5(6).J Am Heart Assoc2016-06-21T00:00:002016Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.27289121White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CPDiabetes careCardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73.Diabetes Care2016-06-11T00:00:002016Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.27339506Murphy SA, Cannon CP, Blazing MA, Giugliano RP, Tershakovec AM, Braunwald EJournal of the American College of CardiologyReply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? J Am Coll Cardiol. 2016 06 28; 67(25):3025-6.J Am Coll Cardiol2016-06-28T00:00:002016Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?Authorship 581643Authorship 581662Authorship 585273Authorship 585355Authorship 592124Authorship 5939582Assistant Professor1Associate Professor0Full Professor4InstructorAuthorship 599946Authorship 600374Authorship 603366Authorship 604111Authorship 606080Authorship 606511Authorship 606759Authorship 610765Authorship 612708Authorship 614333Authorship 623459Authorship 665974Authorship 721726Authorship 85862Authorship 865871Authorship 942462Authorship 8915622Authorship 891045727417011Bonaca MP, O'Malley RG, Jarolim P, Scirica BM, Murphy SA, Conrad MJ, Cannon CP, White HD, Braunwald E, Morrow DA, Sabatine MSJournal of the American College of CardiologySerial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.J Am Coll Cardiol2016-07-19T00:00:002016Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.27417014Murphy SA, Cannon CP, Blazing MA, Giugliano RP, Tershakovec AM, Braunwald EJournal of the American College of CardiologyReply: Personalize and Optimize Lipid-Lowering Therapies. J Am Coll Cardiol. 2016 07 19; 68(3):326.J Am Coll Cardiol2016-07-19T00:00:002016Reply: Personalize and Optimize Lipid-Lowering Therapies.Authorship 4869663Authorship 577425Authorship 578161Authorship 587515Authorship 589354Authorship 593629Authorship 593669Authorship 598837Authorship 600810Authorship 601500Authorship 601560Authorship 601694Authorship 606166Authorship 608168Authorship 608240Authorship 608595Authorship 608857Authorship 611425Authorship 612501Authorship 614078Authorship 617009Authorship 617232Authorship 620154Authorship 620771Authorship 626061Authorship 628233Authorship 963131Authorship 5345552Authorship 578696Authorship 585598Authorship 597635Authorship 598145Authorship 598283Authorship 897050527480840White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer SHypertension (Dallas, Tex. : 1979)Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.Hypertension2016-08-01T00:00:002016Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.Authorship 603918Authorship 606216Authorship 607687Authorship 608048Authorship 608580Authorship 608903Authorship 609355Authorship 617151Authorship 617358Authorship 623943Authorship 781105Authorship 805281Authorship 4814453Authorship 482051Authorship 4847223Authorship 5009351Authorship 90866314Authorship 908104227143321Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DLThe American journal of medicineEfficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016 Sep; 129(9):1002-5.Am J Med2016-04-30T00:00:002016Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.27561775Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CPJournal of the American College of CardiologyReply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol. 2016 08 30; 68(9):981-2.J Am Coll Cardiol2016-08-30T00:00:002016Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment.27569841Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald EEuropean heart journalThe benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 Dec 21; 37(48):3576-3584.Eur Heart J2016-08-28T00:00:002016The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.Authorship 535172Authorship 5726032Authorship 57635016Authorship 578559Authorship 580909Authorship 582751Authorship 584512Authorship 586047Authorship 592559Authorship 595281Authorship 595425Authorship 595475Authorship 599068Authorship 601717Authorship 602389Authorship 602973Authorship 606335Authorship 608720Authorship 609758Authorship 610633Authorship 610657Authorship 611700Authorship 615573Authorship 620625Authorship 622273Authorship 622467Authorship 625816Authorship 626174Authorship 628240Authorship 683298Authorship 590964Authorship 592068Authorship 599377Authorship 600643Authorship 604352Authorship 605423Authorship 608428Authorship 608849Authorship 615601Authorship 617181Authorship 617504Authorship 620006Authorship 621053Authorship 621241Authorship 6354518Authorship 715796Authorship 7421Authorship 877811Authorship 926266Authorship 3368441Authorship 3554262Authorship 3782796Authorship 37945411Authorship 927706327740972Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier MCoronary artery diseaseEffect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coron Artery Dis. 2017 05; 28(3):190-197.Coron Artery Dis2017-05-01T00:00:002017Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.Authorship 4487448Authorship 4547491Authorship 46638810Authorship 4694788Authorship 4757807Authorship 1891382Authorship 1893501Authorship 5052219Authorship 5624936Authorship 566668Authorship 9332981Authorship 937048725828786Cannon C, Borgatti A, Henson M, Husbands BThe Journal of small animal practiceEvaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015 Jul; 56(7):425-9.J Small Anim Pract2015-04-01T00:00:002015Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.27803042Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DPCirculation. Cardiovascular interventionsAntithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 11; 9(11).Circ Cardiovasc Interv2016-11-01T00:00:002016Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.Authorship 581046Authorship 582137Authorship 587019Authorship 592065Authorship 592636Authorship 593123Authorship 593179Authorship 595112Authorship 600509Authorship 602509Authorship 602928Authorship 605797Authorship 607485Authorship 607733Authorship 609509Authorship 611040Authorship 611251Authorship 612156Authorship 620893Authorship 622221Authorship 623557Authorship 624353Authorship 625260Authorship 627671Authorship 628878Authorship 213934Authorship 2205975Authorship 232331Authorship 2425224Authorship 9393801Authorship 938949420157362Cannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, Dibattiste PMArchives of drug informationA Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Arch Drug Inf. 2008 Jul; 1(1):4-13.Arch Drug Inf2008-07-01T00:00:002008A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.27914504Blazing MA, Giugliano RP, de Lemos JA, Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tershakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald EAmerican heart journalOn-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.Am Heart J2016-09-23T00:00:002016On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).Authorship 2767844Authorship 292552Authorship 3206651Authorship 939627527932413Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin LClinical chemistryBiomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584.Clin Chem2016-12-08T00:00:002016Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.Authorship 3687202Authorship 372694Authorship 3874476Authorship 943313827777279Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CPCirculationReductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.Circulation2016-10-24T00:00:002016Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.Authorship 4035412Authorship 4037334Authorship 4046174Authorship 4096922Authorship 4232189Authorship 43414612Authorship 9469526Authorship 9480361328058763Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CPDiabetes, obesity & metabolismRelationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.Diabetes Obes Metab2017-02-27T00:00:002017Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.27811204Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin LClinical chemistryGrowth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017 Jan; 63(1):325-333.Clin Chem2016-11-03T00:00:002016Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.28077384Eisen A, Cannon CP, Braunwald E, Steen DL, Zhou J, Goodrich EL, Im K, Dalby AJ, Spinar J, Daga S, Lukas MA, O'Donoghue MLJournal of the American Heart AssociationPredictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 01 11; 6(1).J Am Heart Assoc2017-01-11T00:00:002017Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.Authorship 464638Authorship 4844436Authorship 9488912Authorship 9499312Authorship 49595313Authorship 5153843Authorship 950327327502078Reed GW, Rossi JE, Cannon CPLancet (London, England)Acute myocardial infarction. Lancet. 2017 01 14; 389(10065):197-210.Lancet2016-08-05T00:00:002016Acute myocardial infarction.Authorship 5647785Authorship 5763122Authorship 577654Authorship 577691Authorship 578557Authorship 583637Authorship 584684Authorship 584830Authorship 585673Authorship 954994227977392Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OEHypertension (Dallas, Tex. : 1979)Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension. 2016 12; 68(6):1355-1364.Hypertension2016-10-10T00:00:002016Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.Authorship 589657Authorship 589823Authorship 591406Authorship 598004Authorship 599369Authorship 600020Authorship 600861Authorship 601587Authorship 602729Authorship 602805Authorship 605752Authorship 606911Authorship 956121127565018Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SHClinical cardiologyDesign and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol. 2016 Oct; 39(10):555-564.Clin Cardiol2016-08-26T00:00:002016Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.Authorship 608083Authorship 608274Authorship 609284Authorship 610672Authorship 613084Authorship 613992Authorship 621822Authorship 624406Authorship 957514228195387Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DADiabetes, obesity & metabolismBaseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017 07; 19(7):962-969.Diabetes Obes Metab2017-03-17T00:00:002017Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.Authorship 725811Authorship 794412Authorship 884082Columbia College of Physicians and Surgeons1986Upjohn Achievement in Research AwardBest Doctors in America20072005Best Doctors in AmericaMt. Sinai School Of Medicine20012001Simon Dack Visiting ProfessorYale College1982Magna Cum LaudeNational Institute of Health1983NIH Students Research Fellowship AwardNational Institute of Health1985NIH Student Research Fellowship AwardYale College1980Phi Beta KappaColumbia College of Physicians and Surgeons1986Robert F. Loeb Award for Excellence in Clinical MedicineThompson Reuters20162014Highly Cited Researchers; World’s Most Influential Scientific MindsPartners Healthcare20042004Partners in Excellence AwardColumbia College of Physicians and Surgeons1986Alpha Omega AlphaColumbia College of Physicians and Surgeons1985Aldred Steiner Research AwardPartners Healthcare20072006Partners In Excellence AwardBoston Magazine20072007Best Doctors in Boston8857017Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald EThe New England journal of medicineCardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31; 335(18):1342-9.N Engl J Med1996-10-31T00:00:001996Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.8806332Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo JThe American journal of cardiologyUsefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996 Sep 01; 78(5):503-10.Am J Cardiol1996-09-01T00:00:001996Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.8914880Cannon CP, Goldhaber SZThe American journal of cardiologyCardiovascular risk stratification of pulmonary embolism. Am J Cardiol. 1996 Nov 15; 78(10):1149-51.Am J Cardiol1996-11-15T00:00:001996Cardiovascular risk stratification of pulmonary embolism.8752182Birnbaum Y, Kloner RA, Sclarovsky S, Cannon CP, McCabe CH, Davis VG, Zaret BL, Wackers FJ, Braunwald EThe American journal of cardiologyDistortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial). Am J Cardiol. 1996 Aug 15; 78(4):396-403.Am J Cardiol1996-08-15T00:00:001996Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial).9459338Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TWThrombosis and haemostasisPharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998 Jan; 79(1):134-9.Thromb Haemost1998-01-01T00:00:001998Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.9592435Wieczorek RR, Price MR, Cannon CJournal of nursing staff development : JNSDA pharmacology review for private duty nurses using computers and self learning concepts. J Nurs Staff Dev. 1998 Mar-Apr; 14(2):95-7.J Nurs Staff Dev1998-03-01T00:00:001998A pharmacology review for private duty nurses using computers and self learning concepts.10072215Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, Spertus JA, Feeny D, Cohen DJ, Krumholz H, Ellis SG, Demopoulos L, Robertson D, Boccuzzi SJ, Barr E, Cannon CPThe American journal of cardiologyEconomics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. Am J Cardiol. 1999 Feb 01; 83(3):317-22.Am J Cardiol1999-02-01T00:00:001999Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.10220625Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald EAmerican heart journalSafety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999 May; 137(5):786-91.Am Heart J1999-05-01T00:00:001999Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.10492852Cannon CPClinical cardiologyCombination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV37-43.Clin Cardiol1999-08-01T00:00:001999Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.10599534Cannon CPCoronary artery diseaseGlycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coron Artery Dis. 1999 Dec; 10(8):561-6.Coron Artery Dis1999-12-01T00:00:001999Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction.11050380Cannon CP, Sayah AJ, Walls RMThe Journal of emergency medicineER TIMI-19: testing the reality of prehospital thrombolysis. J Emerg Med. 2000 Oct; 19(3 Suppl):21S-25S.J Emerg Med2000-10-01T00:00:002000ER TIMI-19: testing the reality of prehospital thrombolysis.11054614Cannon CPAmerican heart journalMultimodality reperfusion therapy for acute myocardial infarction. Am Heart J. 2000 Nov; 140(5):707-16.Am Heart J2000-11-01T00:00:002000Multimodality reperfusion therapy for acute myocardial infarction.11113418Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MH, Antman EM, Cannon CP, Braunwald EThe American journal of cardiologyImpact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Dec 15; 86(12):1378-9, A5.Am J Cardiol2000-12-15T00:00:002000Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction.11560541Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald EJAMAApplication of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.JAMA2001-09-19T00:00:002001Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3.11738323Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli TJournal of the American College of CardiologyAmerican College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001 Dec; 38(7):2114-30.J Am Coll Cardiol2001-12-01T00:00:002001American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee).11960542Cannon CPJAMAPrimary percutaneous coronary intervention for all? JAMA. 2002 Apr 17; 287(15):1987-9.JAMA2002-04-17T00:00:002002Primary percutaneous coronary intervention for all?12724583Cannon CThe Journal of invasive cardiologyImproving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. J Invasive Cardiol. 2003 Mar; 15 Suppl B:22B-27B; discussion 27B-29B.J Invasive Cardiol2003-03-01T00:00:002003Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways.14581255Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KAArchives of internal medicinePredictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003 Oct 27; 163(19):2345-53.Arch Intern Med2003-10-27T00:00:002003Predictors of hospital mortality in the global registry of acute coronary events.15342161Cannon CPEuropean heart journalRevascularisation for everyone? Eur Heart J. 2004 Sep; 25(17):1471-2.Eur Heart J2004-09-01T00:00:002004Revascularisation for everyone?15541835Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald EEuropean heart journalAssociation of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.Eur Heart J2004-11-01T00:00:002004Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials.9462575Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyTime to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol. 1998 Feb; 31(2):326-30.J Am Coll Cardiol1998-02-01T00:00:001998Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.16887854Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CMEuropean heart journalBenefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6.Eur Heart J2006-08-03T00:00:002006Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.16989592Ray KK, Cannon CPExpert opinion on investigational drugsIntensive statin therapy for treating acute coronary syndromes. Expert Opin Investig Drugs. 2006 Oct; 15(10):1151-9.Expert Opin Investig Drugs2006-10-01T00:00:002006Intensive statin therapy for treating acute coronary syndromes.9626820Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyC-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun; 31(7):1460-5.J Am Coll Cardiol1998-06-01T00:00:001998C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.9973029Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ, Antman EMJournal of the American College of CardiologyFatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol. 1999 Feb; 33(2):479-87.J Am Coll Cardiol1999-02-01T00:00:001999Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.11136484Wang-Clow F, Fox NL, Cannon CP, Gibson CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DCAmerican heart journalDetermination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001 Jan; 141(1):33-40.Am Heart J2001-01-01T00:00:002001Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.11431653Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA, Sokol S, Braunwald E, Mueller HSAmerican heart journalMyoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J. 2001 Jul; 142(1):29-36.Am Heart J2001-07-01T00:00:002001Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy.12975594Serrano CV, Nicolau JC, Venturinelli M, Baracioli LM, Anders RJ, Cannon CP, Ramires JACardiovascular drugs and therapyRole of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther. 2003 Mar; 17(2):129-32.Cardiovasc Drugs Ther2003-03-01T00:00:002003Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.14584479Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelson JEReviews in cardiovascular medicineRole of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S54-9.Rev Cardiovasc Med2003-01-01T00:00:002003Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction.75 Francis StBrigham and Women's HospitalCardiovascular75 Francis StBoston02115MA15215808Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CPAmerican heart journalValidated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J. 2004 Jul; 148(1):173-80.Am Heart J2004-07-01T00:00:002004Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18.15374786Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux PThe American journal of cardiologyUsefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6.Am J Cardiol2004-09-15T00:00:002004Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).15635109Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald EThe New England journal of medicineC-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 06; 352(1):20-8.N Engl J Med2005-01-06T00:00:002005C-reactive protein levels and outcomes after statin therapy.15670541Kirtane AJ, Kosmidou I, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CMThe American journal of cardiologyAssociation of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.Am J Cardiol2005-02-01T00:00:002005Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy.Authorship 963112810150348Cannon CPContemporary internal medicineImproved management of unstable angina and non-Q-wave MI. Contemp Intern Med. 1995 May; 7(5):11-2, 15-6, 19-24.Contemp Intern Med1995-05-01T00:00:001995Improved management of unstable angina and non-Q-wave MI.Authorship 966514227044282Giannitsis E, Wallentin L, James SK, Bertilsson M, Siegbahn A, Storey RF, Husted S, Cannon CP, Armstrong PW, Steg PG, Katus HAEuropean heart journal. Acute cardiovascular careOutcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. Eur Heart J Acute Cardiovasc Care. 2017 Sep; 6(6):500-510.Eur Heart J Acute Cardiovasc Care2016-04-04T00:00:002016Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.26909669Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & InterventionsInfluence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):190-198.Catheter Cardiovasc Interv2016-02-23T00:00:002016Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.15936996Reid IR, Tonkin A, Cannon CPBoneComparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. Bone. 2005 Aug; 37(2):190-1.Bone2005-08-01T00:00:002005Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial.15952920Ray KK, Cannon CPExpert opinion on pharmacotherapyAtorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother. 2005 Jun; 6(6):915-27.Expert Opin Pharmacother2005-06-01T00:00:002005Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.10577436Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CPAmerican heart journalRacial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. 1999 Dec; 138(6 Pt 1):1065-72.Am Heart J1999-12-01T00:00:001999Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry.10608003Cannon CPJournal of thrombosis and thrombolysisHirudin in Acute Myocardial Infarction. J Thromb Thrombolysis. 1995; 1(3):259-267.J Thromb Thrombolysis1995-01-01T00:00:001995Hirudin in Acute Myocardial Infarction.10608025Cannon CPJournal of thrombosis and thrombolysisOptimizing the Treatment of Unstable Angina. J Thromb Thrombolysis. 1995; 2(3):205-218.J Thromb Thrombolysis1995-01-01T00:00:001995Optimizing the Treatment of Unstable Angina.Authorship 96769810Authorship 96911713Authorship 969448628246236Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DACirculationSerial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.Circulation2017-02-28T00:00:002017Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).28206704Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman YDiabetes, obesity & metabolismLipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.Diabetes Obes Metab2017-04-18T00:00:002017Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.28231942Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald EJournal of the American College of CardiologyAtherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921.J Am Coll Cardiol2017-02-28T00:00:002017Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.9823789Cannon CPCurrent opinion in cardiologyAdvances in the medical management of acute coronary syndromes. Curr Opin Cardiol. 1998 Sep; 13(5):327-47.Curr Opin Cardiol1998-09-01T00:00:001998Advances in the medical management of acute coronary syndromes.9929749Cannon CP, Johnson EB, Cermignani M, Scirica BM, Sagarin MJ, Walls RMClinical cardiologyEmergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol. 1999 Jan; 22(1):17-20.Clin Cardiol1999-01-01T00:00:001999Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction.28297015Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB, Massaro JM, Mauri LJAMA cardiologyMortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.JAMA Cardiol2017-05-01T00:00:002017Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.16534008Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald ECirculationA tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14.Circulation2006-03-13T00:00:002006A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.16687939Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald EJournal of clinical hypertension (Greenwich, Conn.)Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.J Clin Hypertens (Greenwich)2006-05-01T00:00:002006Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome.16874355Wiviott SD, Cannon CPNature clinical practice. Cardiovascular medicineUpdate on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug; 3(8):424-36.Nat Clin Pract Cardiovasc Med2006-08-01T00:00:002006Update on lipid-lowering therapy and LDL-cholesterol targets.16954134Ahmed S, Cannon CP, Murphy SA, Braunwald EEuropean heart journalAcute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct; 27(19):2323-9.Eur Heart J2006-09-05T00:00:002006Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial.17177205Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AWCancerChemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer. 2007 Feb 01; 109(3):603-11.Cancer2007-02-01T00:00:002007Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.9052337Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald EThe American journal of cardiologyHemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol. 1997 Feb 15; 79(4):391-6.Am J Cardiol1997-02-15T00:00:001997Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).10364769Cannon CPJournal of thrombosis and thrombolysisAdvances in the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999 Apr; 7(2):171-89.J Thromb Thrombolysis1999-04-01T00:00:001999Advances in the medical management of acute coronary syndromes.10676681Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologySerum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000 Feb; 35(2):358-62.J Am Coll Cardiol2000-02-01T00:00:002000Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy.10728022Cannon CPJournal of thrombosis and thrombolysisBridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. J Thromb Thrombolysis. 2000 Apr; 9(3):235-41.J Thromb Thrombolysis2000-04-01T00:00:002000Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI.10783408Zalenski RJ, Selker HP, Cannon CP, Farin HM, Gibler WB, Goldberg RJ, Lambrew CT, Ornato JP, Rydman RJ, Steele PAnnals of emergency medicineNational Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia. Ann Emerg Med. 2000 May; 35(5):462-71.Ann Emerg Med2000-05-01T00:00:002000National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia.Authorship 9713889Authorship 971481728291866Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald EJAMA cardiologyLong-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 05 01; 2(5):547-555.JAMA Cardiol2017-05-01T00:00:002017Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.11416575McKay CR, Rich MW, Vlietstra RE, Kitzman DW, Fleg JL, Krumholz HM, Lakatta EG, Cooke JP, Cannon CP, Ezekowitz MD, Frohlich ED, Jalife J, Kass DA, Kottke BA, Muller JE, Saltin B, Shen WK, Somers VKThe American journal of geriatric cardiologyExecutive Summary: Pivotal Research in Cardiovascular Syndromes in the Elderly. Am J Geriatr Cardiol. 2000 Oct; 9(5):243-250.Am J Geriatr Cardiol2000-10-01T00:00:002000Executive Summary: Pivotal Research in Cardiovascular Syndromes in the Elderly.11863347Leebeek FW, Boersma E, Cannon CP, van de Werf FJ, Simoons MLEuropean heart journalOral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J. 2002 Mar; 23(6):444-57.Eur Heart J2002-03-01T00:00:002002Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.11909576Cannon CP, McCabe CH, Belder R, Breen J, Braunwald EThe American journal of cardiologyDesign of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002 Apr 01; 89(7):860-1.Am J Cardiol2002-04-01T00:00:002002Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.17624497Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Gibson CMJournal of thrombosis and thrombolysisAngiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. J Thromb Thrombolysis. 2008 Oct; 26(2):106-12.J Thromb Thrombolysis2007-07-12T00:00:002007Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days.18340192Morrow DA, Cannon CPCritical pathways in cardiologyBrigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarction. Crit Pathw Cardiol. 2005 Jun; 4(2):107-9.Crit Pathw Cardiol2005-06-01T00:00:002005Brigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarction.18340219Steinberg BA, French WJ, Peterson ED, Frederick PD, Cannon CPCritical pathways in cardiologyMissed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction. Crit Pathw Cardiol. 2006 Mar; 5(1):59-63.Crit Pathw Cardiol2006-03-01T00:00:002006Missed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction.18387931Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EMJAMAEffect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 02; 299(13):1547-60.JAMA2008-04-01T00:00:002008Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.18481816Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyAssessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.Clin Cardiol2008-03-01T00:00:002008Assessing the current role of platelet function testing.19130984Diercks DB, Kontos MC, Chen AY, Pollack CV, Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, Roe MTJournal of the American College of CardiologyUtilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009 Jan 13; 53(2):161-6.J Am Coll Cardiol2009-01-13T00:00:002009Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.19335707Husted S, Harrington RA, Cannon CP, Storey RF, Mitchell P, Emanuelsson HInternational journal of clinical practiceBleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract. 2009 Apr; 63(4):667-70.Int J Clin Pract2009-04-01T00:00:002009Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.19423566Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, Braunwald E, Cannon CP, Choudhry NKClinical journal of the American Society of Nephrology : CJASNEarly angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1032-43.Clin J Am Soc Nephrol2009-05-07T00:00:002009Early angiography in patients with chronic kidney disease: a collaborative systematic review.20102867Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BMAmerican heart journalExtent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.Am Heart J2010-01-01T00:00:002010Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.20102907Ambardekar AV, Fonarow GC, Dai D, Peterson ED, Hernandez AF, Cannon CP, Krantz MJThe American journal of cardiologyQuality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). Am J Cardiol. 2010 Jan 15; 105(2):139-43.Am J Cardiol2009-11-14T00:00:002009Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program).20152237Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DLThe American journal of cardiologyCurrent use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52.Am J Cardiol2010-01-05T00:00:002010Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).12031730Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K, Cannon CPThe American journal of cardiologyComparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period. Am J Cardiol. 2002 Jun 01; 89(11):1291-3.Am J Cardiol2002-06-01T00:00:002002Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period.12355029Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, Gibson CMJournal of thrombosis and thrombolysisThe smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002 Jun; 13(3):133-9.J Thromb Thrombolysis2002-06-01T00:00:002002The smoker's paradox: insights from the angiographic substudies of the TIMI trials.15518603Karmpaliotis D, Turakhia MP, Kirtane AJ, Murphy SA, Kosmidou I, Morrow DA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CMThe American journal of cardiologySequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.Am J Cardiol2004-11-01T00:00:002004Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction.15758000Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald EThe New England journal of medicineAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179-89.N Engl J Med2005-03-09T00:00:002005Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.16046952Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CVAnnals of emergency medicinePractical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. Ann Emerg Med. 2005 Aug; 46(2):185-97.Ann Emerg Med2005-08-01T00:00:002005Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department.9351728Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald EAmerican heart journalMyoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997 Oct; 134(4):622-30.Am Heart J1997-10-01T00:00:001997Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A.9761082Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald EThe American journal of cardiologyInvasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol. 1998 Sep 15; 82(6):731-6.Am J Cardiol1998-09-15T00:00:001998Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.10767103Goel M, Dodge JT, Rizzo M, McLean C, Ryan KA, Daley WL, Cannon CP, Gibson CMJournal of thrombosis and thrombolysisThe Open Artery Hypothesis: Past, Present, and Future. J Thromb Thrombolysis. 1998 05; 5(2):101-112.J Thromb Thrombolysis1998-05-01T00:00:001998The Open Artery Hypothesis: Past, Present, and Future.10806604Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald EJournal of clinical pharmacologyPharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000 May; 40(5):508-15.J Clin Pharmacol2000-05-01T00:00:002000Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.15846265Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwauld E, Langer AAmerican heart journalEarly cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Am Heart J. 2005 Feb; 149(2):275-83.Am Heart J2005-02-01T00:00:002005Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.15992655Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CMJournal of the American College of CardiologyU-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 05; 46(1):178-80.J Am Coll Cardiol2005-07-05T00:00:002005U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction.16152646Levine GN, Lincoff AM, Ferguson JJ, Mahaffey KW, Goodman SG, Cannon CP, Theroux P, Fox KACatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & InterventionsUtilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv. 2005 Oct; 66(2):149-57.Catheter Cardiovasc Interv2005-10-01T00:00:002005Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade.16379780Cannon CPEvidence-based cardiovascular medicineReteplase was not better than alteplase in reducing 30-day mortality among patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7.Evid Based Cardiovasc Med1998-03-01T00:00:001998Reteplase was not better than alteplase in reducing 30-day mortality among patients with acute MI.16697306Gelfand EV, Cannon CPJournal of the American College of CardiologyRimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16; 47(10):1919-26.J Am Coll Cardiol2006-04-24T00:00:002006Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.16880323O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MSCirculationPrognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 08; 114(6):550-7.Circulation2006-07-31T00:00:002006Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.16278114Cannon CPCardiology clinicsAcute coronary syndromes: risk stratification and initial management. Cardiol Clin. 2005 Nov; 23(4):401-9, v.Cardiol Clin2005-11-01T00:00:002005Acute coronary syndromes: risk stratification and initial management.16750703Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald EJournal of the American College of CardiologyIntensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.J Am Coll Cardiol2006-05-04T00:00:002006Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.17008974Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald EJournal of thrombosis and thrombolysisDrug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102.J Thromb Thrombolysis2006-10-01T00:00:002006Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.17056321Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC, Roe MTThe American journal of cardiologyTemporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 01; 98(9):1172-6.Am J Cardiol2006-08-31T00:00:002006Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE).17169625Cannon CPThe American journal of cardiologyEvolving management of ST-segment elevation myocardial infarction: update on recent data. Am J Cardiol. 2006 Dec 18; 98(12A):10Q-21Q.Am J Cardiol2006-11-07T00:00:002006Evolving management of ST-segment elevation myocardial infarction: update on recent data.Authorship 977344528411246Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin LJournal of the American Heart AssociationGrowth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc. 2017 Apr 14; 6(4).J Am Heart Assoc2017-04-14T00:00:002017Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.17502590Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EMCirculationAcute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2549-69.Circulation2007-05-15T00:00:002007Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.17717132Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald EClinical chemistryClinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.Clin Chem2007-08-23T00:00:002007Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.9453518Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BLAmerican heart journalRelation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J. 1998 Jan; 135(1):29-37.Am Heart J1998-01-01T00:00:001998Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.10080462Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald EJournal of the American College of CardiologyPlatelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Mar; 33(3):634-9.J Am Coll Cardiol1999-03-01T00:00:001999Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.12446059Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, Gibson CMJournal of the American College of CardiologyRelationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002 Nov 20; 40(10):1761-8.J Am Coll Cardiol2002-11-20T00:00:002002Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.12706919Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald EJournal of the American College of CardiologyEvaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16; 41(8):1264-72.J Am Coll Cardiol2003-04-16T00:00:002003Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.10551685Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald EJournal of the American College of CardiologyDeterminants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.J Am Coll Cardiol1999-11-01T00:00:001999Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.10613990Cannon CPJournal of thrombosis and thrombolysisTime to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(3):249-255.J Thromb Thrombolysis1996-01-01T00:00:001996Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.11067784Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CMCirculationAssociation between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000 Nov 07; 102(19):2329-34.Circulation2000-11-07T00:00:002000Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.11969270Cannon CPEuropean heart journalEnoxaparin in ST elevation MI - a bright future. Eur Heart J. 2002 Apr; 23(8):591-2.Eur Heart J2002-04-01T00:00:002002Enoxaparin in ST elevation MI - a bright future.12039481Cannon CP, Baim DSJournal of the American College of CardiologyExpanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2002 Jun 05; 39(11):1720-2.J Am Coll Cardiol2002-06-05T00:00:002002Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction.12127617Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald EThe American journal of cardiologyValidation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.Am J Cardiol2002-08-01T00:00:002002Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry.15927980Scirica BM, Cannon CPCirculationTreatment of elevated cholesterol. Circulation. 2005 May 31; 111(21):e360-3.Circulation2005-05-31T00:00:002005Treatment of elevated cholesterol.16125484Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E, Cannon CPThe American journal of cardiologyC-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). Am J Cardiol. 2005 Sep 01; 96(5):635-8.Am J Cardiol2005-09-01T00:00:002005C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial).16126024Ray KK, Cannon CPThe American journal of cardiologyEarly time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005 Sep 05; 96(5A):54F-60F.Am J Cardiol2005-09-05T00:00:002005Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?9989959Cannon CP, Dingemanse J, Kleinbloesem CH, Jannett T, Curry KM, Valcke CPCirculationAutomated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers. Circulation. 1999 Feb 16; 99(6):751-6.Circulation1999-02-16T00:00:001999Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers.10569321Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Sapp SK, Booth JE, Ferguson JJ, Cannon CPThe American journal of cardiologyDifferences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15; 84(10):1145-50.Am J Cardiol1999-11-15T00:00:001999Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators.10851205Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NSCirculationHigh levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.Circulation2000-06-13T00:00:002000High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.11676942Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald EThe American journal of cardiologyEarly coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.Am J Cardiol2001-10-15T00:00:002001Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience).20633817Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JSJournal of the American College of CardiologyTreatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010 Jul 20; 56(4):254-63.J Am Coll Cardiol2010-07-20T00:00:002010Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.21988948Acharjee S, Cannon CPCritical pathways in cardiologyDabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. Crit Pathw Cardiol. 2011 Jun; 10(2):84-6.Crit Pathw Cardiol2011-06-01T00:00:002011Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.23377899Steen DL, Cannon CP, Lele SS, Rajapurkar MM, Mukhopadhyay B, Scirica BM, Murphy SA, Morrow DAClinical cardiologyPrognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol. 2013 Mar; 36(3):139-45.Clin Cardiol2013-02-03T00:00:002013Prognostic evaluation of catalytic iron in patients with acute coronary syndromes.Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, National Academy of Clinical Biochemistry Laboratory Medicine Practice GuidelinesCirculationClinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; e356-75.2007-01-01T00:00:002007Clinical characteristics and utilization of biochemical markers in acute coronary syndromesEdwards NM, Maurer MS, Wellner RB, editorsCannon CP, series editor. Contemporary CardiologyAging, heart disease, and it's management facts and controversies. Cannon CP, series editor. Contemporary Cardiology. 2003; 389.2003-01-01T00:00:002003Aging, heart disease, and it's management facts and controversiesScirica BM, Sabatine MS, Murphy SA, Kirtane J, Aroesty J, Cannon CP, Gibson CMCirculationImproved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST elevation myocardial infarction - Results from CLARITY-TIMI 28. Circulation. 2005; 112(17):II-693.2005-01-01T00:00:002005Improved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST elevation myocardial infarction - Results from CLARITY-TIMI 28Cannon CPCase study: Acute coronary syndromeCase study: Acute coronary syndrome. 2003.2003-01-01T00:00:002003Case study: Acute coronary syndromeCannon CP.Clopidogrel as adjunctive reperfusion therapy (CLARITY): Thrombolysis in myocardial infarction (TIMI) 28Clopidogrel as adjunctive reperfusion therapy (CLARITY): Thrombolysis in myocardial infarction (TIMI) 28. 2005.2005-11-01T00:00:002005Clopidogrel as adjunctive reperfusion therapy (CLARITY): Thrombolysis in myocardial infarction (TIMI) 28McLean DS, Cannon CPFuture MedicineA point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):255-67.2006-01-01T00:00:002006A point-of-care assay to measure platelet aggregation in patients taking clopidogrelCannon CPPfeffer M, editor. Cardiology Scientific UpdateThe 4th global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO IV-ACS): What happened?. Pfeffer M, editor. Cardiology Scientific Update. 2000; 1-6.2000-01-01T00:00:002000The 4th global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO IV-ACS): What happened?Abendschein DR, Puleo PR, Cannon CP, and the TIMI IV and V InvestigatorsCirculationNoninvasive detection of early coronary artery patency based on plasma MM and MB creatine kinase (CK) isoforms. Circulation. 1992; 86(Suppl I):266.1992-01-01T00:00:001992Noninvasive detection of early coronary artery patency based on plasma MM and MB creatine kinase (CK) isoformsCannon CP, Gibson CMEquivalence trials: Understanding the statistical and clinical issuesEquivalence trials: Understanding the statistical and clinical issues. 2003.2003-01-01T00:00:002003Equivalence trials: Understanding the statistical and clinical issuesCannon CPJ Thromb ThrombolysisOptimizing the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999; 7:171-89.1999-01-01T00:00:001999Optimizing the medical management of acute coronary syndromesArmstrong P, Gibler B, Cannon CP, Cohen E, Calder LDetermining therapy by risk stratification in ACSDetermining therapy by risk stratification in ACS. 2001.2001-01-01T00:00:002001Determining therapy by risk stratification in ACSHernandez AF, Fonarow GC, Dai D, O'Brien SM, LaBresh KA, Schwamm LH, Cannon CP, GWTG Steering CommitteeJ Am Coll CardiolWhat is the best measure for rewarding quality of care: Defect-free vs composite scoring? An analysis from the American Heart Association's get with the guidelines-coronary artery disease (GWTG-CAD) program?. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):291A.2007-03-06T00:00:002007What is the best measure for rewarding quality of care: Defect-free vs composite scoring? An analysis from the American Heart Association's get with the guidelines-coronary artery disease (GWTG-CAD) program?Canon CPMedical Roundtable"Super-aggressive" management of acute myocardial infarction. Medical Roundtable. 1998; 3-4.1998-05-01T00:00:001998"Super-aggressive" management of acute myocardial infarctionCannon CPManaging multiple risk factors to target global cardiometabolic riskManaging multiple risk factors to target global cardiometabolic risk. 2007.2007-03-25T00:00:002007Managing multiple risk factors to target global cardiometabolic riskCannon CPNew Era of ReperfusionBolus thrombolysis: r-PA, t-PA, n-PA and TNK-tPA. New Era of Reperfusion. 1998; 2:1-3.1998-01-01T00:00:001998Bolus thrombolysis: r-PA, t-PA, n-PA and TNK-tPACannon CP.Interview with: Christopher Cannon, MDInterview with: Christopher Cannon, MD. 2004.2004-05-01T00:00:002004Interview with: Christopher Cannon, MDBarr SA, Zaret BL, Cannon CP, Wackers FJT, and the TIMI 4 and 5 InvestigatorsCirculationDoes decreasing defect size in serial quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction correlate with improved left ventricular function. Circulation. 1993; 88(I):486.1993-01-01T00:00:001993Does decreasing defect size in serial quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction correlate with improved left ventricular functionStorey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Price D, Husted SCirculationAZD6140 Exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. Circulation. 2006; 114(18):II-698.2006-01-01T00:00:002006AZD6140 Exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary diseaseAntman EM, for the TIMI 9A InvestigatorsCirculationHirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994; 90:1624-30..1994-01-01T00:00:001994Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A TrialRay KK, Cannon CP, Rader DJ, Cairns R, McCabe CH, Sacks FM, Braunwald EEur Heart JBaseline ApoB predicts benefits of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005.2005-01-01T00:00:002005Baseline ApoB predicts benefits of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22Cannon CPNew approaches to the prevention of atherothrombotic events in patients with vascular diseaseNew approaches to the prevention of atherothrombotic events in patients with vascular disease. 2002.2002-01-01T00:00:002002New approaches to the prevention of atherothrombotic events in patients with vascular disease12106926de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald EJournal of the American College of CardiologyThe prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44.J Am Coll Cardiol2002-07-17T00:00:002002The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies.12745096Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Kraimer N, Katsiyiannis PT, Marble SJ, DiBattiste PM, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CMThe American journal of cardiologyTime for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. Am J Cardiol. 2003 May 15; 91(10):1163-7.Am J Cardiol2003-05-15T00:00:002003Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction.17665746Cannon CPThe American journal of cardiologyIntroduction: rationale for tight control of hyperglycemia. Am J Cardiol. 2007 Jun 04; 99(11A):1H-4H.Am J Cardiol2007-06-04T00:00:002007Introduction: rationale for tight control of hyperglycemia.10653672Cannon CPEuropean heart journalDefining acute myocardial infarction by ST segment deviation. Eur Heart J. 2000 Feb; 21(4):266-7.Eur Heart J2000-02-01T00:00:002000Defining acute myocardial infarction by ST segment deviation.11073480Richards CF, Cannon CPAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineReducing medication errors: potential benefits of bolus thrombolytic agents. Acad Emerg Med. 2000 Nov; 7(11):1285-9.Acad Emerg Med2000-11-01T00:00:002000Reducing medication errors: potential benefits of bolus thrombolytic agents.11302313Cannon CP, Nelson SD, Panosian CB, Seeger LL, Eilber FR, Eckardt JJClinical orthopaedics and related researchSoft tissue echinococcosis: a report of two cases and review of the literature. Clin Orthop Relat Res. 2001 Apr; (385):186-91.Clin Orthop Relat Res2001-04-01T00:00:002001Soft tissue echinococcosis: a report of two cases and review of the literature.11545752Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald EThe American journal of cardiologyThe platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52.Am J Cardiol2001-08-15T00:00:002001The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.12270844Cannon CPCirculationEvidence-based risk stratification to target therapies in acute coronary syndromes. Circulation. 2002 Sep 24; 106(13):1588-91.Circulation2002-09-24T00:00:002002Evidence-based risk stratification to target therapies in acute coronary syndromes.12423724Sharis PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, Gibson CM, Stone PH, Braunwald EThe American journal of cardiologyPredictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). Am J Cardiol. 2002 Nov 15; 90(10):1154-6.Am J Cardiol2002-11-15T00:00:002002Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry).12918637Cannon CPClinical cardiologyOral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. Clin Cardiol. 2003 Aug; 26(8):358-64.Clin Cardiol2003-08-01T00:00:002003Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I.15063425Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald EJournal of the American College of CardiologyAssociation of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.J Am Coll Cardiol2004-04-07T00:00:002004Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.16503766Gelfand EV, Cannon CPExpert opinion on investigational drugsRimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15.Expert Opin Investig Drugs2006-03-01T00:00:002006Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.16622607Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald EJournal of thrombosis and thrombolysisPoor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.J Thromb Thrombolysis2006-04-01T00:00:002006Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials).18001618Dibble CT, Gelfand EV, Cannon CPCurrent atherosclerosis reportsRimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007 Nov; 9(5):359-66.Curr Atheroscler Rep2007-11-01T00:00:002007Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.10483955Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald EJournal of the American College of CardiologyMyoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999 Sep; 34(3):739-47.J Am Coll Cardiol1999-09-01T00:00:001999Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B.10793176Cannon CPThe American journal of cardiologyThrombolysis medication errors: benefits of bolus thrombolytic agents. Am J Cardiol. 2000 Apr 27; 85(8A):17C-22C.Am J Cardiol2000-04-27T00:00:002000Thrombolysis medication errors: benefits of bolus thrombolytic agents.11092649Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyCardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15; 36(6):1812-7.J Am Coll Cardiol2000-11-15T00:00:002000Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy.12578870de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald ECirculationAssociation between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5.Circulation2003-02-11T00:00:002003Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.Authorship 98102610Authorship 982734528507057Stanifer JW, Charytan DM, White J, Lokhnygina Y, Cannon CP, Roe MT, Blazing MAJournal of the American Society of Nephrology : JASNBenefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol. 2017 Oct; 28(10):3034-3043.J Am Soc Nephrol2017-05-15T00:00:002017Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.28506979Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davies G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EACirculation. Cardiovascular quality and outcomesImpact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 05; 10(5).Circ Cardiovasc Qual Outcomes2017-05-01T00:00:002017Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).17160548Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CPJournal of thrombosis and thrombolysisPrehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis. 2007 Jun; 23(3):173-9.J Thromb Thrombolysis2006-12-09T00:00:002006Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.9416931Gibson CM, Dodge JT, Goel M, Al-Mousa EN, Rizzo M, McLean C, Ryan K, Sparano A, Marble SJ, Daley WL, Cannon CP, Antman EMThe American journal of cardiologyAngioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flow. Am J Cardiol. 1997 Dec 15; 80(12):1536-9.Am J Cardiol1997-12-15T00:00:001997Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flow.18340189Gurjeva OS, Roe MT, Murphy SA, Moliterno DJ, Cannon CPCritical pathways in cardiologyUnfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). Crit Pathw Cardiol. 2005 Jun; 4(2):81-7.Crit Pathw Cardiol2005-06-01T00:00:002005Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry).9735068Sharis PJ, Cannon CP, Loscalzo JAnnals of internal medicineThe antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998 Sep 01; 129(5):394-405.Ann Intern Med1998-09-01T00:00:001998The antiplatelet effects of ticlopidine and clopidogrel.12354426Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald EJournal of the American College of CardiologyProspective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002 Sep 18; 40(6):1044-50.J Am Coll Cardiol2002-09-18T00:00:002002Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes.12377083Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WSJAMACost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002 Oct 16; 288(15):1851-8.JAMA2002-10-16T00:00:002002Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.10856384Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CMThe American journal of cardiologyDegree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol. 2000 Jun 15; 85(12):1409-13.Am J Cardiol2000-06-15T00:00:002000Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials).19061694Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RMAmerican heart journalRationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.Am Heart J2008-09-02T00:00:002008Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.19332184James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin LAmerican heart journalComparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009 Apr; 157(4):599-605.Am Heart J2009-04-01T00:00:002009Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.19376306Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJAmerican heart journalEvaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009 May; 157(5):818-24, 824.e1.Am Heart J2009-05-01T00:00:002009Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.19934421Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF, Peterson ED, Bhatt DLJAMAAssociation of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13.JAMA2009-11-25T00:00:002009Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes.11179533Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald EThe American journal of cardiologyCan we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6.Am J Cardiol2001-02-15T00:00:002001Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group.20031882Peterson ED, Roe MT, Rumsfeld JS, Shaw RE, Brindis RG, Fonarow GC, Cannon CPCirculation. Cardiovascular quality and outcomesA call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):491-9.Circ Cardiovasc Qual Outcomes2009-09-01T00:00:002009A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction.11230853Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald EThe American journal of cardiologyAssociation of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001 Mar 01; 87(5):636-9, A10.Am J Cardiol2001-03-01T00:00:002001Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.20167360Cannon CPLancet (London, England)Balancing the benefits of statins versus a new risk-diabetes. Lancet. 2010 Feb 27; 375(9716):700-1.Lancet2010-02-16T00:00:002010Balancing the benefits of statins versus a new risk-diabetes.11231699O'Rourke RA, Hochman JS, Cohen MC, Lucore CL, Popma JJ, Cannon CPArchives of internal medicineNew approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. Arch Intern Med. 2001 Mar 12; 161(5):674-82.Arch Intern Med2001-03-12T00:00:002001New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.20354760Ray KK, Nazer B, Cairns R, Michael Gibson C, Cannon CPJournal of thrombosis and thrombolysisAssociation between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. J Thromb Thrombolysis. 2010 Jul; 30(1):10-3.J Thromb Thrombolysis2010-07-01T00:00:002010Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.20569707Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MSAmerican heart journalEarly dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1.Am Heart J2010-06-01T00:00:002010Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.11712935Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald EJAMAAbility of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21; 286(19):2405-12.JAMA2001-11-21T00:00:002001Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.20925534Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CPThe New England journal of medicineClopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17.N Engl J Med2010-10-06T00:00:002010Clopidogrel with or without omeprazole in coronary artery disease.21176752Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, Cannon CClinical nephrologyPharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol. 2011 Jan; 75(1):63-9.Clin Nephrol2011-01-01T00:00:002011Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.21245461Alexander KP, Wang TY, Li S, Lytle BL, Slattery LE, Calhoun S, Poteat J, Roe MT, Rumsfeld JS, Cannon CP, Peterson EDCirculation. Cardiovascular quality and outcomesRandomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. Circ Cardiovasc Qual Outcomes. 2011 Jan 01; 4(1):129-35.Circ Cardiovasc Qual Outcomes2011-01-01T00:00:002011Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care.21345849Nazer B, Ray KK, Sloan S, Scirica B, Morrow DA, Cannon CP, Braunwald EEuropean heart journalPrognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7.Eur Heart J2011-02-22T00:00:002011Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.11994554Gibson CM, Chen M, Angeja BG, Murphy SA, Marble SJ, Barron HV, Cannon CPJournal of thrombosis and thrombolysisPrecordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. J Thromb Thrombolysis. 2002 Feb; 13(1):9-12.J Thromb Thrombolysis2002-02-01T00:00:002002Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery.11994555Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DCJournal of thrombosis and thrombolysisPlatelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis. 2002 Feb; 13(1):13-9.J Thromb Thrombolysis2002-02-01T00:00:002002Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients.21641362Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DAAmerican heart journalAssessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1.Am Heart J2011-05-11T00:00:002011Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22).15312862Sadanandan S, Cannon CP, Gibson CM, Murphy SA, DiBattiste PM, Braunwald EJournal of the American College of CardiologyA risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):799-803.J Am Coll Cardiol2004-08-18T00:00:002004A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction.15589011Karha J, Gibson CM, Murphy SA, Dibattiste PM, Cannon CPThe American journal of cardiologySafety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. Am J Cardiol. 2004 Dec 15; 94(12):1537-9.Am J Cardiol2004-12-15T00:00:002004Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction.Kraus WE, Keteyian SJ, editorsCannon CP, series editor. Contemporary CardiologyCardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Cardiac RehabilitationAhmed S, Cannon CP, Giugliano RP, Shui A, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CMJ Am Coll CardiolThe independent and combined risks of diabetes and non-endstage renal impairment in non ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006; 47(4):207A.2006-02-21T00:00:002006The independent and combined risks of diabetes and non-endstage renal impairment in non ST-segment elevation acute coronary syndromesCannon CPCardiovasc Rev RepBreaking the thrombolytic barrier: Combining glycoprotein IIb/IIIa receptor inhibitors with thrombolytic therapy in the treatment of acute myocardial infarction. Cardiovasc Rev Rep. 2000; 21:595-601.2000-01-01T00:00:002000Breaking the thrombolytic barrier: Combining glycoprotein IIb/IIIa receptor inhibitors with thrombolytic therapy in the treatment of acute myocardial infarctionCannon CPEfficacy of percutaneous coronary intervention after thrombolysis for acute ST-elevation (Q wave) myocardial infarctionEfficacy of percutaneous coronary intervention after thrombolysis for acute ST-elevation (Q wave) myocardial infarction. 2004.2004-01-01T00:00:002004Efficacy of percutaneous coronary intervention after thrombolysis for acute ST-elevation (Q wave) myocardial infarction15680712Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald EJournal of the American College of CardiologyAssociation of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.J Am Coll Cardiol2005-02-01T00:00:002005Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients.Cannon CP, Rikers PMAHA/CDC scientific statement-markers of inflammation and cardiovascular disease: Application to clinical and public health practiceAHA/CDC scientific statement-markers of inflammation and cardiovascular disease: Application to clinical and public health practice. 2003.2003-01-01T00:00:002003AHA/CDC scientific statement-markers of inflammation and cardiovascular disease: Application to clinical and public health practice15820292Gurjeva OS, Bukhman G, Murphy S, Cannon CPInternational journal of cardiologyTreatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16. Int J Cardiol. 2005 Apr 08; 100(1):101-7.Int J Cardiol2005-04-08T00:00:002005Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16.15956636Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf SJAMARoutine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15; 293(23):2908-17.JAMA2005-06-15T00:00:002005Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.9207634Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, Pearce DJ, Diver DJ, Kells C, Feldman T, Williams M, Gibson RS, Kronenberg MW, Ganz LI, Anderson HV, Braunwald EJournal of the American College of CardiologyThe electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul; 30(1):133-40.J Am Coll Cardiol1997-07-01T00:00:001997The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia.15846259Sabatine MS, McCabe CH, Gibson CM, Cannon CPAmerican heart journalDesign and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J. 2005 Feb; 149(2):227-33.Am Heart J2005-02-01T00:00:002005Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.16226165Ray KK, Cannon CPJournal of the American College of CardiologyThe potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005 Oct 18; 46(8):1425-33.J Am Coll Cardiol2005-10-18T00:00:002005The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.21875913Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJCirculationPlatelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 Sep 06; 124(10):1132-7.Circulation2011-08-29T00:00:002011Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.16784909Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CMThe American journal of cardiologyAssociation of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006 Jul 01; 98(1):1-5.Am J Cardiol2006-04-27T00:00:002006Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials).Authorship 9851126Authorship 985623228575274Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PGEuropean heart journalVisit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J. 2017 Oct 01; 38(37):2813-2822.Eur Heart J2017-10-01T00:00:002017Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.28561001Reed GW, Cannon CPLancet (London, England)STREAM characterisation correction - Authors' reply. Lancet. 2017 05 27; 389(10084):2102-2103.Lancet2017-05-27T00:00:002017STREAM characterisation correction - Authors' reply.17301621Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood AEuropean journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise PhysiologyCollaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil. 2007 Feb; 14(1):3-11.Eur J Cardiovasc Prev Rehabil2007-02-01T00:00:002007Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.Authorship 9879691328598510Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CPClinical cardiologyRelative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol. 2017 Jun; 40(6):390-398.Clin Cardiol2017-06-09T00:00:002017Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.12881457Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA, Braunwald E, Cannon CPClinical chemistryEvaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003 Aug; 49(8):1396-8.Clin Chem2003-08-01T00:00:002003Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.16875966Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald EJournal of the American College of CardiologyMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 01; 48(3):438-45.J Am Coll Cardiol2006-07-12T00:00:002006Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.14597924Januzzi JL, Cannon CP, Theroux P, Boden WEAmerican heart journalOptimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Am Heart J. 2003 Nov; 146(5):764-74.Am Heart J2003-11-01T00:00:002003Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.14980229Cannon CPAtherosclerosis. SupplementsThe next step in cardiovascular protection. Atheroscler Suppl. 2003 Dec; 4(5):3-9.Atheroscler Suppl2003-12-01T00:00:002003The next step in cardiovascular protection.16950180Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CPThe American journal of cardiologyUsefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15; 98(6):761-3.Am J Cardiol2006-08-02T00:00:002006Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).Authorship 989824628608165Lowenstern A, Storey RF, Neely M, Sun JL, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn A, Steg PG, Wallentin L, Becker RCJournal of thrombosis and thrombolysisPlatelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis. 2017 Aug; 44(2):145-153.J Thromb Thrombolysis2017-08-01T00:00:002017Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.17126675Ray KK, Cannon CP, Ganz PThe American journal of cardiologyBeyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 Dec 04; 98(11A):18P-25P.Am J Cardiol2006-09-29T00:00:002006Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?17169629Cannon CP, Bhatt DLThe American journal of cardiologyClinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q.Am J Cardiol2006-10-24T00:00:002006Clinical trials update from the annual scientific session of the American College of Cardiology 2006.18340295Cannon CPCritical pathways in cardiologyPalm Pilot programs to improve quality of care in acute coronary syndromes. Crit Pathw Cardiol. 2002 Jun; 1(2):113-5.Crit Pathw Cardiol2002-06-01T00:00:002002Palm Pilot programs to improve quality of care in acute coronary syndromes.17671020Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AWThe Journal of bone and joint surgery. American volumePatient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007 Aug; 89(8):1794-801.J Bone Joint Surg Am2007-08-01T00:00:002007Patient survival after surgery for osseous metastases from renal cell carcinoma.18481820Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyClinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.Clin Cardiol2008-03-01T00:00:002008Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.18481821Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyAntiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.Clin Cardiol2008-03-01T00:00:002008Antiplatelet therapy and platelet function testing.9315571Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald EThe American journal of cardiologyProspective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol. 1997 Sep 15; 80(6):696-9.Am J Cardiol1997-09-15T00:00:001997Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.18237683Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson MEJournal of the American College of CardiologyAssociation of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 05; 51(5):546-51.J Am Coll Cardiol2008-02-05T00:00:002008Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.18340121Cannon CPCritical pathways in cardiologyPROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome. Crit Pathw Cardiol. 2003 Sep; 2(3):188-96.Crit Pathw Cardiol2003-09-01T00:00:002003PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome.9878929Cannon CPAmerican heart journalTimely thrombolysis: synergism to open arteries and reduce mortality rates. Am Heart J. 1999 Jan; 137(1):1-3.Am Heart J1999-01-01T00:00:001999Timely thrombolysis: synergism to open arteries and reduce mortality rates.10392322Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld EJournal of clinical pharmacologyPharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 Jul; 39(7):675-84.J Clin Pharmacol1999-07-01T00:00:001999Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.10865271Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJJAMARelationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000 Jun 14; 283(22):2941-7.JAMA2000-06-14T00:00:002000Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.10980843Cannon CPCurrent cardiology reportsLow molecular weight heparin in acute coronary syndromes. Curr Cardiol Rep. 1999 Sep; 1(3):206-11.Curr Cardiol Rep1999-09-01T00:00:001999Low molecular weight heparin in acute coronary syndromes.Society of Cardiovascular Patient Care2012Raymond Bahr Award of ExcellenceAmerican College of Cardiology2010Leadership Award American Heart Association2008Get With The Guidelines Special Recognition,Authorship 991947428623740Mancini GBJ, Gupta M, Tsigoulis M, Cannon CP, Genest J, Ray KK, Santos RD, Watts GF, Raggi PAtherosclerosisDetection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis. 2017 Aug; 263:112-118.Atherosclerosis2017-06-03T00:00:002017Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.11419424Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald EThe New England journal of medicineComparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21; 344(25):1879-87.N Engl J Med2001-06-21T00:00:002001Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.11586953de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald EThe New England journal of medicineThe prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 04; 345(14):1014-21.N Engl J Med2001-10-04T00:00:002001The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.11835931Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald EThe American journal of cardiologyPrognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15; 89(4):463-5.Am J Cardiol2002-02-15T00:00:002002Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes.11956114Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald ECirculationMultimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3.Circulation2002-04-16T00:00:002002Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.19050418Cannon CPCritical pathways in cardiologyUpdated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Dec; 7(4):223-31.Crit Pathw Cardiol2008-12-01T00:00:002008Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit.19332194Truong QA, Cannon CP, Zakai NA, Rogers IS, Giugliano RP, Wiviott SD, McCabe CH, Morrow DA, Braunwald EAmerican heart journalThrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1.Am Heart J2009-02-23T00:00:002009Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial.12686341Pinto DS, Lorenz DP, Murphy SA, Marble SJ, DiBattiste PM, Demopoulos LA, Cannon CP, Gibson CMThe American journal of cardiologyAssociation of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2003 Apr 15; 91(8):976-8, A4.Am J Cardiol2003-04-15T00:00:002003Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).12888707Cannon CPThe American journal of geriatric cardiologyElderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Am J Geriatr Cardiol. 2003 Jul-Aug; 12(4):259-62.Am J Geriatr Cardiol2003-07-01T00:00:002003Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies.22949493Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Schwamm L, Saxon LACirculation. Cardiovascular quality and outcomesGuideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):654-61.Circ Cardiovasc Qual Outcomes2012-09-01T00:00:002012Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.19121441Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LHThe American journal of cardiologyDifferential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009 Jan 15; 103(2):227-31.Am J Cardiol2008-11-07T00:00:002008Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation.19212461Truong QA, Singh JP, Cannon CP, Sarwar A, Nasir K, Auricchio A, Faletra FF, Sorgente A, Conca C, Moccetti T, Handschumacher M, Brady TJ, Hoffmann UJACC. Cardiovascular imagingQuantitative analysis of intraventricular dyssynchrony using wall thickness by multidetector computed tomography. JACC Cardiovasc Imaging. 2008 Nov; 1(6):772-81.JACC Cardiovasc Imaging2008-11-01T00:00:002008Quantitative analysis of intraventricular dyssynchrony using wall thickness by multidetector computed tomography.19223284Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CPRheumatology (Oxford, England)Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009 Apr; 48(4):425-32.Rheumatology (Oxford)2009-02-17T00:00:002009Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).Cannon CPDrugsSibrafiban. Drugs. 1999; 57:231-2.1999-01-01T00:00:001999SibrafibanCannon CPLincoff AM, editor. Contempory Cardiology: Platelet Glyocoprotein IIa/IIIb Inhibitors in Cardiovascular DiseasePlatelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Contempory Cardiology: Platelet Glyocoprotein IIa/IIIb Inhibitors in Cardiovascular Disease. 2003; 263-73.2003-01-01T00:00:002003Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategyCannon CPOvercoming thrombolytic resistanceOvercoming thrombolytic resistance. 1999.1999-01-01T00:00:001999Overcoming thrombolytic resistanceLoscalzo J, Vita JA, editorsCannon CP, series editor. Contemporary CardiologyNitric oxide and the cardiovascular system. Cannon CP, series editor. Contemporary Cardiology. 2000; 601.2000-01-01T00:00:002000Nitric oxide and the cardiovascular systemGibson CM, Sabatine MS, Murphy E, Morrow DA, Wiviott SD, Smith S, McCabe CH, Cannon CP, Braunwald ECirculationAssociation of intensive lipid lowering with reductions in target vessel revascularization (clinical restenois) and non-target vessel revascularization (lesion progression): A PROVE IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):696.2004-01-01T00:00:002004Association of intensive lipid lowering with reductions in target vessel revascularization (clinical restenois) and non-target vessel revascularization (lesion progression): A PROVE IT TIMI 22 Substudy21045772Waheed S, Cannon CPReviews in cardiovascular medicineCardiac rehabilitation. Cardiac rehabilitation reduces the long-term risk of death and cardiovascular complications. Rev Cardiovasc Med. 2010; 11(3):e181-4.Rev Cardiovasc Med2010-01-01T00:00:002010Cardiac rehabilitation. Cardiac rehabilitation reduces the long-term risk of death and cardiovascular complications.21060072Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin LCirculationTicagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41.Circulation2010-11-08T00:00:002010Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.Otten MHC, Murphy SA, Angela G, Hynes CA, Lim JS, Luu LL, Kermgard SR, Marble SJ, Cannon CP, Braunwald E, Gibson CMJ Am Coll CardiolKinetics of myocardial perfusion in the setting of ST segment elevation acute myocardial infarction vs unstable angina/non-Q wave MI. J Am Coll Cardiol. 2001; 37(Suppl A):333.2001-01-01T00:00:002001Kinetics of myocardial perfusion in the setting of ST segment elevation acute myocardial infarction vs unstable angina/non-Q wave MI21119338Acharjee S, Cannon CPCritical pathways in cardiologyDuration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. Crit Pathw Cardiol. 2010 Dec; 9(4):203-6.Crit Pathw Cardiol2010-12-01T00:00:002010Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence.Cannon CPCombination thrombolytic and antiplatelet therapyCombination thrombolytic and antiplatelet therapy. 2000.2000-01-01T00:00:002000Combination thrombolytic and antiplatelet therapy21402801Cannon CPClinical chemistryClopidogrel: to test or not to test? That is the question--still. Clin Chem. 2011 May; 57(5):659-61.Clin Chem2011-03-14T00:00:002011Clopidogrel: to test or not to test? That is the question--still.21464051Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio GCirculationClinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011 Apr 19; 123(15):1622-32.Circulation2011-04-04T00:00:002011Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies.Cannon CPFormularyLatest advances in aggressive lipid management. Formulary. 2005; 40:3-12.2005-01-01T00:00:002005Latest advances in aggressive lipid managementSaw J, Exaire JE, Lee DS, Yadav JS, editorsCannon CP, series editor. Contemporary CardiologyHandbook of Complex Percutaneous Carotid Intervention. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Handbook of Complex Percutaneous Carotid InterventionCannon CPTeaching case of non-ST elevation myocardial infarctionTeaching case of non-ST elevation myocardial infarction. 1997.1997-01-01T00:00:001997Teaching case of non-ST elevation myocardial infarctionCannon CPIn: Ferguson JJ, Chronos NAF, Harrington RA, editors. Antiplatelet Therapy in Clinical Practice.Oral platelet glycoprotein IIb/IIIa receptor blockers. In: Ferguson JJ, Chronos NAF, Harrington RA, editors. Antiplatelet Therapy in Clinical Practice. 2000; 163-80.2000-01-01T00:00:002000Oral platelet glycoprotein IIb/IIIa receptor blockersCannon CPLewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment ProgramUnstable angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.2002-01-01T00:00:002002Unstable angina: Clinical presentationBraunwald E, Topol EJ, Cannon CP, Jesse RL, Ohman EM, White HDAcute coronary syndromes town hall meeting: Applying clinical trials to clinical practiceAcute coronary syndromes town hall meeting: Applying clinical trials to clinical practice. 2000.2000-01-01T00:00:002000Acute coronary syndromes town hall meeting: Applying clinical trials to clinical practiceCannon CP, Gibson CM, Lambrew CT, Tiefenbrunn AJ, Sun H, Malmgren HJ, Frederick P, Every NR, Zalenski R, for the NRMI 2 and 3 InvestigatorsJ Am Coll CardiolLonger thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the national registry of myocardial infarction 2+3. J Am Coll Cardiol. 2000; 35(Suppl A):376.2000-01-01T00:00:002000Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the national registry of myocardial infarction 2+3Cannon CPCannon chronicles: Guidelines for CRPCannon chronicles: Guidelines for CRP. 2003.2003-01-01T00:00:002003Cannon chronicles: Guidelines for CRPCannon CPCase presentation in hypertensionCase presentation in hypertension. 2001.2001-01-01T00:00:002001Case presentation in hypertensionFox NL, Cannon CP, Berioli S, Wang-Clow F, Danays T, Sarelin H, Braunwald E, Van de Werf FJ Am Coll CardiolRates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPA. J Am Coll Cardiol. 1999; 33(Suppl A):353.1999-01-01T00:00:001999Rates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPACannon CPBraunwald E, editor. Heart Disease UpdatesPlatelet glycoprotein IIb/IIIa receptor inhibitors in the management of acute coronary syndromes and coronary intervention. Braunwald E, editor. Heart Disease Updates. 1999; 1-10.1999-01-01T00:00:001999Platelet glycoprotein IIb/IIIa receptor inhibitors in the management of acute coronary syndromes and coronary intervention15911720Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CVCirculationPractical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation. 2005 May 24; 111(20):2699-710.Circulation2005-05-24T00:00:002005Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers.Cannon CP, Hutter AMThe TIMI 10B and ASSENT-I trials with TNK-tPAThe TIMI 10B and ASSENT-I trials with TNK-tPA. 1997.1997-01-01T00:00:001997The TIMI 10B and ASSENT-I trials with TNK-tPACannon CPExpert column: Lessons learned (so far) from the PROVE IT - TIMI 22 trialExpert column: Lessons learned (so far) from the PROVE IT - TIMI 22 trial. 2005.2005-01-01T00:00:002005Expert column: Lessons learned (so far) from the PROVE IT - TIMI 22 trialCannon CP, Ganz, LJ, Stone PH, Becker RC.Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine.Complicated myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 202-10.2006-01-01T00:00:002006Complicated myocardial infarctionAuthorship 9981516Authorship 997649928454837Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E, Wallentin L, Steg PGAmerican heart journalBalancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J. 2017 Apr; 186:91-99.Am Heart J2017-01-26T00:00:002017Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.28692742Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP, Bauters C, Bhatt DL, Steg PGClinical cardiologyVitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clin Cardiol. 2017 Oct; 40(10):932-939.Clin Cardiol2017-07-10T00:00:002017Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.16039260Cannon CP, Mehta SR, Aranki SFThe Annals of thoracic surgeryBalancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg. 2005 Aug; 80(2):768-79.Ann Thorac Surg2005-08-01T00:00:002005Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.16226162Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald EJournal of the American College of CardiologyEarly and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1405-10.J Am Coll Cardiol2005-10-18T00:00:002005Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.17221324Rich JD, Maraganore JM, Young E, Lidon RM, Adelman B, Bourdon P, Charenkavanich S, Hirsh J, Theroux P, Cannon CPJournal of thrombosis and thrombolysisHeparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007 Apr; 23(2):93-100.J Thromb Thrombolysis2007-01-13T00:00:002007Heparin resistance in acute coronary syndromes.17356403Lemme SD, Kevin Raymond A, Cannon CP, Normand AN, Smith KC, Hughes DPJournal of pediatric hematology/oncologyPrimary tuberculosis of bone mimicking a lytic bone tumor. J Pediatr Hematol Oncol. 2007 Mar; 29(3):198-202.J Pediatr Hematol Oncol2007-03-01T00:00:002007Primary tuberculosis of bone mimicking a lytic bone tumor.17548728Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald ECirculationLong-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007 Jun 19; 115(24):3071-8.Circulation2007-06-04T00:00:002007Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.18339606Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SLEuropean heart journalConcurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008 May; 29(9):1096-102.Eur Heart J2008-03-12T00:00:002008Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.18433693Kumar A, Cannon CPHeart failure clinicsThe role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail Clin. 2008 Apr; 4(2):129-39.Heart Fail Clin2008-04-01T00:00:002008The role of statins in the prevention of heart failure after acute coronary syndrome.18440341Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CPAmerican heart journalEfficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008 May; 155(5):910-7.Am Heart J2008-02-21T00:00:002008Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.19704091Cannon CPCirculationShould we manage patients with non-ST segment elevation myocardial infarction with renal failure with an invasive strategy? Circulation. 2009 Sep 08; 120(10):828-30.Circulation2009-08-24T00:00:002009Should we manage patients with non-ST segment elevation myocardial infarction with renal failure with an invasive strategy?20215907Cannon CP, Hoekstra JW, Larson DM, Carter RD, Cornish J, Karcher RB, Mencia WA, Berry CA, Stowell SACritical pathways in cardiologyPhysician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. Crit Pathw Cardiol. 2010 Mar; 9(1):23-9.Crit Pathw Cardiol2010-03-01T00:00:002010Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program.20520214Cannon CPCritical pathways in cardiologyStrategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Crit Pathw Cardiol. 2010 Jun; 9(2):55-81.Crit Pathw Cardiol2010-06-01T00:00:002010Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.6289300Gluck S, Cannon C, Al-Awqati QProceedings of the National Academy of Sciences of the United States of AmericaExocytosis regulates urinary acidification in turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci U S A. 1982 Jul; 79(14):4327-31.Proc Natl Acad Sci U S A1982-07-01T00:00:001982Exocytosis regulates urinary acidification in turtle bladder by rapid insertion of H+ pumps into the luminal membrane.7963104Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RDJournal of the American College of CardiologyComparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994 Dec; 24(7):1602-10.J Am Coll Cardiol1994-12-01T00:00:001994Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.16847010Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CMEuropean heart journalAngiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J. 2006 Sep; 27(17):2040-5.Eur Heart J2006-07-17T00:00:002006Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.16923461Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PSThe American journal of cardiologyOnset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006 Sep 01; 98(5):681-4.Am J Cardiol2006-07-07T00:00:002006Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.9185630Anderson HV, Gibson RS, Stone PH, Cannon CP, Aguirre F, Thompson B, Knatterud GL, Braunwald EThe American journal of cardiologyManagement of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Am J Cardiol. 1997 Jun 01; 79(11):1441-6.Am J Cardiol1997-06-01T00:00:001997Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry).9205014Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, Diver DJ, Baim DS, Braunwald EThe American journal of cardiologyRescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol. 1997 Jul 01; 80(1):21-6.Am J Cardiol1997-07-01T00:00:001997Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial.22700906Cannon CP, Cannon PJScience (New York, N.Y.)Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012 Jun 15; 336(6087):1386-7.Science2012-06-15T00:00:002012Physiology. COX-2 inhibitors and cardiovascular risk.22740110Grinstein J, Cannon CPClinical cardiologyAspirin resistance: current status and role of tailored therapy. Clin Cardiol. 2012 Nov; 35(11):673-81.Clin Cardiol2012-06-27T00:00:002012Aspirin resistance: current status and role of tailored therapy.22744844Medina HM, Cannon CP, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Frank Peacock W, Laskey W, Peterson ED, Schwamm L, Bhatt DLClinical cardiologyReperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40.Clin Cardiol2012-06-28T00:00:002012Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease.22753250Huang PH, Kim CX, Lerman A, Cannon CP, Dai D, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Smith EE, Fonarow GC, Schwamm LH, Bhatt DLClinical cardiologyTrends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403.Clin Cardiol2012-01-01T00:00:002012Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines.10155224Cannon CP, Braunwald E, McCabe CH, Antman EMJournal of interventional cardiologyThe Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995 Apr; 8(2):117-35.J Interv Cardiol1995-04-01T00:00:001995The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.10603508Cannon CP, Antman EM, Walls R, Braunwald EJournal of thrombosis and thrombolysisTime as an Adjunctive Agent to Thrombolytic Therapy. J Thromb Thrombolysis. 1994; 1(1):27-34.J Thromb Thrombolysis1994-01-01T00:00:001994Time as an Adjunctive Agent to Thrombolytic Therapy.17531568Tickoo S, Roe MT, Peterson ED, Milford-Beland S, Ohman EM, Gibler WB, Pollack CV, Cannon CPThe American journal of cardiologyPatterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. Am J Cardiol. 2007 Jun 01; 99(11):1496-9.Am J Cardiol2007-04-12T00:00:002007Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.18340233Kugelmass AD, Sadanandan S, Lakkis N, Dibattiste PM, Robertson DH, Demopoulos LA, Gibson CM, Weintraub WS, Murphy SA, Cannon CPCritical pathways in cardiologyEarly invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. Crit Pathw Cardiol. 2006 Sep; 5(3):167-72.Crit Pathw Cardiol2006-09-01T00:00:002006Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18.18340298Scirica BM, Cannon CP, Gibson CM, Murphy SA, Moliterno DJ, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald ECritical pathways in cardiologyAssessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8.Crit Pathw Cardiol2002-09-01T00:00:002002Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries.18772061Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyBaseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 09; 52(11):914-20.J Am Coll Cardiol2008-09-09T00:00:002008Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.19015285Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Sabatine MS, Resnic FSMedical decision making : an international journal of the Society for Medical Decision MakingValidation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making. 2009 Mar-Apr; 29(2):247-56.Med Decis Making2008-11-17T00:00:002008Validation of an automated safety surveillance system with prospective, randomized trial data.19064680Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler LCirculationSex differences in medical care and early death after acute myocardial infarction. Circulation. 2008 Dec 16; 118(25):2803-10.Circulation2008-12-08T00:00:002008Sex differences in medical care and early death after acute myocardial infarction.19410160Cannon CPClinical cornerstoneCardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2008; 9(2):24-38; discussion 39-41.Clin Cornerstone2008-01-01T00:00:002008Cardiovascular disease and modifiable cardiometabolic risk factors.19880693Kumar A, Cannon CPMayo Clinic proceedingsAcute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc. 2009 Nov; 84(11):1021-36.Mayo Clin Proc2009-11-01T00:00:002009Acute coronary syndromes: Diagnosis and management, part II.20962294Natarajan P, Cannon CPArteriosclerosis, thrombosis, and vascular biologyCould direct inhibition of inflammation be the "next big thing" in treating atherosclerosis? Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2081-3.Arterioscler Thromb Vasc Biol2010-11-01T00:00:002010Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis?21087753Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BMJACC. Cardiovascular interventionsUse of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77.JACC Cardiovasc Interv2010-11-01T00:00:002010Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines).21545948Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin LJournal of the American College of CardiologyThe incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16.J Am Coll Cardiol2011-05-10T00:00:002011The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.21964173Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liau CS, Wilson PW, Salette G, Smith SC, Steg PGMayo Clinic proceedingsEthnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7.Mayo Clin Proc2011-10-01T00:00:002011Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.22898071Cannon CP, Kohli PJournal of the American College of CardiologyDanger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012 Aug 21; 60(8):747-8.J Am Coll Cardiol2012-08-21T00:00:002012Danger ahead: watch out for indirect comparisons!23277305Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CPCirculationReduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation. 2013 Feb 12; 127(6):673-80.Circulation2012-12-31T00:00:002012Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.23357718Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WSCirculation2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 05; 127(9):1052-89.Circulation2013-01-28T00:00:0020132013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).Cannon CPWhat is new in acute coronary syndromes?What is new in acute coronary syndromes?. 2000.2000-01-01T00:00:002000What is new in acute coronary syndromes?20215903Laskey W, Spence N, Zhao X, Mayo R, Taylor R, Cannon CP, Hernandez AF, Peterson ED, Fonarow GCCritical pathways in cardiologyRegional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease program. Crit Pathw Cardiol. 2010 Mar; 9(1):1-7.Crit Pathw Cardiol2010-03-01T00:00:002010Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease program.20215906Mega S, Patti G, Cannon CP, Di Sciascio GCritical pathways in cardiologyPreprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials. Crit Pathw Cardiol. 2010 Mar; 9(1):19-22.Crit Pathw Cardiol2010-03-01T00:00:002010Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials.20736202Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, Cannon CP, Rumsfeld JSHeart (British Cardiac Society)The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart. 2010 Nov; 96(22):1798-802.Heart2010-08-23T00:00:002010The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care.21693744Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KKJAMARisk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64.JAMA2011-06-22T00:00:002011Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E for the TIMI 10B InvestigatorsJ Am Coll CardiolMyoglobin, CK-MB and cardiac troponin - I - 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction: Results from TIMI 10B. J Am Coll Cardiol. 1999; 34:739-47..1999-01-01T00:00:001999Myoglobin, CK-MB and cardiac troponin - I - 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction: Results from TIMI 10BCannon CPTNK-tPA: Easier thrombolysis?TNK-tPA: Easier thrombolysis?. 1997.1997-01-01T00:00:001997TNK-tPA: Easier thrombolysis?Sabatine MS, Cannon CPIrwin RS, Rippe JM, editors. Irwin and Rippe's Intensive Care Medicine.Unstable Angina/non-ST-segment-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Irwin and Rippe's Intensive Care Medicine. 2008; 408-27.2008-01-01T00:00:002008Unstable Angina/non-ST-segment-elevation myocardial infarctionCannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Medical IssuesAcute Myocardial Infarction. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Medical Issues. 2007.2007-01-01T00:00:002007Acute Myocardial InfarctionCannon CP, Ferguson J, Ohman MThrombocardiology seriesThrombocardiology series. 2002.2002-01-01T00:00:002002Thrombocardiology seriesCannon CPJAMAStatins, diet, and low cholesterol. (Letter). JAMA. 2006; 295(21):2479-80.2006-06-07T00:00:002006Statins, diet, and low cholesterol. (Letter)Cannon CPBolus thrombolysis in the new millenniumBolus thrombolysis in the new millennium. 1999.1999-01-01T00:00:001999Bolus thrombolysis in the new millenniumCannon CPLewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment ProgramUnstable Angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005.2005-01-01T00:00:002005Unstable Angina: Clinical presentationHochman JS, Becker RC, Berger PP, Borzak S, Califf RM, Cannon CP, Every NR, Gibler WB, Grines CL, Kopecky SL, Newby LK, Ohman EM, O'Neill WW, Ornato JP Weaver WDBest practices for treating acute myocardial infarctionBest practices for treating acute myocardial infarction. 1999.1999-01-01T00:00:001999Best practices for treating acute myocardial infarctionMega JL, Thakuria JV, Cannon CP, Sabatine MSJACCSequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: Insights from the CLARITY-TIMI 28 genomic study. JACC. 2008; 51(10):A206.2008-03-11T00:00:002008Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: Insights from the CLARITY-TIMI 28 genomic studyAuthorship 10055445Authorship 10062364Authorship 10013032Authorship 10063901Authorship 1007779528750828El Shahawy M, Cannon CP, Blom DJ, McKenney JM, Cariou B, Lecorps G, Pordy R, Chaudhari U, Colhoun HMThe American journal of cardiologyEfficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol. 2017 Sep 15; 120(6):931-939.Am J Cardiol2017-06-28T00:00:002017Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).28838375Bohula EA, Morrow DA, Giugliano RP, Cannon CP, Braunwald EJournal of the American College of CardiologyReply: Ezetimibe, Risk Stratification, and Secondary Prevention. J Am Coll Cardiol. 2017 08 29; 70(9):1200.J Am Coll Cardiol2017-08-29T00:00:002017Reply: Ezetimibe, Risk Stratification, and Secondary Prevention.28844193Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SHThe New England journal of medicineDual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 10 19; 377(16):1513-1524.N Engl J Med2017-08-27T00:00:002017Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.28454811Deedwania P, Acharya T, Kotak K, Fonarow GC, Cannon CP, Laskey WK, Peacock WF, Pan W, Bhatt DLAmerican heart journalCompliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J. 2017 May; 187:78-87.Am Heart J2017-02-23T00:00:002017Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program.28797349Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin LJournal of the American College of CardiologyBiomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017 Aug 15; 70(7):813-826.J Am Coll Cardiol2017-08-15T00:00:002017Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.Cannon CP, O'Gara PTCannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine.Critical pathways following thrombosis. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 93-9..2007-01-01T00:00:002007Critical pathways following thrombosisCannon CPEvidence-based Cardiovascular MedicineCommentary on GUSTO III and COBALT. Evidence-based Cardiovascular Medicine. 1998; 2:17.1998-01-01T00:00:001998Commentary on GUSTO III and COBALTHarrington R, Cannon CPGlobal effort to transform outcomes of acute coronary syndromes (GET ACS) day in reviewGlobal effort to transform outcomes of acute coronary syndromes (GET ACS) day in review. 2002.2002-01-01T00:00:002002Global effort to transform outcomes of acute coronary syndromes (GET ACS) day in reviewCannon CP, Braunwald EFuster V, Nash IS, editors. Efficacy of Myocardial Infarction Therapy: An Evaluation of Clinical Trials EvidenceTIMI IIB. Fuster V, Nash IS, editors. Efficacy of Myocardial Infarction Therapy: An Evaluation of Clinical Trials Evidence. 1999; 437-452.1999-01-01T00:00:001999TIMI IIBWatkins SP, de Lemos JA, Tokol G, Mahoney E, Yegin A, Alexopoulos C, Goldsman D, Goldsman P, Bunt T, Deuson R, Cannon CP, Hamm C, Weintraub WCirculationCost-effectiveness analysis of tirofiban use in acute coronary syndromes. Circulation. 2001; 104(Suppl II):798.2001-01-01T00:00:002001Cost-effectiveness analysis of tirofiban use in acute coronary syndromesCannon CPCurr Op CardiolClinical trial updates in coronary artery disease. Curr Op Cardiol. 1999; 14:359.1999-01-01T00:00:001999Clinical trial updates in coronary artery diseaseFisher G, Cannon CP, Tanasijevic MClinical effectiveness of cardiac markers as indicators of coronary artery patency after thrombolysis for acute myocardial infarctionClinical effectiveness of cardiac markers as indicators of coronary artery patency after thrombolysis for acute myocardial infarction. 1999.1999-01-01T00:00:001999Clinical effectiveness of cardiac markers as indicators of coronary artery patency after thrombolysis for acute myocardial infarctionJohnstone MT, Veves A, editorsCannon CP, series editor. Contemporary CardiologyDiabetes and cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 438.2001-01-01T00:00:002001Diabetes and cardiovascular diseaseCannon CPGoldhaber SZ, Ridker PM, editors. Thrombosis and ThromboembolismPlatelet glyocoprotein IIb/IIIa inhibition in acute coronary syndromes. Goldhaber SZ, Ridker PM, editors. Thrombosis and Thromboembolism. 2002; 101-24.2002-01-01T00:00:002002Platelet glyocoprotein IIb/IIIa inhibition in acute coronary syndromesDasta J, Cannon CPFormularyConfronting challenges in aggressive lipid lowering: A managed care perspective. Formulary. 2005; 40:3-14.2005-01-01T00:00:002005Confronting challenges in aggressive lipid lowering: A managed care perspective19667110Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MSArteriosclerosis, thrombosis, and vascular biologyIdentification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep; 29(9):1310-5.Arterioscler Thromb Vasc Biol2009-08-10T00:00:002009Identification of genetic variants associated with response to statin therapy.19797781Kumar A, Cannon CPMayo Clinic proceedingsAcute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009 10; 84(10):917-38.Mayo Clin Proc2009-10-01T00:00:002009Acute coronary syndromes: diagnosis and management, part I.19909874Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PBJournal of the American College of CardiologyThe relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45.J Am Coll Cardiol2009-11-17T00:00:002009The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.20079528Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin LLancet (London, England)Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.Lancet2010-01-13T00:00:002010Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.20152218Xian Y, Pan W, Peterson ED, Heidenreich PA, Cannon CP, Hernandez AF, Friedman B, Holloway RG, Fonarow GCAmerican heart journalAre quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J. 2010 Feb; 159(2):207-14.Am Heart J2010-02-01T00:00:002010Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals.20934559White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin LAmerican heart journalStudy design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 Oct; 160(4):655-61.Am Heart J2010-10-01T00:00:002010Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.20966402Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KCArteriosclerosis, thrombosis, and vascular biologyGrowth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.Arterioscler Thromb Vasc Biol2010-10-21T00:00:002010Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.20978260Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MSJAMAReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30.JAMA2010-10-27T00:00:002010Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Cannon CPLewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment ProgramUnstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005.2005-01-01T00:00:002005Unstable angina: Medical treatmentSabatine MS, Cannon CPAcute Coronary SyndromesRecent advances with clopidogrel in acute myocardial infarction. Acute Coronary Syndromes. 2005; 7(2):56-60.2005-01-01T00:00:002005Recent advances with clopidogrel in acute myocardial infarctionKraus WE, Keteyian SJ, editorsCannon CP, series editor. Contemporary Cardiology.Cardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Cardiac RehabilitationAuthorship 100847810Authorship 1009118728862971Stewart RAH, Hagström E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, López-Sendón JL, Mohler ER, Hadziosmanovic N, Krug-Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin LJournal of the American Heart AssociationSelf-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2017 Aug 22; 6(8).J Am Heart Assoc2017-08-22T00:00:002017Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.28874358Rachmin I, O'Meara CC, Ricci-Blair EM, Feng Y, Christensen EM, Duffy JF, Zitting KM, Czeisler CA, Pancoast JR, Cannon CP, O'Donoghue ML, Morrow DA, Lee RTAmerican journal of physiology. Endocrinology and metabolismSoluble interleukin-13ra1: a circulating regulator of glucose. Am J Physiol Endocrinol Metab. 2017 12 01; 313(6):E663-E671.Am J Physiol Endocrinol Metab2017-09-05T00:00:002017Soluble interleukin-13ra1: a circulating regulator of glucose.16003832Cannon CP, Murphy SA, Braunwald EThe New England journal of medicineIntensive lipid lowering with atorvastatin in coronary disease. N Engl J Med. 2005 Jul 07; 353(1):93-6; author reply 93-6.N Engl J Med2005-07-07T00:00:002005Intensive lipid lowering with atorvastatin in coronary disease.16442896Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LHAmerican heart journalRisk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2006 Feb; 151(2):338-44.Am Heart J2006-02-01T00:00:002006Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.7747698Cannon CP, Thompson B, McCabe CH, Mueller HS, Kirshenbaum JM, Herson S, Nasmith JB, Chaitman BR, Braunwald EThe American journal of cardiologyPredictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol. 1995 May 15; 75(15):977-81.Am J Cardiol1995-05-15T00:00:001995Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials.7832129Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, Shah PKThe American journal of cardiologyHow do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Am J Cardiol. 1995 Feb 01; 75(4):232-6.Am J Cardiol1995-02-01T00:00:001995How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial)8144799Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JLJournal of the American College of CardiologyA pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994 Apr; 23(5):993-1003.J Am Coll Cardiol1994-04-01T00:00:001994A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.9696170Sagarin MJ, Cannon CP, Cermignani MS, Scirica BM, Walls RMThe Journal of emergency medicineDelay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect. J Emerg Med. 1998 Jul-Aug; 16(4):557-65.J Emerg Med1998-07-01T00:00:001998Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect.9878939Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EMAmerican heart journalTrends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. Am Heart J. 1999 Jan; 137(1):79-92.Am Heart J1999-01-01T00:00:001999Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.11719362O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJBloodGenetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001 Dec 01; 98(12):3256-60.Blood2001-12-01T00:00:002001Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.22115875Kohli P, Cannon CPLancet (London, England)Statins and safety: can we finally be reassured? Lancet. 2011 Dec 10; 378(9808):1980-1981.Lancet2011-11-22T00:00:002011Statins and safety: can we finally be reassured?14660991Budaj A, Brieger D, Steg PG, Goodman SG, Dabbous OH, Fox KA, Avezum A, Cannon CP, Mazurek T, Flather MD, Van De Werf FAmerican heart journalGlobal patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2003 Dec; 146(6):999-1006.Am Heart J2003-12-01T00:00:002003Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).15383484Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schünemann HJ, Ohman EMChestThrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.Chest2004-09-01T00:00:002004Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.16234625Ray KK, Cannon CPCurrent opinion in cardiologyOptimal goals for statin use in patients with coronary artery disease. Curr Opin Cardiol. 2005 Nov; 20(6):525-9.Curr Opin Cardiol2005-11-01T00:00:002005Optimal goals for statin use in patients with coronary artery disease.17095906Wiviott SD, Cannon CPCurrent opinion in lipidologyThe safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec; 17(6):626-30.Curr Opin Lipidol2006-12-01T00:00:002006The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy.17478144Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CPThe American journal of cardiologyComparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 01; 99(9):1212-5.Am J Cardiol2007-03-16T00:00:002007Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).17699010Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EMJAMADiabetes and mortality following acute coronary syndromes. JAMA. 2007 Aug 15; 298(7):765-75.JAMA2007-08-15T00:00:002007Diabetes and mortality following acute coronary syndromes.Authorship 1012814128768335Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJJAMA cardiologySimulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 09 01; 2(9):959-966.JAMA Cardiol2017-09-01T00:00:002017Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.18340185Cannon CPCritical pathways in cardiologyWhat is the optimal timing of clopidogrel in acute coronary syndromes? Crit Pathw Cardiol. 2005 Mar; 4(1):46-50.Crit Pathw Cardiol2005-03-01T00:00:002005What is the optimal timing of clopidogrel in acute coronary syndromes?18458666Cannon CPCritical pathways in cardiologyUpdated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Mar; 7(1):43-81.Crit Pathw Cardiol2008-03-01T00:00:002008Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit.18481817Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyThe problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.Clin Cardiol2008-03-01T00:00:002008The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.18574276Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SGChestAntithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S.Chest2008-06-01T00:00:002008Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).18773984Tickoo S, Fonarow GC, Hernandez AF, Liang L, Cannon CPThe American journal of cardiologyWeekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database). Am J Cardiol. 2008 Sep 15; 102(6):663-7.Am J Cardiol2008-06-28T00:00:002008Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database).19122170Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald EArteriosclerosis, thrombosis, and vascular biologyPrognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):424-30.Arterioscler Thromb Vasc Biol2009-01-02T00:00:002009Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.19726929Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CPCritical pathways in cardiologyRegional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11.Crit Pathw Cardiol2009-09-01T00:00:002009Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.20805431Bangalore S, Bhatt DL, Röther J, Alberts MJ, Thornton J, Wolski K, Goto S, Hirsch AT, Smith SC, Aichner FT, Topakian R, Cannon CP, Steg PGCirculationLate outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100.Circulation2010-08-30T00:00:002010Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry.21324428Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KPThe American journal of cardiologyIn-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011 Apr 15; 107(8):1136-43.Am J Cardiol2011-02-15T00:00:002011In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™.21406646Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJJAMAStandard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16; 305(11):1097-105.JAMA2011-03-16T00:00:002011Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.22337214Sampath J, Dietze DT, Toth PP, Cannon CP, Breslan SACritical pathways in cardiologyAre continuing medical education activities effective in improving the competence and performance of clinicians? Evidence from activities for primary care clinicians who manage patients with acute coronary syndromes. Crit Pathw Cardiol. 2012 Mar; 11(1):1-9.Crit Pathw Cardiol2012-03-01T00:00:002012Are continuing medical education activities effective in improving the competence and performance of clinicians? Evidence from activities for primary care clinicians who manage patients with acute coronary syndromes.Authorship 10146405Authorship 1014760928847206Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJThe New England journal of medicineEffects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 09 28; 377(13):1217-1227.N Engl J Med2017-08-28T00:00:002017Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.28958324Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HDJournal of the American College of CardiologyPhysical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017 Oct 03; 70(14):1689-1700.J Am Coll Cardiol2017-10-03T00:00:002017Physical Activity and Mortality in Patients With Stable Coronary Heart Disease.Bonaca MP, Morrow DA, Sabatine MS, Ray KK, Rifai N, Cannon CPCirculationElevated levels of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in PROVE IT-TIMI 22. Circulation. 2006; 114(8):II-649.2006-01-01T00:00:002006Elevated levels of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in PROVE IT-TIMI 22Cannon CPInvasive vs conservative strategies in UA/NSTEMI: The right TACTICS in 2001Invasive vs conservative strategies in UA/NSTEMI: The right TACTICS in 2001. 2001.2001-01-01T00:00:002001Invasive vs conservative strategies in UA/NSTEMI: The right TACTICS in 2001Cannon CP, Braunwald EBraunwald E, Zipes DP, Libby P, editors. Heart Disease: A Textbook of Cardiovascular MedicineUnstable angina. Braunwald E, Zipes DP, Libby P, editors. Heart Disease: A Textbook of Cardiovascular Medicine. 2001; 1232-63.2001-01-01T00:00:002001Unstable anginaHo KK, Anderson HV, Shaw RE, Klein LW, Beachy JH, Cannon CP, Krumholz HM, Fitzgerald S, Hermann A, Mitchell K, Rumsfeld J, Brindis RG on behalf of the National Cardiovascular Data RegistryCirculationAbsence of flow-limiting coronary artery disease among patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction in the national cardiovascular data registry cathPCI registry: Implications for primary angioplasty programs. Circulation. 2007; 116(16):II-624.2007-10-16T00:00:002007Absence of flow-limiting coronary artery disease among patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction in the national cardiovascular data registry cathPCI registry: Implications for primary angioplasty programsCannon CP, Hawkins D, Wallace-Hixson JCardiology Special EditionGuide to cardiovascular agents. Cardiology Special Edition. 2003; 9:27-37.2003-01-01T00:00:002003Guide to cardiovascular agentsCannon CP, Caprini JA, Merli GJ, Hawkins DDifferentiation of low molecular weight heparins: Clinical and economic implications of treatmentDifferentiation of low molecular weight heparins: Clinical and economic implications of treatment. 1999.1999-01-01T00:00:001999Differentiation of low molecular weight heparins: Clinical and economic implications of treatmentCannon CPAwesome 2002 ACC/AHAAwesome 2002 ACC/AHA. 2002.2002-01-01T00:00:002002Awesome 2002 ACC/AHACannon CPOutcomes in patients with ECG changesOutcomes in patients with ECG changes. 2006.2006-02-01T00:00:002006Outcomes in patients with ECG changesCannon CP, O'Gara PCannon CP, editor. Contemporary Cardiology: Management of Acute Coronary SyndromesCritical pathways for acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 745-69.2003-01-01T00:00:002003Critical pathways for acute coronary syndromesCannon CP, Antman EM, Walls R, Braunwald E: Le TempsUn adjuvant a la thrombolyseUn adjuvant a la thrombolyse. 1994.1994-01-01T00:00:001994Un adjuvant a la thrombolyseRay KK, Morrow DA, Cannon CP, Sabatine MS, Guo W, Rifai N, Braunwauld EJ Am Coll CardiolVon willebrand factor but not tissue factor or soluble CD40 ligand are associated with increased risk of recurrent events after ACS in PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):188A.2007-03-06T00:00:002007Von willebrand factor but not tissue factor or soluble CD40 ligand are associated with increased risk of recurrent events after ACS in PROVE-IT-TIMI 22Cannon CP, editorManagement of Acute Coronary SyndromesManagement of Acute Coronary Syndromes. 1999.1999-01-01T00:00:001999Management of Acute Coronary SyndromesHerrmann HC, Murphy SA, DiBattiste P, DeLucca PT, Demopoulos L, Gibson CM, Cannon CPCrit Path CardiolGreater benefit and early invasive strategy for unstable angina and non-ST elevation myocardial infarction ain United States compated with non-United States patients: A TACTICS-TIMI 18 Substudy. Crit Path Cardiol. 2004; 3:95-100..2004-01-01T00:00:002004Greater benefit and early invasive strategy for unstable angina and non-ST elevation myocardial infarction ain United States compated with non-United States patients: A TACTICS-TIMI 18 SubstudyCannon CPPharmacology of thrombolytic, anticoagulant, and antiplatelet agentsPharmacology of thrombolytic, anticoagulant, and antiplatelet agents. 1994.1994-01-01T00:00:001994Pharmacology of thrombolytic, anticoagulant, and antiplatelet agentsCannon CPTIMI risk calculatorTIMI risk calculator. 2001.2001-01-01T00:00:002001TIMI risk calculatorAuthorship 10165751328972004Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald ECirculationPrevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450.Circulation2017-09-30T00:00:002017Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).6197505Al-Awqati Q, Gluck S, Reeves W, Cannon CThe Journal of experimental biologyRegulation of proton transport in urinary epithelia. J Exp Biol. 1983 Sep; 106:135-41.J Exp Biol1983-09-01T00:00:001983Regulation of proton transport in urinary epithelia.10150659Cannon CPContemporary internal medicineAdvances in the treatment of acute MI. Contemp Intern Med. 1994 Aug; 6(8):11-5, 20-6.Contemp Intern Med1994-08-01T00:00:001994Advances in the treatment of acute MI.10347349Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EMAmerican heart journalMethodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Am Heart J. 1999 Jun; 137(6):1179-84.Am Heart J1999-06-01T00:00:001999Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group.10348947Cannon CPCardiology in reviewThe Ten Most Commonly Asked Questions about Platelet Glycoprotein IIb/IIIa Receptor Antagonists. Cardiol Rev. 1998 Oct; 6(5):252-254.Cardiol Rev1998-10-01T00:00:001998The Ten Most Commonly Asked Questions about Platelet Glycoprotein IIb/IIIa Receptor Antagonists.Fuster V, Pickering T, Cannon CP, Ferguson J, Weber M.ALLHAT and ALLHAT-LLTALLHAT and ALLHAT-LLT. 2002.2002-01-01T00:00:002002ALLHAT and ALLHAT-LLTCannon CP, O'Gara PT, editorsCritical Pathways in Cardiovascular MedicineCritical Pathways in Cardiovascular Medicine. 2007.2007-01-01T00:00:002007Critical Pathways in Cardiovascular MedicineEdwards NM, Chen JM, Mazzeo PA, editorsCannon CP, series editor. Contemporary CardiologyCardiac transplantation. Cannon CP, series editor. Contemporary Cardiology. 2004; 286.2004-01-01T00:00:002004Cardiac transplantationHenry TD, Becker RC, Cannon CP, McCabe CH, Loscalzo J, for the TIMI 5 InvestigatorsJ Am Coll CardiolIs there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction. J Am Coll Cardiol. 1995; 310A.1995-01-01T00:00:001995Is there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction10603506Becker RC, Cannon CPJournal of thrombosis and thrombolysisHirudin: Its Biology and Clinical Use. J Thromb Thrombolysis. 1994; 1(1):7-16.J Thromb Thrombolysis1994-01-01T00:00:001994Hirudin: Its Biology and Clinical Use.10728957Holmes MB, Sobel BE, Cannon CP, Schneider DJThe American journal of cardiologyIncreased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Feb 15; 85(4):491-3, A10.Am J Cardiol2000-02-15T00:00:002000Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.12082590Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJThe pharmacogenomics journalThe contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J. 2002; 2(3):182-90.Pharmacogenomics J2002-01-01T00:00:002002The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.12105159Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CMCirculationElevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation. 2002 Jul 09; 106(2):202-7.Circulation2002-07-09T00:00:002002Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.11489764Cannon CPCirculationImportance of TIMI 3 flow. Circulation. 2001 Aug 07; 104(6):624-6.Circulation2001-08-07T00:00:002001Importance of TIMI 3 flow.12450608Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald EThe American journal of cardiologyEffects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002 Dec 01; 90(11):1246-9.Am J Cardiol2002-12-01T00:00:002002Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).14524594Cannon CPClinical cardiologyOral platelet glycoprotein IIb/IIIa receptor inhibitors--part II. Clin Cardiol. 2003 Sep; 26(9):401-6.Clin Cardiol2003-09-01T00:00:002003Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II.14556865Karha J, Murphy SA, Kirtane AJ, de Lemos JA, Aroesty JM, Cannon CP, Antman EM, Braunwald E, Gibson CMThe American journal of cardiologyEvaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. Am J Cardiol. 2003 Oct 15; 92(8):913-8.Am J Cardiol2003-10-15T00:00:002003Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction.14646728Cannon CP, Eckardt JJ, Kabo JM, Ward WG, Kelly CM, Wirganowicz PZ, Asavamongkolkul A, Nieves R, Eilber FRClinical orthopaedics and related researchCustom cross-pin fixation of 32 tumor endoprostheses stems. Clin Orthop Relat Res. 2003 Dec; (417):285-92.Clin Orthop Relat Res2003-12-01T00:00:002003Custom cross-pin fixation of 32 tumor endoprostheses stems.15312859Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald EJournal of the American College of CardiologyPerformance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.J Am Coll Cardiol2004-08-18T00:00:002004Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.15358021Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA, de Lemos JA, Braunwald E, Gibson CMJournal of the American College of CardiologyAssociation of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 04; 44(3):564-8.J Am Coll Cardiol2004-08-04T00:00:002004Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction.16606819Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RAArchives of internal medicineClopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11.Arch Intern Med2006-04-10T00:00:002006Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.17384000Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, Cannon CP, Francis G, Morrow DA, Ravkilde J, Storrow AB, Tang W, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate JClinical chemistryNational Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):547-51.Clin Chem2007-03-23T00:00:002007National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes.17502591Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EMCirculationAcute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2570-89.Circulation2007-05-15T00:00:002007Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.17598815Gelfand EV, Cannon CPJournal of internal medicineMyocardial infarction: contemporary management strategies. J Intern Med. 2007 Jul; 262(1):59-77.J Intern Med2007-07-01T00:00:002007Myocardial infarction: contemporary management strategies.11809292Cannon CLancet (London, England)Clopidogrel and percutaneous coronary intervention. Lancet. 2002 Jan 12; 359(9301):169.Lancet2002-01-12T00:00:002002Clopidogrel and percutaneous coronary intervention.12231091Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos LA, Cannon CPThe American journal of cardiologyEfficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002 Sep 15; 90(6):631-3.Am J Cardiol2002-09-15T00:00:002002Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.12360161Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CMAmerican heart journalImpact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J. 2002 Oct; 144(4):649-56.Am Heart J2002-10-01T00:00:002002Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy.12679757Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald EAmerican heart journalPrior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003 Apr; 145(4):622-7.Am Heart J2003-04-01T00:00:002003Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.12782615Cannon CP, Turpie AGCirculationUnstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. Circulation. 2003 Jun 03; 107(21):2640-5.Circulation2003-06-03T00:00:002003Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy.14564234Cannon CPReviews in cardiovascular medicineCritical pathways for acute myocardial infarction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S47-53.Rev Cardiovasc Med2003-01-01T00:00:002003Critical pathways for acute myocardial infarction.15104769McCullough PA, Gibson CM, Dibattiste PM, Demopoulos LA, Murphy SA, Weintraub WS, Neumann FJ, Khanal S, Cannon CPJournal of interventional cardiologyTiming of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol. 2004 Apr; 17(2):81-6.J Interv Cardiol2004-04-01T00:00:002004Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial.Authorship 10183313Authorship 1018796229018021Barger LK, Rajaratnam SMW, Cannon CP, Lukas MA, Im K, Goodrich EL, Czeisler CA, O'Donoghue MLJournal of the American Heart AssociationShort Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2017 Oct 10; 6(10).J Am Heart Assoc2017-10-10T00:00:002017Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome.29020411Ference BA, Cannon CP, Landmesser U, Lüscher TF, Catapano AL, Ray KKEuropean heart journalReduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018 07 14; 39(27):2540-2545.Eur Heart J2018-07-14T00:00:002018Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.16786236Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald EJournal of thrombosis and thrombolysisCholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug; 22(1):71-6.J Thromb Thrombolysis2006-08-01T00:00:002006Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.16996863Ray KK, Morrow DA, Shui A, Rifai N, Cannon CPThe American journal of cardiologyRelation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol. 2006 Oct 01; 98(7):861-5.Am J Cardiol2006-08-04T00:00:002006Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).17323134McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CPJournal of thrombosis and thrombolysisBenefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis. 2007 Oct; 24(2):85-91.J Thromb Thrombolysis2007-02-24T00:00:002007Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.17384331Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RHCirculationNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007 Apr 03; 115(13):e356-75.Circulation2007-03-23T00:00:002007National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes.18091407Schreiner GC, Laine L, Murphy SA, Cannon CPCritical pathways in cardiologyEvaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Crit Pathw Cardiol. 2007 Dec; 6(4):169-72.Crit Pathw Cardiol2007-12-01T00:00:002007Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.18340309Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WS, DiBattiste PM, Cannon CPCritical pathways in cardiologyOutcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2002 Dec; 1(4):232-7.Crit Pathw Cardiol2002-12-01T00:00:002002Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy.18513520Mehta RH, Bufalino VJ, Pan W, Hernandez AF, Cannon CP, Fonarow GC, Peterson EDAmerican heart journalAchieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J. 2008 Jun; 155(6):1059-67.Am Heart J2008-03-05T00:00:002008Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program.19074516Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DAClinical chemistryConcentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.Clin Chem2008-12-12T00:00:002008Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.19339044Cannon CPLancet (London, England)Can the polypill save the world from heart disease? Lancet. 2009 Apr 18; 373(9672):1313-4.Lancet2009-03-30T00:00:002009Can the polypill save the world from heart disease?19361588Nallamothu BK, Krumholz HM, Peterson ED, Pan W, Bradley E, Stern AF, Masoudi FA, Janicke DM, Hernandez AF, Cannon CP, Fonarow GCThe American journal of cardiologyDoor-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. Am J Cardiol. 2009 Apr 15; 103(8):1051-5.Am J Cardiol2009-02-28T00:00:002009Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance.20065937Truong QA, Siegel E, Cannon CPReviews in cardiovascular medicineCardiac CT angiography--radiation dose-how effective are we in reducing radiation dose from cardiac CT angiography? Rev Cardiovasc Med. 2009; 10(4):236-9.Rev Cardiovasc Med2009-01-01T00:00:002009Cardiac CT angiography--radiation dose-how effective are we in reducing radiation dose from cardiac CT angiography?Authorship 10214233Authorship 10215185Authorship 1022063329064626Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WBDiabetes, obesity & metabolismHigh-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659.Diabetes Obes Metab2017-11-21T00:00:002017High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.29066452Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin LJournal of the American Heart AssociationInflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).J Am Heart Assoc2017-10-24T00:00:002017Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.29066436Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, Hochman JS, Goodrich EL, Braunwald E, O'Donoghue MLJournal of the American Heart AssociationInterleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).J Am Heart Assoc2017-10-24T00:00:002017Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.18082504Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald EAmerican heart journalEffects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J. 2008 Jan; 155(1):133-9.Am Heart J2007-11-19T00:00:002007Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.18340148Herrmann HC, Murphy SA, Dibattiste PM, Delucca PT, Demopoulos LA, Gibson CM, Cannon CPCritical pathways in cardiologyGreater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2004 Jun; 3(2):95-100.Crit Pathw Cardiol2004-06-01T00:00:002004Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy.18340320Cannon CPCritical pathways in cardiologyForeword to lessons learned. Crit Pathw Cardiol. 2003 Mar; 2(1):54.Crit Pathw Cardiol2003-03-01T00:00:002003Foreword to lessons learned.18435951Albert NM, Birtcher KK, Cannon CP, Goff DC, Mulgund J, Liang L, Fonarow GCThe American journal of cardiologyFactors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database). Am J Cardiol. 2008 May 01; 101(9):1242-6.Am J Cardiol2008-03-05T00:00:002008Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).18440347Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CPAmerican heart journalHigh-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008 May; 155(5):954-8.Am Heart J2008-02-19T00:00:002008High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.18721511Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald EThe American journal of cardiologyOutcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 01; 102(5):552-8.Am J Cardiol2008-06-12T00:00:002008Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).18760147Alexander D, Ou FS, Roe MT, Pollack CV, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DLAmerican heart journalUse of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J. 2008 Sep; 156(3):606-12.Am Heart J2008-07-22T00:00:002008Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).20805430James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin LCirculationTicagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.Circulation2010-08-30T00:00:002010Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.21119336Marchini J, Morrow D, Resnic F, Manica A, Kirshenbaum J, Cannon C, Croce KCritical pathways in cardiologyAn algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol. 2010 Dec; 9(4):192-8.Crit Pathw Cardiol2010-12-01T00:00:002010An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.21996387Motivala AA, Cannon CP, Srinivas VS, Dai D, Hernandez AF, Peterson ED, Bhatt DL, Fonarow GCJournal of the American College of CardiologyChanges in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5.J Am Coll Cardiol2011-10-18T00:00:002011Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?22089726Cannon CPJAMAHigh-density lipoprotein cholesterol as the Holy Grail. JAMA. 2011 Nov 16; 306(19):2153-5.JAMA2011-11-16T00:00:002011High-density lipoprotein cholesterol as the Holy Grail.22766336O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MSJournal of the American College of CardiologyAn invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11.J Am Coll Cardiol2012-07-10T00:00:002012An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.Lee LV, for the TIMI 6 InvestigatorsAm J CardiolInitial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol. 1995; 75:7-13..1995-01-01T00:00:001995Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 6 TrialCogan J, Cannon CP, de Lemos JLlevadot J, editor. Acute Coronary SyndromesTreatment of unstable angina and non-ST elevation myocardial infarction. Llevadot J, editor. Acute Coronary Syndromes. 2003; 229-55.2003-01-01T00:00:002003Treatment of unstable angina and non-ST elevation myocardial infarctionApple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J, National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice GuidelinesCirculationAnalytical issues for biomarkers of heart failure. Circulation. 2007; e95-8.2007-01-01T00:00:002007Analytical issues for biomarkers of heart failureKloner RA, Gibson CM, Cannon CP, Braunwald EN Eng J MedPreinfarction angina (letter). N Eng J Med. 1996; 335:59-60..1996-01-01T00:00:001996Preinfarction angina (letter)Ericsson CD, Cannon CP, Deutsch EUnstable angina: Diagnosis and managementUnstable angina: Diagnosis and management. 1999.1999-01-01T00:00:001999Unstable angina: Diagnosis and managementSadanandan S, Cannon CP, DiBattiste PM, Demopoulos LA, Robertson D, Kugelmass AD, for the TACTICS - TIMI 18 Investigators CirculationOutcomes of patients with spontaneous versus post pci CK-MB elevation: data from TACTICS-TIMI 18 trial. Circulation. 2001; 104(Suppl II):697.2001-01-01T00:00:002001Outcomes of patients with spontaneous versus post pci CK-MB elevation: data from TACTICS-TIMI 18 trialMeadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts M, Goto S, Wilson PW, Steg PG on behalf of the REACH Registry InvestigatorsCirculationEthnic differences in the prevalence and treatment of cardiovascular risk factors in outpatients with peripheral arterial disease: Insights from the REACH Registry. Circulation. 2007; 116(16):II-775.2007-10-16T00:00:002007Ethnic differences in the prevalence and treatment of cardiovascular risk factors in outpatients with peripheral arterial disease: Insights from the REACH RegistryCannon CPThrombolysis and medication errorsThrombolysis and medication errors. 1999.1999-01-01T00:00:001999Thrombolysis and medication errorsCannon CPEvid Based Cardiovasc MedCommentary on GUSTO IV-ACS. Evid Based Cardiovasc Med. 2001; 5:131.2001-01-01T00:00:002001Commentary on GUSTO IV-ACSCannon CPAmerican College Cardiology Oregon Chapter NewsletterRecent update to the ACC/AHA guidelines for the management of patients with UA/NSTEMI. American College Cardiology Oregon Chapter Newsletter. 2003; 8.2003-01-01T00:00:002003Recent update to the ACC/AHA guidelines for the management of patients with UA/NSTEMIScirica BM, Murphy S, Wiviott SD, Morrow DA, Sabatine MS, Gibson CM, Cannon CPJ Am Coll CardiolChest Pain at presentation and delayed resolution of pain patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcomes. J Am Coll Cardiol. 2005; 45(Suppl A):199.2005-01-01T00:00:002005Chest Pain at presentation and delayed resolution of pain patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcomesCannon CP, Goldhaber SZ, Hand MChestsoundingsNational heart attack alert program: Highlights. Chestsoundings. 2001; 15:17.2001-07-01T00:00:002001National heart attack alert program: HighlightsCannon CPA new addition to the treatment of STEMI: The CLARITY TIMI-28 COMMITT/CCS-2 TrialsA new addition to the treatment of STEMI: The CLARITY TIMI-28 COMMITT/CCS-2 Trials. 2005.2005-01-01T00:00:002005A new addition to the treatment of STEMI: The CLARITY TIMI-28 COMMITT/CCS-2 TrialsMarks DS, Gudapati SB, Kleczka J, Murphy S, Cannon CP, Braunwald EJ Am Coll CardiolElectrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction. J Am Coll Cardiol. 2002; 39:331A.2002-01-01T00:00:002002Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarctionCannon CP, Topol ECannon chronicles: Aspirin therapy: What is the appropriate dose?Cannon chronicles: Aspirin therapy: What is the appropriate dose?. 2003.2003-01-01T00:00:002003Cannon chronicles: Aspirin therapy: What is the appropriate dose?Kloner RA, editorCannon CP, series editor. Contemporary CardiologyHeart disease and erectile dysfunction. Cannon CP, series editor. Contemporary Cardiology. 2004.2004-01-01T00:00:002004Heart disease and erectile dysfunctionCannon CPCurr Opin Card Pulm Renal Invest DrugThe evolving story of oral platelet glycoprotein IIb/IIIa inhibitors. Curr Opin Card Pulm Renal Invest Drug. 2000; 2:114-23.2000-01-01T00:00:002000The evolving story of oral platelet glycoprotein IIb/IIIa inhibitorsKing S, Cannon CP, Mehta SR, Roe MIntegrating antiplatelet therapy with early invasive management for acute coronary syndromesIntegrating antiplatelet therapy with early invasive management for acute coronary syndromes. 2002.2002-01-01T00:00:002002Integrating antiplatelet therapy with early invasive management for acute coronary syndromes14600617Eckardt JJ, Kabo JM, Kelly CM, Ward WG, Cannon CPClinical orthopaedics and related researchEndoprosthetic reconstructions for bone metastases. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S254-62.Clin Orthop Relat Res2003-10-01T00:00:002003Endoprosthetic reconstructions for bone metastases.14607434Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald EJournal of the American College of CardiologyAssociation of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.J Am Coll Cardiol2003-11-05T00:00:002003Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.9008448Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald ECirculationTNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997 Jan 21; 95(2):351-6.Circulation1997-01-21T00:00:001997TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.14769678Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald ECirculationDifferential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.Circulation2004-02-10T00:00:002004Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.15199450Cannon CPSeminars in vascular medicineTreatment algorithms and critical pathways for acute coronary syndromes. Semin Vasc Med. 2003 Nov; 3(4):425-32.Semin Vasc Med2003-11-01T00:00:002003Treatment algorithms and critical pathways for acute coronary syndromes.Authorship 1025615429109198Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis GCirculationImpact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey. Circulation. 2017 11 07; 136(19):1860-1862.Circulation2017-11-07T00:00:002017Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.15769761Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CPCirculationInfluence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005 Mar 15; 111(10):1217-24.Circulation2005-03-15T00:00:002005Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment.16226163Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald EJournal of the American College of CardiologyCan low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005 Oct 18; 46(8):1411-6.J Am Coll Cardiol2005-10-18T00:00:002005Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.16644315Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum YAmerican heart journalStatins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006 May; 151(5):976.e1-6.Am Heart J2006-05-01T00:00:002006Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.29141201Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein RJournal of the American College of CardiologyCardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018 01 23; 71(3):292-302.J Am Coll Cardiol2017-11-12T00:00:002017Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry.17502569Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil SCirculationTreatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007 May 29; 115(21):2761-88.Circulation2007-05-14T00:00:002007Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.17577297Ray KK, Cannon CP, Braunwald EInternational journal of clinical practiceRecent trials of lipid lowering. Int J Clin Pract. 2007 Jul; 61(7):1145-59.Int J Clin Pract2007-07-01T00:00:002007Recent trials of lipid lowering.11320361Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald EAmerican heart journalLower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.Am Heart J2001-05-01T00:00:002001Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.18082488Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DIAmerican heart journalMyeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan; 155(1):49-55.Am Heart J2007-11-01T00:00:002007Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.Authorship 10263161218340283Cannon CPCritical pathways in cardiologyCritical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practice. Crit Pathw Cardiol. 2002 Mar; 1(1):1-2.Crit Pathw Cardiol2002-03-01T00:00:002002Critical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practice.18340288Cannon CP, Bahit MC, Haugland JM, Henry TD, Schweiger MJ, McKendall GR, Shah PK, Murphy S, Gibson CM, McCabe CH, Antman EM, Braunwald ECritical pathways in cardiologyUnderutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002 Mar; 1(1):44-52.Crit Pathw Cardiol2002-03-01T00:00:002002Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry.7594376Cannon CP, Walls RMThe Journal of emergency medicineWaiting for Godot: use of chemical markers in the emergency department evaluation of chest pain. J Emerg Med. 1995 Jul-Aug; 13(4):533-5.J Emerg Med1995-07-01T00:00:001995Waiting for Godot: use of chemical markers in the emergency department evaluation of chest pain.1638732Braunwald E, Cannon CP, McCabe CHCirculationAn approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation. 1992 Aug; 86(2):683-7.Circulation1992-08-01T00:00:001992An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.12356393Cannon CPThe American journal of cardiologyEffectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol. 2002 Oct 01; 90(7):760-2.Am J Cardiol2002-10-01T00:00:002002Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).12356395Murphy SA, Chen C, Cannon CP, Antman EM, Gibson CMThe American journal of cardiologyImpact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. Am J Cardiol. 2002 Oct 01; 90(7):766-70.Am J Cardiol2002-10-01T00:00:002002Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction.20096003Maree AO, Vangjeli C, Jneid H, Ryan J, Cox D, Cannon CP, Shields DC, Fitzgerald DJJournal of thrombosis and haemostasis : JTHG-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial. J Thromb Haemost. 2010 May; 8(5):934-41.J Thromb Haemost2010-01-22T00:00:002010G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial.15219518Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EMThe American journal of cardiologyAssociation of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am J Cardiol. 2004 Jul 01; 94(1):108-11.Am J Cardiol2004-07-01T00:00:002004Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction.Authorship 1028143229151034Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RPJournal of the American Heart AssociationEfficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11).J Am Heart Assoc2017-11-18T00:00:002017Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).20802262Birtcher KK, Pan W, Labresh KA, Cannon CP, Fonarow GC, Ellrodt GCritical pathways in cardiologyPerformance achievement award program for Get With The Guidelines--Coronary Artery Disease is associated with global and sustained improvement in cardiac care for patients hospitalized with an acute myocardial infarction. Crit Pathw Cardiol. 2010 Sep; 9(3):103-12.Crit Pathw Cardiol2010-09-01T00:00:002010Performance achievement award program for Get With The Guidelines--Coronary Artery Disease is associated with global and sustained improvement in cardiac care for patients hospitalized with an acute myocardial infarction.20868290Krishnaswamy A, Lincoff AM, Cannon CPExpert opinion on drug safetyBleeding complications of unfractionated heparin. Expert Opin Drug Saf. 2011 Jan; 10(1):77-84.Expert Opin Drug Saf2010-09-25T00:00:002010Bleeding complications of unfractionated heparin.21146668Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GCAmerican heart journalUse of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3.Am Heart J2010-12-01T00:00:002010Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).15629367Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, Morrow DA, Cannon CP, Braunwald E, Lakkis NJournal of the American College of CardiologyPrognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol. 2005 Jan 04; 45(1):19-24.J Am Coll Cardiol2005-01-04T00:00:002005Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy.15642554Kirtane AJ, Weisbord A, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, Roe MT, Braunwald E, Gibson CMThe American journal of cardiologyRelation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.Am J Cardiol2005-01-15T00:00:002005Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction.15843667Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AMThe New England journal of medicineAntibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54.N Engl J Med2005-04-21T00:00:002005Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.15864232Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald EAmerican heart journalEarly initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005 Mar; 149(3):444-50.Am Heart J2005-03-01T00:00:002005Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial.8184639Cannon CP, Braunwald EActa cardiologicaGUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol. 1994; 49(1):1-8.Acta Cardiol1994-01-01T00:00:001994GUSTO, TIMI and the case for rapid reperfusion.8279014Smith SR, Kubacki VB, Rakhit A, Martin LL, Schaffer AV, Jasani MK, Hefty DJ, Johnston T, Cannon C, Bennett WMTransplantationChronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation. 1993 Dec; 56(6):1422-6.Transplantation1993-12-01T00:00:001993Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.Authorship 1030290129188279Cannon C, Khan I, Sanchez RJAMA cardiologySimulation Models of Therapy Intensification in Lipid-Lowering Medicine-Reply. JAMA Cardiol. 2018 01 01; 3(1):89.JAMA Cardiol2018-01-01T00:00:002018Simulation Models of Therapy Intensification in Lipid-Lowering Medicine-Reply.16275863Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJCirculationOptimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. 2005 Nov 15; 112(20):3049-57.Circulation2005-11-07T00:00:002005Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry.16291601Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald ECirculationAngiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54.Circulation2005-11-15T00:00:002005Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.17119457Cannon CP, Lin PP, Lewis VO, Yasko AWClinical orthopaedics and related researchAcetabular outcome after hip hemiarthroplasty in patients with tumors. Clin Orthop Relat Res. 2007 Apr; 457:183-7.Clin Orthop Relat Res2007-04-01T00:00:002007Acetabular outcome after hip hemiarthroplasty in patients with tumors.17384001Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang WClinical chemistryNational Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):552-74.Clin Chem2007-03-23T00:00:002007National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes.17403721Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald EEuropean heart journalSynergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007 Apr; 28(7):806-13.Eur Heart J2007-04-02T00:00:002007Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18.17630411Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair JCirculationNational Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation. 2007 Jul 31; 116(5):e95-8.Circulation2007-07-14T00:00:002007National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure.18346960O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, Sabatine MSEuropean heart journalAssociation between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J. 2008 Apr; 29(8):984-91.Eur Heart J2008-03-16T00:00:002008Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.18481819Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott SClinical cardiologyInvestigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.Clin Cardiol2008-03-01T00:00:002008Investigating the mechanisms of hyporesponse to antiplatelet approaches.Cannon CPUnresolved question in acute coronary syndromes: Rationale for the PROVE IT trial: Future directions in atherosclerosisUnresolved question in acute coronary syndromes: Rationale for the PROVE IT trial: Future directions in atherosclerosis. 2000.2000-01-01T00:00:002000Unresolved question in acute coronary syndromes: Rationale for the PROVE IT trial: Future directions in atherosclerosisHasdai D, Berger PB, Batter A, Holmes DR, editorsCannon CP, series editor. Contemporary CardiologyCardiogenic shock-diagnosis and treatment. Cannon CP, series editor. Contemporary Cardiology. 2005; 381.2005-01-01T00:00:002005Cardiogenic shock-diagnosis and treatmentCannon CPWhen is it safe to take a plane after I have had a heart attack?When is it safe to take a plane after I have had a heart attack?. 2008.2008-01-31T00:00:002008When is it safe to take a plane after I have had a heart attack?Cannon CP, Tracy RJ Thromb ThrombolysisClotting for the clinician: An overview of thrombosis and antithrombotic therapy. J Thromb Thrombolysis. 1995; 2:95-106.1995-01-01T00:00:001995Clotting for the clinician: An overview of thrombosis and antithrombotic therapyJurkovitz C, Mahoney EM, Spertus J, Chu H, Alexander C, Robertson D, Demopoulos L, DiBattiste P, Cannon C, Weintraub WSEur Heart JChanges in Seattle Angina Questionnaire (SAQ) following treatment for acute coronary syndromes: A follow-up evaluation from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):718.2001-01-01T00:00:002001Changes in Seattle Angina Questionnaire (SAQ) following treatment for acute coronary syndromes: A follow-up evaluation from the TACTICS-TIMI 18 trialNatale A, Jalife JCannon CP, series editor. Contemporary CardiologyAtrial fibrillation: From bench to bedside. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-01-01T00:00:002008Atrial fibrillation: From bench to bedsideCannon CP, Gibson CM, Lincoff AMDetermining the combination therapy in acute myocardial infarctionDetermining the combination therapy in acute myocardial infarction. 2001.2001-01-01T00:00:002001Determining the combination therapy in acute myocardial infarctionRay KK, Cannon CP, Cairns R, Wiviott SD, Kirtane AJ, Sabatine MS, McCabe CH, Braunwald E, Gibson CMJ Am Coll CardiolBeyond LDL control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):332.2005-01-01T00:00:002005Beyond LDL control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI 22Cannon CP, Gibson CM, Braunwald E, Antman EM, Ornato JIntegrating the TIMI risk score into ACSIntegrating the TIMI risk score into ACS. 2001.2001-01-01T00:00:002001Integrating the TIMI risk score into ACSCannon CP, King S, Ohman MDay in review-inhibiting platelets in the cath labDay in review-inhibiting platelets in the cath lab. 2002.2002-01-01T00:00:002002Day in review-inhibiting platelets in the cath labCannon CPAtherothrombosis: Bridging the gap between clinical evidence and current practiceAtherothrombosis: Bridging the gap between clinical evidence and current practice. 2004.2004-01-01T00:00:002004Atherothrombosis: Bridging the gap between clinical evidence and current practiceWackers FJT, Cannon CP, McMahon M, Zaret BL, and TIMI InvestigatorsJ Am Coll CardiolNatural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1993; 21(Suppl A):249.1993-01-01T00:00:001993Natural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarctionO'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CMJ Am Coll CardiolAssociation of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudy. J Am Coll Cardiol. 2006; 47(4):222A.2006-02-21T00:00:002006Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudyHill NS, Farber HWCannon CP, series editor. Contemporary CardiologyPulmonary hypertension. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-06-06T00:00:002008Pulmonary hypertensionCannon CP.The need for a national heart attack treatment strategyThe need for a national heart attack treatment strategy. 2005.2005-11-01T00:00:002005The need for a national heart attack treatment strategyConstant J, editorCannon CP, series editor. Contemporary Cardiology.Essentials of Bedside Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2003.2003-01-01T00:00:002003Essentials of Bedside CardiologyCannon CPGertsch M, editor. Two-step approach to diagnosisForward. Gertsch M, editor. Two-step approach to diagnosis. 2004; 607.2004-01-01T00:00:002004ForwardSteinberg BA, Fonarow GC, Hernandez AF, Liang L, Peterson ED, Cannon CP, GWTG Scientific Advisory Committee and InvestigatorsCirculationMetabolic syndrome in patients with CAD: Is it more than obesity? Analysis of 79,677 hospitalizations in get with the guidelines. Circulation. 2006; 114(18):II-894.2006-01-01T00:00:002006Metabolic syndrome in patients with CAD: Is it more than obesity? Analysis of 79,677 hospitalizations in get with the guidelinesCannon CP, Farkouh M, Gibler BGuidelines in chest pain emergency departments: The experience and futureGuidelines in chest pain emergency departments: The experience and future. 2000.2000-01-01T00:00:002000Guidelines in chest pain emergency departments: The experience and futureLaham RD, Baim DS, editorsCannon CP, series editor. Contemporary CardiologyAngiogenesis and direct myocardial revascularization. Cannon CP, series editor. Contemporary Cardiology. 2005; 357.2005-01-01T00:00:002005Angiogenesis and direct myocardial revascularizationCannon CPNon-PCI Approaches in ACS: Guidelines for Risk Stratification and Medical ManagementNon-PCI Approaches in ACS: Guidelines for Risk Stratification and Medical Management. 2007.2007-01-01T00:00:002007Non-PCI Approaches in ACS: Guidelines for Risk Stratification and Medical ManagementCannon CP, Braunwald EAHA/ACC 2002 guideline update for the management of patients with unstable angina and non-ST-segment-elevation myocardial infarctionAHA/ACC 2002 guideline update for the management of patients with unstable angina and non-ST-segment-elevation myocardial infarction. 2003.2003-01-01T00:00:002003AHA/ACC 2002 guideline update for the management of patients with unstable angina and non-ST-segment-elevation myocardial infarction8673790Walls RM, Cannon CP, Teich JAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineThrombolysis "door-to-drug" interval. Acad Emerg Med. 1996 Mar; 3(3):285; author reply 286-7.Acad Emerg Med1996-03-01T00:00:001996Thrombolysis "door-to-drug" interval.8712133Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald BThe American journal of cardiologyPrognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial) Am J Cardiol. 1996 Jul 15; 78(2):142-7.Am J Cardiol1996-07-15T00:00:001996Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)22925314Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Pan W, Schwamm LH, Bhatt DLThe American journal of medicinePredictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9.Am J Med2012-08-24T00:00:002012Predictors of adherence to performance measures in patients with acute myocardial infarction.23032550Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DLJAMAß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 03; 308(13):1340-9.JAMA2012-10-03T00:00:002012ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.23131034Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald EChronobiology internationalCircadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.Chronobiol Int2012-11-06T00:00:002012Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction.Cannon CPApplication of the NHAAP guidelines in chest pain emergency departmentApplication of the NHAAP guidelines in chest pain emergency department. 2000.2000-01-01T00:00:002000Application of the NHAAP guidelines in chest pain emergency departmentHerrmann HC, editorCannon CP, series editor. Contemporary CardiologyInterventional cardiology-percutaneous noncoronary intervention. Cannon CP, series editor. Contemporary Cardiology. 2005; 433.2005-01-01T00:00:002005Interventional cardiology-percutaneous noncoronary interventionCannon CP, Ornato JPCrit Pathw CardiolHow to develop a critical pathway: The ACS ACTION program. Crit Pathw Cardiol. 2002; 1:53-60.2002-01-01T00:00:002002How to develop a critical pathway: The ACS ACTION programRay KK, Cannon CP, Morrow DA, TIMI Study GroupCirculationCRP is additive and independent of apo B/A1 ratio in explaining the clinical benefits of atorvastatin 80mg in ACS patients in PROVE IT-TIMI 22. Circulation. 2005; 112(17):II-483-4.2005-01-01T00:00:002005CRP is additive and independent of apo B/A1 ratio in explaining the clinical benefits of atorvastatin 80mg in ACS patients in PROVE IT-TIMI 22Pollack C, Agostinelli N, Jiang S, Cannon C, Sabatine MAcademic Emergency MedicineImpact of delay to lysis on outcomes and efficacy of clopidogrel in STEMI: An analysis from CLARITY-TIMI 28. Academic Emergency Medicine. 2008.2008-05-01T00:00:002008Impact of delay to lysis on outcomes and efficacy of clopidogrel in STEMI: An analysis from CLARITY-TIMI 28Cannon CPLow molecular weight heparin in acute coronary syndromesLow molecular weight heparin in acute coronary syndromes. 1999.1999-01-01T00:00:001999Low molecular weight heparin in acute coronary syndromesCannon CPUpdate on ACS from the ESC 2005Update on ACS from the ESC 2005. 2005.2005-09-01T00:00:002005Update on ACS from the ESC 2005Topol EJ, Cannon CP, Moliterno DProvocative new data in PCIProvocative new data in PCI. 2001.2001-01-01T00:00:002001Provocative new data in PCIOlenchock BA, Fonarow GC, Wenqin P, Hernandez A, Cannon CPQCORCurrent use of beta-blockers in patients with reactive airway diseases who are hospitalized with acute coronary syndromes. QCOR. 2008.2008-01-01T00:00:002008Current use of beta-blockers in patients with reactive airway diseases who are hospitalized with acute coronary syndromesCannon CP, Lincoff AM, Zidar M, Dippel E, Gibson CM, Popma J, Topol EThrombocardiologyThrombocardiology. 2003.2003-01-01T00:00:002003ThrombocardiologyCefalu WT, Cannon CP, editorsAtlas of Cardiometabolic RiskAtlas of Cardiometabolic Risk. 2007.2007-01-01T00:00:002007Atlas of Cardiometabolic RiskCannon CP, Ornato JP, Antman EM, Braunwald E, Topol EJ, Willerson JTNew perspectives in cardiac care: Thrombolysis 98New perspectives in cardiac care: Thrombolysis 98. 1999.1999-01-01T00:00:001999New perspectives in cardiac care: Thrombolysis 98The ESPRIT InvestigatorsLancetEnhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board). Lancet. 2000; 356:2037-44..2000-01-01T00:00:002000Enhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board)17967585Morrow JP, Cannon CP, Reiffel JAAmerican heart journalNew antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? Am Heart J. 2007 Nov; 154(5):824-9.Am Heart J2007-11-01T00:00:002007New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?18340207Cannon CPCritical pathways in cardiologyUpdate to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI. Crit Pathw Cardiol. 2005 Dec; 4(4):185-6.Crit Pathw Cardiol2005-12-01T00:00:002005Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI.18340285Cannon CPCritical pathways in cardiologyCritical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002. Crit Pathw Cardiol. 2002 Mar; 1(1):12-21.Crit Pathw Cardiol2002-03-01T00:00:002002Critical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002.18565400Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MSJournal of the American College of CardiologyThrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 Jun 24; 51(25):2422-9.J Am Coll Cardiol2008-06-24T00:00:002008Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.18694141Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Resnic FSAMIA ... Annual Symposium proceedings. AMIA SymposiumValidating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]). AMIA Annu Symp Proc. 2007 Oct 11; 1043.AMIA Annu Symp Proc2007-10-11T00:00:002007Validating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]).19001026Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TP, DeLong E, Estes NA, Goff DC, Grady K, Green LA, Loth AR, Peterson ED, Radford MJ, Rumsfeld JS, Shahian DMCirculationACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of performance measurement and reperfusion therapy). Circulation. 2008 Dec 09; 118(24):2649-61.Circulation2008-11-10T00:00:002008ACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of performance measurement and reperfusion therapy).19075103Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, Labresh KACirculationGet With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009 Jan 06; 119(1):107-15.Circulation2008-12-15T00:00:002008Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.Authorship 10317878Authorship 10323925Authorship 103289510Authorship 1032519229263150Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald ECirculationBenefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 04 10; 137(15):1571-1582.Circulation2017-12-20T00:00:002017Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).28454801Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes- Marquez E, Wiviott S, Cannon CP, Braunwald E, Collins R, Landray MJAmerican heart journalRandomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 05; 187:182-190.Am Heart J2017-02-21T00:00:002017Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.29224646Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, Virani S, Turakhia MPAmerican heart journalAssociation of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. Am Heart J. 2018 Jan; 195:50-59.Am Heart J2017-08-31T00:00:002017Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.29253846Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic VAmerican journal of nephrologyThe Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472.Am J Nephrol2017-12-13T00:00:002017The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.19898282Cannon CPReviews in cardiovascular medicineIntroduction: Update on the evaluation and treatment of chronic angina. Rev Cardiovasc Med. 2009; 10 Suppl 1:S1-2.Rev Cardiovasc Med2009-01-01T00:00:002009Introduction: Update on the evaluation and treatment of chronic angina.21890085Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin LThe American journal of cardiologyPulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.Am J Cardiol2011-09-03T00:00:002011Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).21982651O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL, Cicconetti G, Lukas MA, Tarka E, Cannon CPAmerican heart journalStudy design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):613-619.e1.Am Heart J2011-09-15T00:00:002011Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.21989034Bird GC, Cannon CP, Kennison RHCritical pathways in cardiologyResults of a survey assessing provider beliefs of adherence barriers to antiplatelet medications. Crit Pathw Cardiol. 2011 Sep; 10(3):134-41.Crit Pathw Cardiol2011-09-01T00:00:002011Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medications.18340184Ray KK, Cannon CPCritical pathways in cardiologyTime to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Crit Pathw Cardiol. 2005 Mar; 4(1):43-5.Crit Pathw Cardiol2005-03-01T00:00:002005Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease.18340222McLean DS, Cannon CPCritical pathways in cardiologyThe clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Crit Pathw Cardiol. 2006 Jun; 5(2):103-13.Crit Pathw Cardiol2006-06-01T00:00:002006The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel.Authorship 1035521529283450Steen DL, Umez-Eronini AA, Guo J, Khan N, Cannon CPClinical cardiologyThe effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol. 2018 Jan; 41(1):68-73.Clin Cardiol2017-12-28T00:00:002017The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.18574277Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RAChestAcute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):708S-775S.Chest2008-06-01T00:00:002008Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).18926153Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Ballantyne CM, Cannon CPAmerican heart journalNine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27.Am Heart J2008-07-11T00:00:002008Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease.19186077Cannon CP, Paraliticci GU, Lin PP, Lewis VO, Yasko AWJournal of shoulder and elbow surgeryFunctional outcome following endoprosthetic reconstruction of the proximal humerus. J Shoulder Elbow Surg. 2009 Sep-Oct; 18(5):705-10.J Shoulder Elbow Surg2009-01-30T00:00:002009Functional outcome following endoprosthetic reconstruction of the proximal humerus.19358940Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MSJournal of the American College of CardiologyInteraction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009 Apr 14; 53(15):1273-8.J Am Coll Cardiol2009-04-14T00:00:002009Interaction between cigarette smoking and clinical benefit of clopidogrel.19781408Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter PAmerican heart journalDesign of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3.Am Heart J2009-10-01T00:00:002009Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.19840557Depta JP, Cannon CP, Fonarow GC, Zhao X, Peacock WF, Bhatt DLThe American journal of cardiologyPatient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.Am J Cardiol2009-11-01T00:00:002009Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.21459935Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune KThe Journal of rheumatologyEvaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol. 2011 Jun; 38(6):1071-8.J Rheumatol2011-04-01T00:00:002011Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.22748404Bangalore S, Fonarow GC, Peterson ED, Hellkamp AS, Hernandez AF, Laskey W, Peacock WF, Cannon CP, Schwamm LH, Bhatt DLThe American journal of medicineAge and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9.Am J Med2012-06-27T00:00:002012Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction.22902202Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet SJournal of the American College of CardiologyThe controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012 Sep 04; 60(10):875-81.J Am Coll Cardiol2012-08-15T00:00:002012The controversies of statin therapy: weighing the evidence.Fang JC, Couper GS, editorsCannon CP, series editor. Contemporary CardiologySurgical management of congestive heart failure. Cannon CP, series editor. Contemporary Cardiology. 2005; 328.2005-01-01T00:00:002005Surgical management of congestive heart failureCannon CPPharmacy Practice News Special EditionPractical applications of the ACC/AHA guidelines for unstable angina and non-ST-segment elevation myocardial infarction. Pharmacy Practice News Special Edition. 2003; 47-50.2003-01-01T00:00:002003Practical applications of the ACC/AHA guidelines for unstable angina and non-ST-segment elevation myocardial infarctionCannon CPContemporary Diagnosis and Management of the Acute Coronary SyndromeContemporary Diagnosis and Management of the Acute Coronary Syndrome. 2007.2007-01-01T00:00:002007Contemporary Diagnosis and Management of the Acute Coronary SyndromeCannon CPEvidence Based Cardiov MedCommentary on new biomarkers for predicting acute cardiac events. Evidence Based Cardiov Med. 2001; 5:6.2001-01-01T00:00:002001Commentary on new biomarkers for predicting acute cardiac eventsCannon CPEfficacy and safety of the CBI cannabinoid receptor blocker rimonabant: Pooled analysis of the RIO ProgramEfficacy and safety of the CBI cannabinoid receptor blocker rimonabant: Pooled analysis of the RIO Program. 2008.2008-02-01T00:00:002008Efficacy and safety of the CBI cannabinoid receptor blocker rimonabant: Pooled analysis of the RIO ProgramGibson CM, Morrow D, Vicari R, Wong GC, Demopoulos L, DiBattiste P, Murphy S, Cannon CP, Braunwald EJ Am Coll CardiolElevated C reactive protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: A TACTICS TIMI 18 angiographic substudy. J Am Coll Cardiol. 2002; 39:304A.2002-01-01T00:00:002002Elevated C reactive protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: A TACTICS TIMI 18 angiographic substudyCoffman JD, Eberhardt RT, editorsCannon CP, series editor. Contemporary CardiologyPeripheral arterial disease diagnosis and tretment. Cannon CP, series editor. Contemporary Cardiology. 2003; 356.2003-01-01T00:00:002003Peripheral arterial disease diagnosis and tretmentKhan MG, editorCannon CP, series editor. Contemporary Cardiology.Cardiac Drug Therapy. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Cardiac Drug TherapyCannon CPThrombolytic medication dosing errorsThrombolytic medication dosing errors. 2000.2000-01-01T00:00:002000Thrombolytic medication dosing errorsO'Donoghue M, Boden WE, Cannon CP, Clayton TC, de Winter RJ, Fox KAA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MSJACCThe benefit of an invasive strategy in diabetic versus non-diabetic subjects with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. JACC. 2008; 51(10):A216.2008-03-11T00:00:002008The benefit of an invasive strategy in diabetic versus non-diabetic subjects with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trialsSabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CPCirculationHigh-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):834.2004-01-01T00:00:002004High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 SubstudyAntman EM, Tanasijevic MJ, Cannon CPN Engl J MedCardiac troponins in acute coronary syndromes. N Engl J Med. 1997; 336:1259.1997-01-01T00:00:001997Cardiac troponins in acute coronary syndromesCannon CP, Loscalzo JGorlin R, Dangas GD, Toutouzas PK, Konstadoulakis MM, editors. Contemporary Concepts in Cardiology: Pathophysiology and Clinical ManagementThrombolytic and antithrombotic therapies for acute coronary syndromes. Gorlin R, Dangas GD, Toutouzas PK, Konstadoulakis MM, editors. Contemporary Concepts in Cardiology: Pathophysiology and Clinical Management. 1999; 142-175.1999-01-01T00:00:001999Thrombolytic and antithrombotic therapies for acute coronary syndromesKereiakes DJ, Cannon CPLincoff AM, Topol EJ, editors. Platelet IIb/IIIa Inhibitors in CardiologyOral platelet glycoprotein IIb/IIIa blockade. Lincoff AM, Topol EJ, editors. Platelet IIb/IIIa Inhibitors in Cardiology. 1999; 287-314.1999-01-01T00:00:001999Oral platelet glycoprotein IIb/IIIa blockadeGerstenblith G, editorCannon CP, series editor. Contemporary CardiologyCardiovascular disease in the elderly. Cannon CP, series editor. Contemporary Cardiology. 2005; 417.2005-01-01T00:00:002005Cardiovascular disease in the elderlyKumar A, Cannon CPArch Med SciThe current role of statins in acute coronary syndrome. Arch Med Sci. 2007; 3(4A):S115-25.2007-12-01T00:00:002007The current role of statins in acute coronary syndromePenn MS, editorCannon CP, series editor. Contemporary Cardiology.Stem cells and myocardial regeneration. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Stem cells and myocardial regenerationCannon CP, Topol EJRandomized, double blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebovascular diseaseRandomized, double blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebovascular disease. 2003.2003-01-01T00:00:002003Randomized, double blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebovascular diseaseSchoepf JU, editorCannon CP, series editor. Contemporary CardiologyCT of the heart. Cannon CP, series editor. Contemporary Cardiology. 2005; 407.2005-01-01T00:00:002005CT of the heartCannon CPCase history of non-ST elevation myocardial infarctionCase history of non-ST elevation myocardial infarction. 1998.1998-01-01T00:00:001998Case history of non-ST elevation myocardial infarctionWong GC, Murphy S, Morrow D, Giugliano R, Cannon CP, De Lemos J, Sabatine MS, Gibson CMJ Am Coll CardiolA simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarction. J Am Coll Cardiol. 2003; 41:402A.2003-01-01T00:00:002003A simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarctionCannon CP, Fonarow GCStriveASC Update. Strive. 2003.2003-01-01T00:00:002003ASC UpdateCannon CP.Interview with: Christopher Cannon, MDInterview with: Christopher Cannon, MD. 2005.2005-12-01T00:00:002005Interview with: Christopher Cannon, MDWeintraub WS, editorCannon CP, series editor. Contemporary CardiologyCardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2003; 436.2003-01-01T00:00:002003Cardiovascular health care economicsCannon CPCardio Special EditionPractical applications of the 2002 ACC/AHA guidelines for unstble angina and non-ST-segment elevation myocardial infarction. Cardio Special Edition. 2002; 8:29-36.2002-01-01T00:00:002002Practical applications of the 2002 ACC/AHA guidelines for unstble angina and non-ST-segment elevation myocardial infarction19367237Truong QA, Cannon CPReviews in cardiovascular medicineCardiac resynchronization therapy. A perspective on PROSPECT and the continued search for predictors to CRT response. Rev Cardiovasc Med. 2009; 10(1):59-61.Rev Cardiovasc Med2009-01-01T00:00:002009Cardiac resynchronization therapy. A perspective on PROSPECT and the continued search for predictors to CRT response.19660597Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CMThe American journal of cardiologyRelation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol. 2009 Aug 15; 104(4):475-9.Am J Cardiol2009-06-17T00:00:002009Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.20082923Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald EJournal of the American College of CardiologyReduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62.J Am Coll Cardiol2009-12-15T00:00:002009Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.20802264Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB, Steg PG, Bhatt DLCritical pathways in cardiologyPrior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25.Crit Pathw Cardiol2010-09-01T00:00:002010Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.21389919Truong Q, Kallianos K, Cannon CReviews in cardiovascular medicineCoronary artery disease. Calcium score of zero: not a gatekeeper to rule out coronary artery disease. Rev Cardiovasc Med. 2010; 11(4):271-3.Rev Cardiovasc Med2010-01-01T00:00:002010Coronary artery disease. Calcium score of zero: not a gatekeeper to rule out coronary artery disease.21562372Cannon CP, Hoekstra JW, Larson DM, Karcher RB, Mencia WA, Berry CA, Stowell SACritical pathways in cardiologyA report of quality improvement in the care of patients with acute coronary syndromes. Crit Pathw Cardiol. 2011 Mar; 10(1):29-34.Crit Pathw Cardiol2011-03-01T00:00:002011A report of quality improvement in the care of patients with acute coronary syndromes.22152949Reed GW, Cannon CPJournal of the American College of CardiologyPersonalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J Am Coll Cardiol. 2011 Dec 13; 58(25):2640-1.J Am Coll Cardiol2011-12-13T00:00:002011Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein.22446996Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DAJournal of thrombosis and thrombolysisElevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012 Aug; 34(2):222-8.J Thromb Thrombolysis2012-08-01T00:00:002012Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.22447123Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, Coba VMinerva anestesiologicaEarly interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol. 2012 Jun; 78(6):712-24.Minerva Anestesiol2012-03-23T00:00:002012Early interventions in severe sepsis and septic shock: a review of the evidence one decade later.Authorship 1038453929339356Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DMClinical journal of the American Society of Nephrology : CJASNKidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405.Clin J Am Soc Nephrol2018-01-16T00:00:002018Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.23192955Kohli P, Cannon CPClinical cardiologyThe importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data. Clin Cardiol. 2012 Dec; 35(12):714-7.Clin Cardiol2012-11-28T00:00:002012The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data.23520015Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RPClinical cardiologyRelation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.Clin Cardiol2013-03-20T00:00:002013Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.23573650Cannon CThe Journal of invasive cardiologyOverview of clinical trials. J Invasive Cardiol. 2004 Sep; 16 Suppl E:7E-10E.J Invasive Cardiol2004-09-01T00:00:002004Overview of clinical trials.Cannon CPBig news on cholesterolBig news on cholesterol. 2004.2004-01-01T00:00:002004Big news on cholesterolde Lemos JA, Cannon CPCallif RM, editor. Thrombolytic Therapy: New Standards of AMI/ACS Care, Part 6: Patients with Complicating Cardiac ConditionsReocclusion after AMI: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. Callif RM, editor. Thrombolytic Therapy: New Standards of AMI/ACS Care, Part 6: Patients with Complicating Cardiac Conditions. 1998; 3-11.1998-01-01T00:00:001998Reocclusion after AMI: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapyGelfand CV, Cannon CPGelfand CV, Cannon CP, editors. Management of Acute Coronary SyndromesUnstable angina and non-ST-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 37-78.2009-01-01T00:00:002009Unstable angina and non-ST-elevation myocardial infarctionCannon CP, Mehta SEarly and late effects of clopidogrel in patients with acute coronary syndromesEarly and late effects of clopidogrel in patients with acute coronary syndromes. 2003.2003-01-01T00:00:002003Early and late effects of clopidogrel in patients with acute coronary syndromesLincoff AM, Topol EJ, editorsCannon CP, series editor. Contemporary CardiologyPlatelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 1999; 368.1999-01-01T00:00:001999Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular diseaseCannon CP, editorManagement of Acute Coronary SyndromesManagement of Acute Coronary Syndromes. 2003; 781.2003-01-01T00:00:002003Management of Acute Coronary SyndromesCannon CPCrit Pathways CardiolImplementation of crtical pathways in the "Real World". Crit Pathways Cardiol. 2005; 4(2):110-4.2005-01-01T00:00:002005Implementation of crtical pathways in the "Real World"Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 InvestigatorsCirculationUsefulness of APTT to predict bleeding for hirudin (and heparin). Circulation. 1994; 90(Part 2):563.1994-01-01T00:00:001994Usefulness of APTT to predict bleeding for hirudin (and heparin)Upchurch Jr. GR, Criado E, editorsCannon CP, series editor. Contemporary CardiologyAortic aneurysms. Cannon CP, series editor. Contemporary Cardiology. 2008.2008-01-01T00:00:002008Aortic aneurysmsAnderson HV, Williams DO, Powers E, Cannon CP, Stone P, Sharaf B, Thompson B, Schactman M, Willerson JT, for the TIMI-IIIB InvestigatorsCirculationCoronary thrombus seen on early angiography in unstable angina non-Q-wave MI: TIMI-IIIB results. Circulation. 1994; 90(Part 2):664.1994-01-01T00:00:001994Coronary thrombus seen on early angiography in unstable angina non-Q-wave MI: TIMI-IIIB resultsCannon CPMedical RoundtableThe right mix for improve acute myocardial infarction survival: Pre-hospital bolus thrombolysis, lytics + PTCA + GP IIb/IIIa inhibitors. Medical Roundtable. 1998.1998-05-01T00:00:001998The right mix for improve acute myocardial infarction survival: Pre-hospital bolus thrombolysis, lytics + PTCA + GP IIb/IIIa inhibitorsCannon CPAcute coronary syndromes IIAcute coronary syndromes II. 2004.2004-01-01T00:00:002004Acute coronary syndromes IICannon CP, Kearon CComparison of low-intensity warafin therapy with conventional-intensity warafin therapy for long-term prevention of recurrent venous thromboembolismComparison of low-intensity warafin therapy with conventional-intensity warafin therapy for long-term prevention of recurrent venous thromboembolism. 2003.2003-01-01T00:00:002003Comparison of low-intensity warafin therapy with conventional-intensity warafin therapy for long-term prevention of recurrent venous thromboembolismCannon CP, Antman EM, Walls R, Braunwald ETime: An adjunctive agent to thrombolysisTime: An adjunctive agent to thrombolysis. 1994.1994-01-01T00:00:001994Time: An adjunctive agent to thrombolysisCannon CP, Rhee K, Bhatt DL, Boden WEJ Am Coll CardiolUse of aspirin among patients with atherothrombotic disease in the United States: The reduction of atherothrombosis for continued health (REACH) Registry. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):409A.2007-03-06T00:00:002007Use of aspirin among patients with atherothrombotic disease in the United States: The reduction of atherothrombosis for continued health (REACH) RegistryCannon CP, Moliterno DJNew pharmacologic strategies for acute myocardial infarctionNew pharmacologic strategies for acute myocardial infarction. 2001.2001-01-01T00:00:002001New pharmacologic strategies for acute myocardial infarctionCannon CP, McCabe CH, Braunwald EBecker RC, editor. Modern Era of Coronary Thrombolysis.The thrombolysis in myocardial infarction (TIMI) trials. Becker RC, editor. Modern Era of Coronary Thrombolysis. 1994; 53-67.1994-01-01T00:00:001994The thrombolysis in myocardial infarction (TIMI) trialsCannon CPAcute coronary syndromes: More aggressive is betterAcute coronary syndromes: More aggressive is better. 2000.2000-01-01T00:00:002000Acute coronary syndromes: More aggressive is better18340181Lader EW, Cannon CPCritical pathways in cardiologyHow to join a clinical trial. Crit Pathw Cardiol. 2005 Mar; 4(1):26-9.Crit Pathw Cardiol2005-03-01T00:00:002005How to join a clinical trial.18427127Jneid H, Fonarow GC, Cannon CP, Palacios IF, Kilic T, Moukarbel GV, Maree AO, LaBresh KA, Liang L, Newby LK, Fletcher G, Wexler L, Peterson ECirculationImpact of time of presentation on the care and outcomes of acute myocardial infarction. Circulation. 2008 May 13; 117(19):2502-9.Circulation2008-04-21T00:00:002008Impact of time of presentation on the care and outcomes of acute myocardial infarction.Berger JS, Bhatt DL, Cannon CP, Chen Z, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol RJ, Berger PBCirculationThe relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA. Circulation. 2007; 116(16):II-483.2007-10-16T00:00:002007The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMAStorey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Husted SEur Heart JFinal aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation response. Eur Heart J. 2008.2008-01-01T00:00:002008Final aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation responseCannon CPCan cholesterol make your heart healthy?Can cholesterol make your heart healthy?. 2008.2008-01-01T00:00:002008Can cholesterol make your heart healthy?Cannon CP, Noble JRAspirin and clopidogrel is not better than aspirin IIb/IIIa inhibitor for non-ST elevation in acute coronary syndromeAspirin and clopidogrel is not better than aspirin IIb/IIIa inhibitor for non-ST elevation in acute coronary syndrome. 2002.2002-01-01T00:00:002002Aspirin and clopidogrel is not better than aspirin IIb/IIIa inhibitor for non-ST elevation in acute coronary syndromeAuthorship 1041071528761675Bellavia A, Wallentin L, Orsini N, James SK, Cannon CP, Himmelmann A, Sundström J, Renlund H, Lytsy POpen heartTime-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart. 2017; 4(2):e000557.Open Heart2017-06-01T00:00:002017Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial.7594070Hall C, Cannon CP, Forman S, Braunwald EJournal of the American College of CardiologyPrognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol. 1995 Nov 15; 26(6):1452-6.J Am Coll Cardiol1995-11-15T00:00:001995Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators.7639167Boisjolie CR, Sharkey SW, Cannon CP, Brunette D, Haugland JM, Thatcher JL, Henry TDThe American journal of cardiologyImpact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department. Am J Cardiol. 1995 Aug 15; 76(5):396-8.Am J Cardiol1995-08-15T00:00:001995Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department.18953283Cannon CP, Acharjee SReviews in cardiovascular medicineAcute coronary syndrome. Cardiovascular events after clopidogrel discontinuation. Rev Cardiovasc Med. 2008; 9(3):212-4.Rev Cardiovasc Med2008-01-01T00:00:002008Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation.19081406Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC, Dai D, Hernandez A, Fonarow GCAmerican heart journalLipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009 Jan; 157(1):111-117.e2.Am Heart J2008-10-22T00:00:002008Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.19516186Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CPJournal of hypertensionFactors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr; 27(4):886-93.J Hypertens2009-04-01T00:00:002009Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.19593326Truong QA, Okada DR, Cannon CPReviews in cardiovascular medicineCardiac risk - coronary calcium scoring for all? Rev Cardiovasc Med. 2009; 10(2):121-4.Rev Cardiovasc Med2009-01-01T00:00:002009Cardiac risk - coronary calcium scoring for all?19717846Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén MThe New England journal of medicineTicagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.N Engl J Med2009-08-30T00:00:002009Ticagrelor versus clopidogrel in patients with acute coronary syndromes.20435175Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald EAmerican heart journalAn update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9.Am Heart J2010-03-15T00:00:002010An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.20832963Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin LJournal of the American College of CardiologyInhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010 Oct 26; 56(18):1456-62.J Am Coll Cardiol2010-10-26T00:00:002010Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.21318582Ahmed S, Michael Gibson C, Cannon CP, Murphy SA, Sabatine MSJournal of thrombosis and thrombolysisImpact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis. 2011 May; 31(4):493-500.J Thromb Thrombolysis2011-05-01T00:00:002011Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.21835289Medina HM, Cannon CP, Zhao X, Hernandez AF, Bhatt DL, Peterson ED, Liang L, Fonarow GCAmerican heart journalQuality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2.Am Heart J2011-08-01T00:00:002011Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD).22010200Eapen ZJ, Fonarow GC, Dai D, O'Brien SM, Schwamm LH, Cannon CP, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AFCirculation. Cardiovascular quality and outcomesComparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):610-8.Circ Cardiovasc Qual Outcomes2011-10-18T00:00:002011Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program.22754969Steen DL, Cannon CPReviews in cardiovascular medicineAtherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Rev Cardiovasc Med. 2012; 13(1):e48-51.Rev Cardiovasc Med2012-01-01T00:00:002012Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins.23137936Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DLJournal of the American College of CardiologyTemporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 08; 61(1):35-40.J Am Coll Cardiol2012-11-05T00:00:002012Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction.Constant J, editorCannon CP, series editor. Contemporary CardiologyEssentials of bedside cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 298.2005-01-01T00:00:002005Essentials of bedside cardiologyGanz LI, editorCannon CP, series editor. Contemporary CardiologyManagement of cardiac arrhythmias. Cannon CP, series editor. Contemporary Cardiology. 2001.2001-01-01T00:00:002001Management of cardiac arrhythmiasBraunwald E, Aghababian R, Anand S, Cannon CP, Popma JJ, Tierstein PStrategies and therapies for reducing ischemic and vascular events (STRIVE)Strategies and therapies for reducing ischemic and vascular events (STRIVE). 2001.2001-01-01T00:00:002001Strategies and therapies for reducing ischemic and vascular events (STRIVE)Cannon CPCannon CP, editor. Presentations in Focus: Extending Antiplatelet Protection: Optimal Strategies to Reduce Thrombotic RiskEmerging role of clopidogrel as the cornerstone of treatment in acute coronary syndromes. Cannon CP, editor. Presentations in Focus: Extending Antiplatelet Protection: Optimal Strategies to Reduce Thrombotic Risk. 2000.2000-01-01T00:00:002000Emerging role of clopidogrel as the cornerstone of treatment in acute coronary syndromesCannon CPAtherothrombosis: Bridging the Gap Between Clinical Evidence and Current PracticeAtherothrombosis: Bridging the Gap Between Clinical Evidence and Current Practice. 2004.2004-01-01T00:00:002004Atherothrombosis: Bridging the Gap Between Clinical Evidence and Current PracticeCannon CP, Peterson EDChanging the model of care for patients with acute coronary syndromesChanging the model of care for patients with acute coronary syndromes. 2004.2004-01-01T00:00:002004Changing the model of care for patients with acute coronary syndromesGibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E, for the TIMI Study Group (Cannon CP, Co-Principal, Investigator)Am Heart JEarly initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the time to integrilin therapy in acute myocardial infarction (TITAN) - TIMI 34 Trial. Am Heart J. 2006; 152:668-75.2006-01-01T00:00:002006Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the time to integrilin therapy in acute myocardial infarction (TITAN) - TIMI 34 Trial9860780Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald ECirculationTNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14.Circulation1998-12-01T00:00:001998TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.10602552Cannon CP, Braunwald EJournal of thrombosis and thrombolysisTime to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(2):117-125.J Thromb Thrombolysis1996-01-01T00:00:001996Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty.10751785Cannon CP, Smith MJournal of thrombosis and thrombolysisAdvances in Alliteration in Acute Myocardial Infarction: From "Time to Treatment" to "Onset to Opening" J Thromb Thrombolysis. 1998 Jul; 6(1):5-7.J Thromb Thrombolysis1998-07-01T00:00:001998Advances in Alliteration in Acute Myocardial Infarction: From "Time to Treatment" to "Onset to Opening"11382722Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald ECirculationCombination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4.Circulation2001-05-29T00:00:002001Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.12372567Scirica BM, Cannon CP, McCabe CH, Murphy SA, Anderson HV, Rogers WJ, Stone PH, Braunwald EThe American journal of cardiologyPrognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6.Am J Cardiol2002-10-15T00:00:002002Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification.12427661Freedman JE, Becker RC, Adams JE, Borzak S, Jesse RL, Newby LK, O'Gara P, Pezzullo JC, Kerber R, Coleman B, Broderick J, Yasuda S, Cannon CCirculationMedication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation. 2002 Nov 12; 106(20):2623-9.Circulation2002-11-12T00:00:002002Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke.12644340Cannon CPJournal of the American College of CardiologySmall molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):43S-48S.J Am Coll Cardiol2003-02-19T00:00:002003Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.12912804Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck UCirculationSoluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003 Sep 02; 108(9):1049-52.Circulation2003-08-11T00:00:002003Soluble CD40L: risk prediction after acute coronary syndromes.14563340Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJEuropean heart journalPredictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003 Oct; 24(20):1815-23.Eur Heart J2003-10-01T00:00:002003Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).15325937Gibson CM, Singh KP, Murphy SA, DiBattiste PM, Demopoulos LA, Cannon CP, Braunwald EThe American journal of cardiologyAssociation between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2004 Aug 15; 94(4):492-4.Am J Cardiol2004-08-15T00:00:002004Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).15523070Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EMJAMAUtilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104.JAMA2004-11-03T00:00:002004Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.9412306Nichol G, Walls R, Goldman L, Pearson S, Hartley LH, Antman E, Stockman M, Teich JM, Cannon CP, Johnson PA, Kuntz KM, Lee THAnnals of internal medicineA critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. 1997 Dec 01; 127(11):996-1005.Ann Intern Med1997-12-01T00:00:001997A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact.9708465Every NR, Cannon CP, Granger C, Moliterno DJ, Aguirre FV, Talley JD, Booth J, Sapp S, Ferguson JJJournal of the American College of CardiologyInfluence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. J Am Coll Cardiol. 1998 Aug; 32(2):387-92.J Am Coll Cardiol1998-08-01T00:00:001998Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation.Cannon CPCath lab for all patient with unstable angina or non-ST-segment elevation myocardial infarction?Cath lab for all patient with unstable angina or non-ST-segment elevation myocardial infarction?. 2001.2001-01-01T00:00:002001Cath lab for all patient with unstable angina or non-ST-segment elevation myocardial infarction?Cannon CPIs it true that some statins are better than others at raising good cholesterol?Is it true that some statins are better than others at raising good cholesterol?. 2008.2008-01-31T00:00:002008Is it true that some statins are better than others at raising good cholesterol?Cannon CP, O'Gara PTCannon CP, editor. Management of Acute Coronary SyndromesCritical pathways in acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 611-27.1999-01-01T00:00:001999Critical pathways in acute coronary syndromesCannon CPTIMI risk calculatorTIMI risk calculator. 2001.2001-03-01T00:00:002001TIMI risk calculatorCannon CPNew Era of ReperfusionThe glycoprotein IIb/IIIa inhbitors in the treatment of acute coronary syndromes. New Era of Reperfusion. 1997; 1:1-8.1997-01-01T00:00:001997The glycoprotein IIb/IIIa inhbitors in the treatment of acute coronary syndromesCannon CPBhatt DL, Flather MD, editors. Handbook of Acute Coronary SyndromesGuidelines for unstable angina and non-ST-segment elevation myocardial infarction. Bhatt DL, Flather MD, editors. Handbook of Acute Coronary Syndromes. 2004; 223-40.2004-01-01T00:00:002004Guidelines for unstable angina and non-ST-segment elevation myocardial infarctionGelfand EV, Cannon CPContagionDoes anti-infective therapy reduce cardiovascular event rates. Contagion. 2005; 2(10):1-5.2005-01-01T00:00:002005Does anti-infective therapy reduce cardiovascular event ratesCannon CPTIMI risk calculatorTIMI risk calculator. 2001.2001-01-01T00:00:002001TIMI risk calculatorCannon CPCannon CP, editor. Cor Art DisThe era of platelet glycoprotein IIb/IIIa inhibition. Cannon CP, editor. Cor Art Dis. 1999; 10:545-94.1999-01-01T00:00:001999The era of platelet glycoprotein IIb/IIIa inhibitionCannon CPA balanced approach to reperfusion therapyA balanced approach to reperfusion therapy. 1999.1999-01-01T00:00:001999A balanced approach to reperfusion therapyRunge MS, Patterson C, editorsCannon CP, series editor. Contemporary CardiologyPrinciples of molecular cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 617.2005-01-01T00:00:002005Principles of molecular cardiologyJurkovitz C, Mahoney EM, Chu H, Robertson DH, Demopoulos L, DiBattiste P, Alexander C, Cannon CP, Weintraub WSDiabetesThe effect of conservative vs. invasive strategy on outcomes of acute coronary syndromes in diabetics. Diabetes. 2001.2001-01-01T00:00:002001The effect of conservative vs. invasive strategy on outcomes of acute coronary syndromes in diabeticsWiviott SD, Cannon CPNature Clinical PracticeUpdate on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice. 2006; 3(8):424-36.2006-01-01T00:00:002006Update on lipid-lowering therapy and LDL-cholesterol targetsFoody JM, editorCannon CP, series editor. Contemporary CardiologyPreventive cardiology: Strategies for the prevention and treatment of coronary artery disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 366.2001-01-01T00:00:002001Preventive cardiology: Strategies for the prevention and treatment of coronary artery diseaseTcheng JE, editorCannon CP, series editor. Contemporary CardiologyPrimary angioplasty in acute myocardial infarction. Cannon CP, series editor. Contemporary Cardiology. 2005; 182.2005-01-01T00:00:002005Primary angioplasty in acute myocardial infarctionCannon CPJ Evidence Based HealthcareCommentary on cost-effectiveness of GP IIb/IIIa inhibitors. J Evidence Based Healthcare. 2001; 5:87-8.2001-01-01T00:00:002001Commentary on cost-effectiveness of GP IIb/IIIa inhibitorsRyan RJ, Cannon CP, Gibler WBCritical Pathways in Cardiovascular MedicineNon-ST elevation ACS in the Emergency Department. Critical Pathways in Cardiovascular Medicine. 2007; 27-38..2007-01-01T00:00:002007Non-ST elevation ACS in the Emergency DepartmentCannon CPCoron Artery DisBivalirudin: Efficacy and cost effectiveness in PCI. Coron Artery Dis. 2003; 3.2003-01-01T00:00:002003Bivalirudin: Efficacy and cost effectiveness in PCIFuster V, Cannon CP, Ferguson J, Weber MESCESC. 2002.2002-01-01T00:00:002002ESCBlake TM, editorCannon CP, series editor. Contemporary CardiologyAnnoted atlas of electrocardiography. Cannon CP, series editor. Contemporary Cardiology. 1999; 368.1999-01-01T00:00:001999Annoted atlas of electrocardiographyOberg KC, Cannon CP, Plutzky JFormularyFocus on reteplase: A newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45.1997-01-01T00:00:001997Focus on reteplase: A newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarctionWiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald ECirculationBaseline cystatin C measurement is a potent predictor of adverse cardiovascular outcomes following ACS: A PROVE IT - TIMI 22 analysis. Circulation. 2006; 114(18):II-418.2006-01-01T00:00:002006Baseline cystatin C measurement is a potent predictor of adverse cardiovascular outcomes following ACS: A PROVE IT - TIMI 22 analysisCannon CP, Hamm CWCorrespondence soluble CD40 ligand in acute coronary syndromesCorrespondence soluble CD40 ligand in acute coronary syndromes. 2003.2003-01-01T00:00:002003Correspondence soluble CD40 ligand in acute coronary syndromesYoung J, Fonarow G, Hill J, Cannon CP, Heywood T, Peacock F, Berstein-Sackner JHeart failureHeart failure. 2003.2003-01-01T00:00:002003Heart failureSteinberg BA, Cannon CPCefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk.Managing cardiometabolic risk - a brief review. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 137-165..2007-01-01T00:00:002007Managing cardiometabolic risk - a brief reviewCannon CPSpectrum of acute coronary syndromes: The paradigm of myocardial ischemiaSpectrum of acute coronary syndromes: The paradigm of myocardial ischemia. 1998.1998-01-01T00:00:001998Spectrum of acute coronary syndromes: The paradigm of myocardial ischemiaOrnato JP, Cannon CP, Gibler WB, Gonzales ERCritical pathways for the evaluation and treatment of chest painCritical pathways for the evaluation and treatment of chest pain. 1997.1997-01-01T00:00:001997Critical pathways for the evaluation and treatment of chest painHutter A, Abramson W, Califf RM Cannon CPACC conversations with experts.ACC conversations with experts. 2004.2004-01-01T00:00:002004ACC conversations with expertsFuster V, Pickering T, Cannon CP, Ferguson J, Weber MAHA 2002: Part IAHA 2002: Part I. 2002.2002-01-01T00:00:002002AHA 2002: Part ICannon CPWhat is the evidence that chest pain centers improve outcomes and cost-effectiveness?What is the evidence that chest pain centers improve outcomes and cost-effectiveness?. 1998.1998-01-01T00:00:001998What is the evidence that chest pain centers improve outcomes and cost-effectiveness?Cannon CPLewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment ProgramUnstable Angina: Treatment strategies. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002.2002-01-01T00:00:002002Unstable Angina: Treatment strategiesCannon CP, Weintraub WS, Demopoulos L, Vicari R, Bazzino O, Ali N, Robertson DH, DeLucca PT, DiBattiste P, Rifai N, Braunwald E, for the TACTICS-TIMI 18 InvestigatorsJ Am Coll CardiolHigh-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Primary results of the TACTICS-TIMI 18 C-Reactive Protein substudy. J Am Coll Cardiol. 2001; 37(Suppl A):315A.2001-01-01T00:00:002001High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Primary results of the TACTICS-TIMI 18 C-Reactive Protein substudyDavidson MH, Toth PP, Maki KCCannon CP, series editor. Contemporary CardiologyTherapeutic Lipidology. Cannon CP, series editor. Contemporary Cardiology. 2007.2007-01-01T00:00:002007Therapeutic LipidologyCannon CPCase study: Combination GP IIb/IIIa inhibitor plus reduced-dose thrombolytic therapy for acute myocardial infarctionCase study: Combination GP IIb/IIIa inhibitor plus reduced-dose thrombolytic therapy for acute myocardial infarction. 2000.2000-01-01T00:00:002000Case study: Combination GP IIb/IIIa inhibitor plus reduced-dose thrombolytic therapy for acute myocardial infarctionBhatt DL, Peterson ED, Harrington RA, Ou F, Cannon CP, Gibson CM, Kleiman N, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT for the CRUSADE InvestigatorsCirculationPolyvascular disease - a novel risk factor for worse ischemic and bleeding outcomes in acute coronary syndromes. Circulation. 2007; 116(16):II-482.2007-10-16T00:00:002007Polyvascular disease - a novel risk factor for worse ischemic and bleeding outcomes in acute coronary syndromesCannon CP, Steinberg BACardiol QuarterlySpecial report: Chronic stable angina: Past, present, and future. Cardiol Quarterly. 2006; 12.2006-01-01T00:00:002006Special report: Chronic stable angina: Past, present, and futureRanganathan N, Sivaciyan V, Saksena FB, editorsCannon CP, series editor. Contemporary CardiologyThe art and science of cardiac physical examination. Cannon CP, series editor. Contemporary Cardiology. 2006.2006-01-01T00:00:002006The art and science of cardiac physical examination9468207Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald ECirculationRandomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998 Feb 03; 97(4):340-9.Circulation1998-02-03T00:00:001998Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.9531250Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, McCabe CH, Braunwald ECirculationProspective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 Mar 24; 97(11):1042-5.Circulation1998-03-24T00:00:001998Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B.Cannon CPDoor-to-balloon time versus mortality in patients with acute myocrdial infarction treated with primary angioplastyDoor-to-balloon time versus mortality in patients with acute myocrdial infarction treated with primary angioplasty. 1999.1999-01-01T00:00:001999Door-to-balloon time versus mortality in patients with acute myocrdial infarction treated with primary angioplastyCannon CPI have severe angina. Should I ask for supplemental oxygen during a commercial flight?I have severe angina. Should I ask for supplemental oxygen during a commercial flight?. 2008.2008-02-01T00:00:002008I have severe angina. Should I ask for supplemental oxygen during a commercial flight?Becker R, Tracy R, Bovill E, Thompson B, Randall A, Cannon CP, Braunwald EJ Am Coll CardiolShould PTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparin. J Am Coll Cardiol. 1994; 57A.1994-01-01T00:00:001994Should PTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparinCannon CPCannon CP, O'Gara PT, editors. Critical Pathways in CardiologyCritical pathways for thrombolysis in myocardial infarction. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 57-66.2001-01-01T00:00:002001Critical pathways for thrombolysis in myocardial infarctionCannon CPA new standard of care in acute coronary syndromesA new standard of care in acute coronary syndromes. 2002.2002-01-01T00:00:002002A new standard of care in acute coronary syndromes10569649Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald EThe American journal of cardiologyWeight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol. 1999 Nov 01; 84(9):976-80.Am J Cardiol1999-11-01T00:00:001999Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.11360839Kloner RA, Shook T, Cannon CP, Przyklenk KThe American journal of geriatric cardiologyIschemic preconditioning: implications for the geriatric heart. Am J Geriatr Cardiol. 2001 May-Jun; 10(3):145-8; quiz 149-51.Am J Geriatr Cardiol2001-05-01T00:00:002001Ischemic preconditioning: implications for the geriatric heart.11545753de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald EThe American journal of cardiologyEarly noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.Am J Cardiol2001-08-15T00:00:002001Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy.11981103Sekaran NK, Moliterno DJ, Ferguson JJ, Every N, Anderson HV, Aguirre FV, French WJ, Sapp S, Booth JE, Granger CB, Cannon CPJournal of thrombosis and thrombolysis"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. J Thromb Thrombolysis. 2001 Dec; 12(3):207-16.J Thromb Thrombolysis2001-12-01T00:00:002001"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry.Cannon CPIs it true that I should start taking the high dose of statin possible after a heart attack?Is it true that I should start taking the high dose of statin possible after a heart attack?. 2008.2008-01-31T00:00:002008Is it true that I should start taking the high dose of statin possible after a heart attack?Cannon CP, Walls RMJ Emergency MedIs it safe to send this patient home ed markers of ACS move upstream?. J Emergency Med. 2003; 7.2003-01-01T00:00:002003Is it safe to send this patient home ed markers of ACS move upstream?Cannon CPCardio Scientific UpdatePercutaneous coronary intervention in the clopidogrel in unstable angina to prevent recurrent events (PCI-cure) trial. Cardio Scientific Update. 2002.2002-01-01T00:00:002002Percutaneous coronary intervention in the clopidogrel in unstable angina to prevent recurrent events (PCI-cure) trialOrnato JP, Peberdy MA, editorsCannon CP, series editor. Contemporary CardiologyCardiopulmonary resuscitation. Cannon CP, series editor. Contemporary Cardiology. 2005; 764.2005-01-01T00:00:002005Cardiopulmonary resuscitationCannon CPAm J CardiolIntroduction. Am J Cardiol. 2006; 98(10S1):S1.2006-11-01T00:00:002006Introduction7585777Cannon CPCardiology clinicsThrombin inhibitors in acute myocardial infarction. Cardiol Clin. 1995 Aug; 13(3):421-33.Cardiol Clin1995-08-01T00:00:001995Thrombin inhibitors in acute myocardial infarction.Desai NR, Mega JL, Guo W, Cannon CP, Sabatine MSJACCThe smoker's paradox with a clopidogrel twist: Insights from CLARITY-TIMI 28. JACC. 2008; 51(10):A203.2008-03-11T00:00:002008The smoker's paradox with a clopidogrel twist: Insights from CLARITY-TIMI 289036740Cannon CP, McCabe CH, Stone PH, Schactman M, Thompson B, Theroux P, Gibson RS, Feldman T, Kleiman NS, Tofler GH, Muller JE, Chaitman BR, Braunwald EThe American journal of cardiologyCircadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol. 1997 Feb 01; 79(3):253-8.Am J Cardiol1997-02-01T00:00:001997Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB).